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ABSTRACT 
 
Background:  Worldwide, prices for cancer drugs have been under downward pressure 
where several governments have mandated price cuts of branded and generic products.  
A better alternative to mandated price cuts would be the estimation of a launch price 
based on drug performance, cost effectiveness and a country’s ability to pay.  In this 
study, the development of a global pricing index for new drugs that encompasses all of 
these attributes in patients with metastatic colorectal cancer (mCRC) is described. 
Methods: A pharmacoeconomic model was developed to simulate clinical outcomes in 
mCRC patients receiving chemotherapy with the addition of a “new drug” that improves 
survival by 1.4, 3 and 6 months.  Cost and health state utility data were obtained from 
cancer centers and oncology nurses (total n=112) in Canada (n=24), Spain (n=24), 
India (n=24), South Africa (n=16) and Malaysia (n=24).  A price per dose was estimated 
for each survival increment using a target value threshold of three times the per capita 
gross domestic product (GDP) for each country, as recommended by the World Health 
Organisation (WHO).  Multivariable analysis was then used to develop the pricing index, 
which considers survival benefit, per capita GDP and income dispersion as measured 
by the Gini coefficient as predictor variables. 
Results:  Higher survival benefits were associated with elevated drug prices, especially 
in wealthier countries such as Canada and Spain.  For a nation like Argentina with a per 
capita GDP of $15,000 and a Gini coefficient of 51, it is estimated that for a drug which 
provides a 4 month survival benefit in mCRC, the value based price would be $US 630 
per dose.  In contrast, the same drug in a wealthier country like Norway could command 
a price of $US 2,775 and still be considered cost effective according to the WHO 
criteria. 
x 
 
Conclusions:  A global pricing index was presented that can be used to estimate a 
value based price in different countries for new drugs in mCRC.  The application of this 
index to estimate a price based on cost effectiveness would be a good starting point for 
opening dialogue between the key stakeholders and a better alternative to 
governments’ mandated price cuts. 
 
Key words:  Colorectal cancer, drug price, value, cost, chemotherapy 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  Introduction 
 Cancer has always been with human kind, with the first recorded case being 
discovered in Egyptian hieroglyphic tablets (Mukherjee, 2010). The underlying causes 
of all cancers in general are not fully known.  However, one underlying theory is that 
cancer is a form a speciation, where cancer cells are, in a sense, a new living organism 
attempting to break out of the human host (Vincent, 2010).  Notwithstanding the history 
or causes of human cancers, the majority of patients seek some form of treatment.  The 
intent of cancer therapy is to cure the disease or to at least palliate symptoms and 
improve quality of life.  Drugs have always been an intergral part of cancer therapy.  
The work presented in this thesis attempts to address a fundamental challenge faced by 
cancer patients around the world; timely access to effective drugs.  The first chapter 
begins with a brief presentation of global cancer trends, highlighting that the disease 
remains one of the most common causes of death worldwide.  It then continues with a 
description of pharmacotherapy in cancer care and how the high prices of new cancer 
drugs have limited patient access to these important agents.  The impact of these high 
prices on health care budgets is then highlighted.  The challenges that health care 
systems face in terms of rising drugs expenditures and how they have responded are 
then presented.  The chapter then closes with a proposal for determining an optimal 
drug price based on product value.  The pricing strategy proposed in this study could 
improve patient access by identifying a more affordable price based on the wealth of a 
nation. 
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1.2  Cancer, a global problem 
 The populations of many countries around the world are aging (Kinsella et al., 2005).  
This is of concern to health care authorities because cancer is a disease that usually 
occurs later in life.  It has been estimated that in the United States alone, 60% of all new 
cancers occur in people over the age of 65 years (Surveillance Epidemiology and End 
Results, 2010).  Since the population is aging, a sharp increase in the number of new 
cases can also be expected over the next 10 to 20 years.  Cancer is now considered to 
be a chronic condition because some patients with advanced stage disease can live for 
five to ten years after the initial diagnosis (National Cancer Institute of Canada, 2010).  
From the perspective of cancer centres, these factors are causing sharp increases in 
the number of patients seeking treatment.  As a result, health care systems around the 
world are being strained as they attempt to meet the needs of patients. 
 The primary tools used by oncologists to treat cancer consist of surgery, 
chemotherapy, radiation and hormonal therapy.  The use of these interventions, alone 
or in combination, depends on the type of cancer, the extent of disease and patient 
factors.  Surgery is usually, but not exclusively, reserved for early stage tumours where 
the intent is cure.   Chemotherapy, radiation and hormonal therapy are used in both 
early stage disease and in incurable tumours that have metastasized to distant sites 
(Devita et al., 2001). 
For many years, the backbone of cancer treatment has been the use of cytotoxic 
agents such as anthracylines, taxanes and platinum analogues (Table 1.1).  One 
characteristic of traditional chemotherapy is its non-specificity to the target.  As a result, 
side effects such as neutropenia, anemia and thrombocytopenia are common (Schiller, 
2002).  However over the past decade, there has been an emergence of new anticancer 
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drugs that are more specific to the target (Köhne et al., 2009; Mahalingam et al., 2009).  
These new compounds which include imatinib, bevacizumab, cetuximab and 
trastuzumab are collectively known as “targeted therapies” (Köhne et al., 2009; 
Mahalingam et al., 2009 and Motzer et al., 2007) – (see Table 1.1).  Unlike traditional 
chemotherapy which can affect both healthy and malignant cells, targeted agents are 
specific to the latter.  Therefore, they tend to be better tolerated than chemotherapy and 
the main side effects described above are less common (Köhne et al., 2009; 
Mahalingam et al., 2009).  The use of these agents has also resulted in a prolongation 
of survival in some types of cancer such as breast, lung and colorectal (Van Cutsem et 
al., 2009; Sandler et al., 2006). 
 
Table 1.1.  Anticancer agents currently used in the treatment of solid tumour 
malignancies (Köhne et al., 2009; Mahalingam et al., 2009) 
Anthracyclines Taxanes non-Anthracycline Targeted agents 
Doxorubicin 
 
Epirubicin 
 
Liposomal doxorubicin 
 
Mitoxantrone 
 
Daunorubicin 
 
 
 
Paclitaxel 
 
Docetaxel 
 
Abraxane 
 
Capecitabine 
 
Vinorelbine 
 
Gemcitabine 
 
Cisplatin 
 
Carboplatin 
 
Oxaliplatin 
 
Cyclophosphamide 
 
5-fluorouracil 
 
Methotrexate 
 
Irinotecan 
 
Pemetrexed 
Lapatinib 
 
Trastuzumab 
 
Bevacizumab 
 
Cetuximab 
 
Panitumumab 
 
Sunitinib 
 
Sorafenib 
 
Pazopanib 
 
Erlotinib 
 
Everolimus 
 
Temsirolimus 
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1.3  Patient access to new cancer drugs 
 Despite the effectiveness and safety of the new targeted agents, not all cancer 
patients around the world have access to them.  One of the single biggest barriers to 
drug access is price.  All of these new therapies have been priced at levels that are 
several times higher than traditional chemotherapy (Schrag, 2004).  As an illustration, 
sunitinib, which is an orally administered targeted agent used in advanced kidney 
cancer, has a cost of approximately $US 8,000 (R57,028) per month with the median 
duration of therapy being approximately 8 months (Motzer et al., 2007).  The previous 
agent used in kidney cancer (interferon alfa) has a monthly cost of $US 900 (R 6,390).  
At the time when the pivotal study results were reported, sunitinib was associated with a 
statistically significant 6 month improvement in progression free survival, but the overall 
survival increment did not reach statistical significance (Motzer et al., 2007).  
Notwithstanding the decision to use sunitinib in kidney cancer, such costs are out of 
reach for many cancer patients even in higher income countries.  For example, in the 
Canadian province of Ontario with a population of 12 million, approximately one-third of 
the population does not have private or public medical insurance (Fraser Report, 2008).  
As a result, about one third of such patients would have to use their own funds to pay 
for sunitinib.  For many such patients, even in developed nations, drugs such as 
sunitinib are simply out of reach. 
 These challenges to drug access are especially relevant in developing nations.  It is 
unclear how multinational pharmaceutical companies make the final decision on how to 
price a drug for a given country, but what is certain is that prices for such agents have 
been increasing almost exponentially, far beyond the rate of inflation (Fojo and Grandy, 
2009; Hillner and Smith, 2009). Furthermore; it is not uncommon to find that prices for 
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specific drugs in less developed countries are comparable to the cost of the drug in the 
United States.    For example, the annual cost of bevacizumab, a targeted agent used in 
colorectal cancer is $US 52,800 (R 374,880) in the United States compared to $US 
45,000 (R 319,500) in South Africa.  Gross Domestic Product (GDP) per capita for 
South Africa in 2010 was approximately $US 10,000 (R 71,000) compared to $US 
47,000 (R 333,700) in the United States (World Fact Book, 2010).  Hence, it is unclear 
why the price of a cancer drug such as bevacizumab should be comparable between 
two countries with such a wide variance in per capita GDP.  As a result, a more 
transparent method needs to be developed to determine a fair price for new cancer 
drugs that is linked to overall clinical performance, economic efficiency and the wealth 
of the country. 
 
1.4  Problem Definition 
 To help overcome barriers to patient access for new cancer drugs secondary to high 
launch prices, national governments should have the necessary tools available that 
would help them negotiate a more reasonable price with the manufacturer that is based 
on clinical performance measure by survival benefit, economic value as measured by 
the cost per QALY gained.  Therefore, what is needed is an index for estimating a price 
that is based on the survival benefits that a new drug offers, an individual country’s 
direct health care costs that could potentially be offset by a new drug (for example, 
hospitalisations, palliative care services) along with societal utilities for improvements in 
health outcomes.  A range of drug prices could then be evaluated against a societal 
value threshold for cost effectiveness that considers the wealth of the nation (for 
example, less than three times the per capita GDP for a given country as recommended 
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by the World Health Organisation - Hillner and Smith, 2009; Murray, 2000; Sarin, 2008).  
Such information may then be used by national governments or formulary committees 
to negotiate a drug price for their patient population that is based on overall value. 
 In this study, the development of a value based pricing index that can be applied to 
new targeted therapies indicated for the treatment of metastatic colorectal cancer 
(mCRC) in described.  Colorectal cancer was chosen because it is the second most 
common cause of cancer death worldwide and it is a site where several new high cost 
drugs have been approved for clinical use in many countries around the world (NCIC 
2010; Engstrom, 2008). 
 
1.5  Primary aim and objectives 
Economic efficiency refers to the use of resources so as to maximize the production 
of goods and services.  For pharmaceuticals, pharmacoeconomics is applied to 
measure the economic efficiency of two or more drugs indicated for the same medical 
condition (Drummond et al, 2005). Cost-effectiveness analysis (CEA) is a form of 
economic analysis that compares the relative costs and outcomes (effects) of two or 
more courses of action.  A related concept is economic value.  With respect to 
pharmaceutical, a drug is said to provide economic value if it avoids downstream direct 
health care costs or indirect patient related resources (Kolassa, 2009).  Therefore, a 
drug is considered to be cost effective if it avoids down stream direct or direct health 
care resources. 
In this study, pharmacoeconomic (PE) modeling techniques along with cost and 
utility data collected in Canada, Spain, South Africa, Malaysia and India were used to 
develop an index for determining a cost effective price for new agents in mCRC.  The 
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index could then be used to estimate appropriate drugs prices based on societal value 
thresholds, the survival benefit offered by a new drug, income dispersion as measured 
by the Gini coefficient (De Maio, 2007) and the country specific per capita GDP. 
The specific objectives of the study were to: 
 Estimate societal utilities for improvements in mCRC related health outcomes in 
the five reference countries. 
 Develop a PE model that could be used to estimate an optimal drug price for the 
treatment of mCRC in the five reference countries. 
 From the data generated in the five reference countries, develop a pricing index 
for estimating an optimal drug price based on societal value thresholds, the 
survival benefit offered by the drug, income dispersion within a country and per 
capita GDP. 
 
1.6 Overview of objectives 
 The first main objective of this research described in section 1.5 was addressed 
through the collection of cost and utility data from the five reference countries.  These 
data were used to populate the PE model that simulated the treatment of patients with 
mCRC.  Therefore, the second objective was met through the PE model that was made 
specific to each country.  With the PE model, price points that were based on societal 
value thresholds were generated for each country.  With the estimated price points, a 
pricing index was then developed through the application of multivariate regression 
analysis.  To fulfill the third objective of the study, the final pricing index is able to 
estimate a drug price based on the survival benefit offered by the drug, income 
dispersion within a country and per capita GDP.  
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 The thesis contains five articles that were recently published in peer reviewed 
journals.  Two additional articles have been accepted for publication and are currently in 
press (see page 56 of the thesis).  Articles two to six are the country specific 
publications for Canada, India, Spain, South African and Malaysia.  It is within these five 
articles that objectives one and two have been addressed.  The third and final objective 
has been fulfilled in the seventh publication, which describes how the global pricing 
index was developed and how it can be applied.  There is also an editorial to the 
seventh publication, which describes the utility of the pricing index. 
 
1.7  Research Hypothesis 
 
Countries with a lower per capita GDP and lower income dispersions are likely to 
have a lower predicted launch price for a new drug and the estimated price would be 
proportional to overall survival benefit over the current standard of care. 
 
1.8  Conclusions 
 What would be useful to all the key stakeholders would be the development of a drug 
pricing index that is linked to product performance, economic value as measured by the 
cost per QALY gained, a country’s GDP and income dispersion within a nation.  In this 
study, the development of such an index that can be applied to new therapies indicated 
for the treatment of metastatic colorectal cancer (mCRC) is described.  The final index 
is transparent, easy to apply and uses information that is readily available to all drug 
formulary committees.  In the next chapter, the clinical and PE literature for the key 
targeted agents is reviewed.  This is followed by a review of the health policy issues that 
have been created as a result of the high cost of these agents. 
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CHAPTER 2 
CANCER THE DISEASE 
 
2.1  Introduction 
 Cancer remains a leading cause of death worldwide.  As the population ages, the 
problem of quality patient care will become more acute.  This chapter provides a 
descriptive overview of the many aspects of cancer.  It begins with a discussion of the 
known causes and how patients are staged upon diagnosis.  Cancer epidemiology in 
terms of new cases and trends in overall survival over time is then presented.  The 
chapter continues with a discussion of the burden of illness in terms of costs to society.  
The chapter closes with a presentation of the current concepts of cancer care. 
 
 
2.2  Disease characteristics 
 Cancer is a group of diseases that are characterised by uncontrolled cell growth, 
invasion into adjacent tissues and sometimes spread to distant parts of the body 
(Kinzler et al., 2002).   It is these three properties of cancer cells that distinguish them 
from benign tumours which do not tend to spread to distant sites.  All cancers contain 
many DNA mutations that impact cell growth and contribute to distant spread.  
Substances that cause DNA mutations are known as mutagens, and mutagens that 
cause cancer are known as carcinogens (Devita et al., 2001).  There are many causes 
of cancer ranging from internal factors such as genetic predispositions to external 
factors such as tobacco, chemical agents such as asbestos, infectious pathogens and 
exposure to radiation (Sasco et al., 2004, Biesalski et al., 1998).  As an illustration, 
tobacco has been implicated as the major cause of approximately 90% of human lung 
cancers (Cancer WHO, 2008). 
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 The three main forms of cancer are based on the types of cells that are affected. 
Solid tumours, are derived from epithelial cells and represent the most common cancers 
such as lung, breast and colorectal (Surveillance Epidemiology and End Results, 2010).  
In contrast, sarcomas are malignancies derived from connective tissue while 
lymphomas, leukemias and myeloma originate from hematopoietic cells. 
 Upon diagnosis, cancer patients with solid tumours and lymphomas are staged 
according to the degree of tumour spread (from Stage I to IV).  Descriptively, tumours 
are staged as follows (Devita, 2001): 
• Stage I cancers are localised to one part of the body. 
• Stage II cancers are locally advanced. 
• Stage III cancers are also locally advanced. Whether a cancer is designated as 
Stage II or Stage III depends on type of cancer; for example, in lymphoma, Stage II 
indicates affected lymph nodes on only one side of the diaphragm, whereas Stage III 
indicates affected lymph nodes above and below the diaphragm. The specific criteria 
for Stages II and III therefore differ according to diagnosis. 
• Stage IV cancers have often metastasized to other organs or throughout the body. 
 
2.3  Cancer epidemiology 
 Cancer is a global issue with 7.4 million deaths per year, which is approximately 13% 
of all cause mortality (Cancer WHO, 2008).  The incidence of cancer has also been on 
the rise for several reasons such as an aging population (Kinsella, 2009).  It has been 
estimated that in the United States alone, 60% of all new cancers occur in people over 
the age of 65 years (Surveillance Epidemiology and End Results, 2010).  Similar trends 
have also been identified in Europe in both men and women (Figure 2.1). 
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Figure 2.1 Number of new cases and age specific rates per 100,000 of the population, 
2000 European estimates (source – Cancer Trends. Cancer Research UK, 1999). 
 
 The disease is now considered to be a chronic condition because some patients with 
advanced stage cancer receiving effective treatment can live for five to ten  years after 
the initial diagnosis (Surveillance Epidemiology and End Results 2010, National Cancer 
Institute of Canada 2010).  In addition, the overall rate of cancer mortality has been 
steadily decreasing.  In one study, Wilking and Jonsson (2005) estimated the expected 
increases in the number of new diagnoses and cancer-related mortality in 25 European 
countries from 2002 to 2006 (see Table 2.1).  These investigators identified a 10% 
increase in the number of new diagnoses over the four year period.   Encouragingly, 
there was stability in the number of deaths over the same time period.  Similar findings 
have also been reported by the Surveillance Epidemiology and End Results (SEER) of 
the United States (SEER, 2010). 
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Table 2.1. Number of new cancer cases and deaths:  2002 to 2006 (Stark, 2009) 
EU25+CH+IS+NO Events 1 2002 2006 Change 
All cancers except 
skin 
 
Breast 
 
 
Colorectal 
 
 
Lung female 
 
 
Lung male 
 
 
Prostate 
 
 
Stomach 
 
 
Uterus 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
 
No of cases 
No of Deaths 
2,138,700 
1,188,100 
 
277,300 
89,900 
 
283,600 
142,400 
 
60,500 
54,300 
 
199,900 
182,100 
 
201,700 
69,300 
 
92,200 
70,200 
 
85,900 
26,700 
2,351,100 
1,192,500 
 
328,600 
87,200 
 
307,000 
142,700 
 
73,500 
65,800 
 
198,100 
175,200 
 
311,100 
70,300 
 
81,600 
58,400 
 
84,900 
24,200 
9.93% 
0.37% 
 
18.51% 
-2.97% 
 
8.27% 
0.20% 
 
21.46% 
21.11% 
 
-0.86% 
-3.80% 
 
54.25% 
1.48% 
 
-11.46% 
-16.76% 
 
-1.17% 
-9.49% 
 
1
 
Abbreviations:  EU25  = 25 European countries, CH = Switzerland, IS = Iceland, NO = Norway 
2.4  The social burden of cancer 
The economic burden of a disease represents all aspects in the personal cost of the 
illness.  The cost to the patient may be financial, social, psychological or personal loss 
to self, family, or community.  These latter costs are best reflected in lost quality of life 
related to the illness (Drummond et al, 2005).  The societal burden may be reflected in 
absenteeism, productivity losses and the direct financial cost of providing services 
related to the delivery of health care, rather than personal impact on the individual.  
The social burden of cancer consists of both direct and indirect costs of care.  Direct 
costs are the resources used to prevent and treat the disease and can be represented 
by the proportion of a nation’s total health care budget that is allocated for cancer.  The 
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average for 28 European countries in 2004 was 6.4% of total health care expenditures, 
which ranged from 3% to 7.2% (Wilking and Jonsson, 2005; Stark, 2009).  For the 19 
European countries covered by Organization for European Cooperation and 
Development (OECD), total annual expenditures were €147 billion in 2007 or €1148 per 
person (Stark, 2009).  Similarly in the United States, absolute cancer related 
expenditures rose from $1.3 billion in 1963 to $72.1 billion in 2007 (Cancer Trends, 
2007).   
 Indirect costs represent the resources lost as a result of an illness, and primarily 
consist of lost productivity due to absence from work and permanent disability or death 
from the disease before the age of 65 years (Drummond et al., 2005, Canadian 
Guidelines, 2006).  There are several ways that the indirect costs of cancer can be 
expressed.  The Canadian Cancer Society reports such outcomes as the potential years 
of life lost (PYLL) due to cancer.  For the year 2003, the Canadian Cancer Society 
estimated that there were approximately 1 million PYLL or one PYLL for every 33 
people (NCIC, 2010).  When this was compared to PYLL from all other causes of death 
(both disease and non-disease related), cancer deaths represented approximately 32% 
of the total burden of illness, even surpassing that of heart disease (National Cancer 
Institute of Canada, 2010). 
 One of the limitations of expressing indirect costs in terms of PYLL is that it does not 
consider disease-related morbidity.  Disability adjusted life years (DALYs) is an 
economic measure that considers both mortality and disability associated with the 
condition in question (Havelaar et al., 2009).  DALYs are calculated by taking the sum of 
life years lost due to illness and the number of years lived with disability.  Using the 
DALY approach, cancer was responsible for 16.7% of all DALYs lost in 25 European 
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countries and 12.5% of all DALYs lost in United States and Canada (Wilking and 
Jonsson, 2005, 2007). 
 
  In Europe alone, cancer at 9.8 million DALYs lost ranked third 
after mental illness and cardiovascular disease (Wilking and Jonsson, 2007).  In 
summary, cancer represents a substantial burden on society, both in terms of direct and 
indirect costs.  The burden will increase as the number of new cases increase, which is 
the trend seen in many countries today.  However comparing total health care 
expenditures that are allocated to the treatment of cancer to the number of DALYs lost 
(that is, 6.4% versus 16.7% of all DALYs lost), cancer care would appear to be under 
funded. 
2.5  Current concepts of care 
 Upon diagnosis, cancer patients with solid tumours are staged according to the 
degree of tumour spread (from Stage I to IV).  The intent of treating patients with Stage I 
to III disease is clinical cure.  Patients with early stage disease (typically Stage I to III) 
are initially treated surgically with or without radiation.  This is often followed by adjuvant 
chemotherapy which is intended to eradicate any remaining tumour cells.  Patients who 
are diagnosed with advanced disease (Stage IV) usually do not undergo a major 
surgical intervention.  Instead, they would typically be offered palliative chemotherapy, 
radiation therapy or hormonal therapy if indicated (Devita et al., 2001).  Advanced stage 
disease is usually terminal and the intent of treatment is to increase survival, the 
palliation of disease-related symptoms and improvement in patient quality of life. 
 The selection of treatments for advanced stage cancer is guided by patient and 
disease related factors (Table 2.2).  Patient factors that are critical in the selection of 
therapy include patient age, performance status and the presence of comorbidities.  
Important disease related factors that guide medical decision making in the advanced 
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setting consist of the duration of the disease-free interval following adjuvant anticancer 
therapy, drugs previously used during early stage disease, response to these previous 
therapies, tumour burden and the presence of life threatening metastases (Cardoso et 
al, 2010).  Once a decision for systemic therapy is made, there are several options 
available to the patient.  These consist of chemotherapy, endocrine therapy, the newer 
targeted agents, radiation therapy and supportive care drugs to prevent and treat the 
common drug toxicities.  These interventions may be used alone or in combination.  The 
initial systemic therapy is continued until the patient experiences disease progression 
(Devita et al., 2001).  Following an initial disease progression, it is not uncommon to 
offer multiple lines of therapy until the patient is no longer responding to treatment.  
Once all pharmacotherapeutic options are exhausted, patients are offered palliative 
care (Cardoso et al., 2010).  Palliative care consists of radiation for bone pain, blood 
transfusions, analgesics for pain control, home care assistance and a possible 
admission into a hospice for end of life support (Zafar et al., 2010). 
 
Table 2.2.  Factors associated with treatment decisions in advanced stage cancer  
Patient Factors  Disease Factors 
Patient age and performance status 
 
Treatment objectives 
 
Existing comorbidities 
 
Socioeconomic factors 
 
Treatment availability 
Recurrence free survival interval 
 
Previous anticancer therapies 
 
Response to previous therapies 
 
Number and sites of metastases 
 
Need for rapid disease control 
 
From (Cardoso et al, 2010). 
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2.6   Conclusions 
 The past ten years has been witness to major changes in the management of 
cancer.  In the prior decade, the approach to chemotherapy was a “one size fits all” 
approach where the same regimens would be offered to all patients (Mahalingam, 
2009).  However, an increased understanding of cancer has led to the determination 
that it is not homogenous, but a heterogeneous disease with responses to therapy 
being influenced by the presence of important prognostic factors and associated 
biomarkers.  Coupled with advances in biotechnology, several new and important 
anticancer therapies have become available or are in clinical development (Alvarez et 
al., 2010).  Therefore, this will mean that overall patient survival and quality of life 
should continue to increase as we enter the new decade. 
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CHAPTER 3 
OVERVIEW OF THE CLINICAL, ECONOMIC AND HEALTH POLICY LITERATURE 
 
3.1  Introduction 
 Before the development of a value based pricing model is begun, the clinical, 
economic and health policy literature relevant to the newer targeted anticancer drugs 
needs to be reviewed.  This literature capture is composed of two parts.  The first part of 
this chapter reviews the clinical and PE data associated with key targeted agents.  
Agent selection was based on the impact that these drugs had on the management of 
their selected diseases and the magnitude of the health policy issues that they raised 
because of their high prices.  The agents selected for review consisted of rituximab, 
imatinib, trastuzumab, bevacizumab and cetuximab.  While other commonly used 
targeted agents such as erlotinib, sorafenib and sunitinib are also important targeted 
therapies, they were not included in the literature review because the intent was to 
provide only a “snap shot” of selected high profile agents rather than a comprehensive 
review.  Furthermore, bevacizumab and cetuximab are two agents that are currently 
used in mCRC, which is the selected disease site for developing the value based pricing 
index in the current study. 
 In the second part of the chapter, the health policy literature related to the high 
priced cancer drugs was reviewed.  This also included an overview of how health care 
systems around the world have responded to the challenges created by these high 
prices agents.  These two sections were subsequently used to prepare a review article 
that was recently published in Pharmacoeconomics (Dranitsaris et al., 2011)  The 
article, which is presented below, will provide the core text for this chapter. 
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Abstract Globally, there are approximately 7.4 million cancer deaths annually,
approximately 13% of deaths from all causes. Cancer is a disease of older
people and, as the population ages over the next 10–20 years, we can expect
an increase in the cancer incidence. Encouragingly, cancer mortality has
stabilized in many countries. Part of this success may be attributed to the
development of new cancer agents, collectively called ‘targeted therapies’,
that are more specific to key components of tumour growth. Worldwide,
however, one of the main factors that limit patient access to these important
new drugs is their cost, which is higher than traditional chemotherapy. In this
review, the clinical and pharmacoeconomic data of selected targeted agents
are discussed. In the second part of this article, the challenges faced by
healthcare systems in making such drugs available to patients is reviewed.
Current strategies used by many countries around the world to manage
cancer drug budgets are presented, along with a proposed approach using
pharmacoeconomic methodology that may increase patient access.
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Globally, there are approximately 7.4 million
cancer deaths per year, which is approximately
13% of deaths from all causes.[1] Since the popu-
lation of many countries around the world is
aging, it can be expected that cancer incidence
will increase.[2] This is of concern to healthcare
authorities because cancer is a disease that usually
occurs later in life. It has been estimated that, in the
US alone, 60% of all new cancers occur in people
aged >65 years.[3] Cancer is now often considered to
be a chronic condition because some patients with
advanced stage disease can live for 5–10 years after
the initial diagnosis, with effective treatment.[3,4]
From the perspective of cancer care policy, these
factors are causing increases in the burden of care.
Pharmacotherapy consisting of chemotherapy
and hormonal agents has a central role in the
management of cancer. For many years, the back-
bone of cancer treatment has been the use of cy-
totoxic agents such as anthracylines, taxanes and
platinum analogues. One characteristic of tradi-
tional chemotherapy is its non-specificity to the
target. As a result, adverse effects such as neutro-
penia, anaemia and thrombocytopenia are com-
mon.[5] However, over the past decade, there
has been an emergence of new anticancer drugs
that are more specific to their cancer target.[6,7]
These new compounds are collectively known
as ‘targeted therapies’. Unlike traditional chemo-
therapy, which can affect both healthy and ma-
lignant cells, targeted agents are specific to the
latter. Therefore, they tend to be better tolerated
than chemotherapy and the adverse effects are
less common.[8] One defining feature of these new
targeted therapies is that their cost is higher than
established chemotherapy.[9] Patient access to these
new drugs has been less than optimal as health-
care systems struggle to manage their pharmacy
budgets to make them available.[10] The first part
of this article reviews the clinical and pharmaco-
economic data associated with key targeted
agents. Agent selection was based on the impact
that these drugs had on the management of their
selected diseases and the magnitude of the health
policy issues that they raised. In the second part of
the article, the challenges faced by many countries
around the world with respect to health policy and
patient access to such drugs is discussed. An ap-
proach using pharmacoeconomic methodology
that may increase patient access is then presented.
1. Literature Review
Two independent literature searches were
conducted on PubMed, EMBASE, the Cochrane
Database and Google Scholar for the years
January 1995 to January 2010. The first focused
on identifying the clinical and pharmacoeconomic
data associated with a selection of targeted ther-
apies currently in clinical use. The agents selected
for review were rituximab, imatinib, trastuzumab,
bevacizumab and cetuximab because these are
high-cost targeted therapies that have faced bar-
riers to reimbursement by government payers
in many countries. While other commonly used
targeted agents such as erlotinib, sorafenib and
sunitinib are also important targeted therapies,
they were not included in the review because our
intent was to provide only a ‘snap shot’ of selected
high-profile agents rather than a comprehensive
review. For each drug, search terms consisted of
‘randomized controlled trial’ OR ‘cost analysis’ OR
‘economic evaluation’. The second literature search
focused on the cancer drug policy and patient access
issues. Search parameters consisted of ‘cancer’ AND
‘targeted therapies’ AND ‘health policy’OR ‘patient
access’. International media reports covering cancer
drug pricing issues were also reviewed. Over 100 ci-
tations were identified and 74 papers/reports related
to the selected cancer drugs or to global issues
associated with drug cost and patient access.
Over the past 10 years, there have been impor-
tant advances in cancer therapeutics character-
ized by agents that target specific components of
cancer cell growth. As indicated earlier, these com-
pounds include, but are not limited to, rituximab,
imatinib, trastuzumab, bevacizumab and cetux-
imab and are collectively known as ‘targeted ther-
apies’. The information in sections 2–6 presents
some of the important clinical and economic
findings associated with these agents.
2. Rituximab
Rituximab, a monoclonal antibody, was the
first targeted therapy approved in many countries
Dranitsaris et al.
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for clinical use in patients with haematological
neoplasms such as lymphoma and certain types
of leukaemia.[11] The target for this agent is the
protein CD20, which is primarily found on the sur-
face of B-lymphocytes associated with the above
cancers.[11,12] The first major patient group that
benefited from the addition of rituximab to standard
chemotherapy was elderly patients with diffuse
large-cell lymphoma.[12] In the pivotal study where
rituximab was added to CHOP (cyclophos-
phamide, doxorubicin, vincristine and prednisone)
chemotherapy (CHOP-rituximab [CHOP-R]),
median overall survival was significantly improved
(3.1 vs >5 years; p= 0.0073).[13,14]
Being the first targeted agent approved for clin-
ical use, rituximab has been the subject of many
pharmacoeconomic evaluations for various indica-
tions.[15-17] In one study from the French health-
care payer perspective, Best et al.[15] evaluated the
cost effectiveness of CHOP-R versus CHOP alone
in patients with diffuse large B-cell lymphoma.
Total direct medical costs were estimated to be
h13 170 higher with CHOP-R. However, when
the overall survival benefit was incorporated into
the analysis, the incremental cost-effectiveness ratio
(ICER) was h12 259 or $US16 500 per QALY
gained. The investigators concluded that the ad-
dition of rituximab was cost effective relative to
other agents used in oncology.[15] Similar conclu-
sions were also reported by other groups evalu-
ating rituximab in some of the other approved
cancer indications.[16,17]
3. Imatinib
Imatinib was the second targeted agent to be
approved for clinical use worldwide. The two main
disease sites for imatinib are chronic myelogenous
leukaemia (CML) and gastrointestinal stromal
tumours (GISTs).[18,19] The targets for imatinib
are a number of tyrosine kinase enzymes, among
which are ABL (the Abelson proto-oncogene),
C-KIT and PDGF-R (platelet-derived growth fac-
tor receptor).[18,19] In the case of CML, imatinib
works by binding to the ATP-binding site of the
(BCR)-Abelson (ABL) fusion protein that results
from the chromosomal abnormality known as
the Philadelphia chromosome.[18] Clinical trials
have demonstrated that imatinib is effective in
both GIST and CML. In newly diagnosed CML
patients, imatinib has demonstrated complete
cytogenetic response rates of more than 80%.[18]
For the treatment of advanced GIST, median
overall survival was reported to be 55 months,
compared with <12 months before the avail-
ability of imatinib.[19,20] Drug approval was rap-
idly received in the US in May of 2001 based on
phase II data alone.[21] Given the impressive clin-
ical trial results for imatinib relative to previous
treatments in both disease sites, the pharmaco-
economics studies suggested that imatinib was
cost effective. The costs per QALY gained were
less than $US50 000 for the treatment of both
CML and advanced GIST from the healthcare
system perspective.[22-24]
4. Trastuzumab
Breast cancer patients with human epidermal
growth factor receptor (HER)-2-positive tumours
benefit from the targeted agent trastuzumab, a
humanized monoclonal antibody directed against
the extracellular domain of HER-2.[25] In the first
randomized trial evaluating patients with meta-
static breast cancer, trastuzumab combined with
chemotherapy significantly prolonged both pro-
gression-free survival and overall survival when
compared with chemotherapy alone.[26,27]
The evaluation of trastuzumab was then extend-
ed to patients with early-stage HER-2-positive
breast cancer. Several large randomized trials have
demonstrated that 1 year of trastuzumab after ad-
juvant chemotherapy in HER-2-positive patients
was associated with a 50% relative reduction in the
risk of disease recurrence.[28] After 2 years of follow-
up, these findings have also translated into an in-
cremental survival benefit of 2.7% (92.4% vs 89.7%)
in favour of patients who received trastuzumab
compared with those who received chemotherapy
alone (hazard ratio [HR]= 0.66; p= 0.0115).[29]
The economic value of trastuzumab has been
widely studied, particularly when used in the treat-
ment of early-stage HER-2-positive breast can-
cer. Skedgel et al.[30] recently determined that the
incremental cost per QALY gained with 1 years’
treatment with trastuzumab was $Can72 292 and
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$Can127 862 under a 5- and 3-year time horizon.
The base-case findings were influenced by the
magnitude and duration of carryover benefit as-
sociated with the drug ($Can1= $US1 as at May
2010). In contrast, other evaluations have reported
more favourable ICERs under most of the sce-
narios evaluated, with a range of $US5020–
134 610 per QALY gained, but most were below
the $US50 000 threshold.[31,32] The cause of this
uncertainty could be related to the modelling
assumptions used for the overall duration of
benefit.
5. Bevacizumab
Blood vessels grow rapidly during tumour
growth; a process known as angiogenesis. Vascular
endothelial growth factor (VEGF) is a chemical
signal that stimulates angiogenesis.[33] As a result,
it represents a tempting target for anticancer ther-
apy. Bevacizumab is a humanizedmonoclonal anti-
body, and the first commercially available direct
angiogenesis inhibitor. It hinders tumour growth
by preventing the formation of new blood vessels by
targeting and inhibiting the function of VEGF.[34]
The first patient population in which bev-
acizumab was tested consisted of previously un-
treated patients with advanced-stage colorectal
cancer (CRC).[35] In that first trial, 813 patients
were randomized to receive chemotherapy con-
sisting of irinotecan, bolus fluorouracil and leu-
covorin (IFL) with or without bevacizumab until
disease progression. The median duration of sur-
vival was 20.3 months in the IFL+bevacizumab
group compared with 15.6 months in the control
(HR = 0.66; p< 0.001). Since the publication of
the first trial, bevacizumab has shown benefit in
combination with second-line chemotherapy in
patients with advanced CRC.[36] The drug has
also been approved by the US FDA in patients
with advanced breast cancer, non-small-cell lung
cancer (NSCLC), kidney cancer and glioblastoma,
based on positive randomized trial results.[37-40]
The cost effectiveness of bevacizumab has been
evaluated in metastatic breast cancer and CRC.
Published pharmacoeconomic studies were not
identified for NSCLC, kidney cancer and glio-
blastoma. In the case of metastatic breast can-
cer, a modelling study conducted in Switzerland
reported that the addition of bevacizumab to
weekly paclitaxel for the treatment of metastatic
breast cancer resulted in an ICER of h189 427
(>$US250 000) per QALY gained versus pacli-
taxel alone.[41] Probabilistic sensitivity analysis
demonstrated that the willingness-to-pay thresh-
old of h60 000 was never reached. Similar con-
clusions were also derived when the economic
value of bevacizumab was investigated for the treat-
ment of metastatic CRC in England, Wales and
Japan, with cost-effectiveness ratios ranging from
$US91000 to $US118000 per QALY gained.[42,43]
6. Cetuximab
Cetuximab is a monoclonal antibody that binds
to the extracellular ligand-binding domain and
prevents epidermal growth factor receptor (EGFR)
activation.[44] The drug is active in combina-
tion with chemotherapy or as a single agent in
several populations, including advanced CRC,
head and neck cancer, and NSCLCs.[45,46] Most
recently, the drug was also found to be primarily
effective in a subgroup of patients with metastatic
CRC, namely those who have KRAS wild-type
tumours.[47,48]
A review of the economic literature found a
limited number of published pharmacoeconomic
studies regarding cetuximab. The National Can-
cer Institute of Canada Clinical Trials Group
(NCICCTG) recently reported the results of a
prospective economic evaluation of cetuximab
versus best supportive care in patients with chemo-
therapy-resistant metastatic CRC who were en-
rolled in a randomized trial.[49] Healthcare resources
collected during the trial included all medication,
physician visits, adverse effects management, the
use of blood products, emergency department visits
and hospitalizations. The investigators determined
that the incremental cost per QALY gained with
cetuximab was approximately $Can300000. When
the analysis was confined to patients with wild-
type KRAS tumours, the ICER was reduced to
$Can186 761 per QALY gained, suggesting im-
proved economic value. TheNCICCTG concluded
that the ICER of cetuximab for this indication was
high and sensitive to drug cost.[49]
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Other economic evaluations have also drawn
the same conclusions about cetuximab when com-
bined with chemotherapy in metastatic CRC.[50]
However, such conclusions cannot be generalized
to other tumour types. A recent economic anal-
ysis[51] compared radiotherapy with or without
cetuximab in locally advanced head and neck can-
cer. The study was conducted in Belgium, France,
Italy, Switzerland and theUKusing country-specific
costs-of-care data. From the base-case findings, the
incremental cost per QALY gained ranged from
h7538 to h10836 between the five countries.
7. Health Policy Issues in the Era of
Targeted Therapies
The new targeted agents have taken patient
care forward into an era of personalized medicine.
However, despite their effectiveness, improved
safety and cost effectiveness for some of the in-
dications, not all cancer patients have access to
them. One of the single biggest barriers to drug
access is their high acquisition cost. All of these
new targeted therapies have been priced at levels
that are several times higher than traditional
chemotherapy. In one editorial,[9] the cost of an
8-week course of chemotherapy for metastatic
CRC was estimated to be less than $US300 in the
mid-1990s. Ten years later, the costs for an 8-week
regimen containing bevacizumab or cetuximab
ranged from $US21000 to $US31000. These costs
would be prohibitively high for most patients
without good healthcare insurance. In countries
with socialized healthcare systems, such drugs
have either been rejected for reimbursement by
national healthcare agencies, or patient access
has been delayed or limited following initial reg-
ulatory approval.[10,52]
The challenge is that these incremental costs
have to be considered in context with gains in
overall survival and improvements in patient
quality of life (QOL). In the 1990s, when fluoro-
uracil plus leucovorin was the only active che-
motherapy regimen for metastatic CRC, median
overall survival did not exceed 6 months.[9] With
the emergence of agents such as bevacizumab and
cetuximab, overall survival in combination with
first-line fluorouracil-based chemotherapy has
now exceeded 20 months.[53,54] Formulary deci-
sion making can be further complicated given the
design of modern randomized trials. It is often
ethically mandated that patients in the control
group be allowed to crossover into the experi-
mental arm once a predefined clinical threshold
in terms of progression- or disease-free survival is
reached. A common impact of such crossover is
contamination of the assessment of overall sur-
vival, leading to non-statistically significant dif-
ferences. Therefore, the question of overall survival
benefit with new agents often remains unknown,
thereby complicating the associated economic
analysis.
Notwithstanding this, as a society we must
determine what we are willing to pay for ad-
vances in cancer care. This is one of the most
difficult questions for any national cancer pro-
gramme to address. There are a few countries,
such as the UK, that have stated what they are
willing to pay for a (quality-adjusted) life-year
gained.[55] However, many nations have been reluc-
tant to publicly state such a figure because of the ethi-
cal issue of placing a monetary value on human life.
Most developed countries spend 5–14% of
their GDP on healthcare. Governments and na-
tional advisory bodies need to determine a rea-
sonable amount that should be spent on cancer
care given the burden of illness. Wilking and
Jonsson[56] estimated that cancer accounts for 16.7%
of all disability-adjusted life-years (DALYs) lost,
with only mental health disorders and cardiovas-
cular disease surpassing it. Considering 19 European
countries, direct cancer-related expenditures were
responsible for only 6.4% of total healthcare
costs.[9] Cancer drugs were responsible for ap-
proximately 10% of total oncology healthcare
costs. In the US, resource allocation was some-
what lower, with 4.7% of the 2004 overall health-
care budget dedicated to cancer.[57] It was also
interesting to note that, in the US, absolute can-
cer-related expenditures rose from $US1.3 billion
in 1963 to $US72.1 billion in 2004. However, the
proportion dedicated to cancer remained be-
tween 4% and 6% over the 40-year period.[57]
Hence, there was a large absolute increase in
cancer expenditures, but relative costs remained
constant. Considering the total impact of the
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disease on society, there does appear to be an im-
balance in overall resource allocation for cancer.
A discrepancy in cancer spending relative to
the burden of disease is also suggested by the rate
of patient access to new cancer drugs. In their
review of drug access in Europe, Wilking and
Jonsson[52,56] determined that new cancer drugs
accounted for 51% of total drug sales from 1993
to 1998. However, from 1999 to 2004, new cancer
drugs accounted for only 17% of total drug sales,
a marked decrease from the previous 5-year period.
Increasing oncology drug costs are likely a major
contributor to the reduction in new drug uptake.
Between 1993 and 2004, total European sales for
oncology drugs increased from h840 million to
h6170 million.[56] Similar trends have also been
reported in the US, where cancer drug expendi-
tures increased from $US3 billion in 1997 to
$US11 billion in 2004.[57] It was also reported
that over 90% of FDA new cancer drug approvals
in the last 4 years have costs that exceed
$US20 000 for a 12-week course of therapy.[58]
Therefore, it is easy to see how the debate over
investment in cancer care can shift to drug cost
containment.
To address rising drug costs, countries have
responded in different ways, with the intention to
contain growth. The UK, Canada and Australia
have used cost effectiveness through agencies
such as the UK National Institute for Health
and Clinical Excellence (NICE), the Pan Cana-
dian Oncology Drug Review Program and the
Australian Pharmaceutical Benefits AdvisoryCom-
mittee as a mechanism to limit or deny drug
access.[57] Numerous other countries in Europe
also consider cost-effectiveness data to some de-
gree. In the US, where a national health tech-
nology agency to oversee new drugs does not
exist, drug access is sometimes rationed by the
creation of high patient co-payments in some
private drug plans.[59] Both systems can act as a
barrier to patient access from the time of reg-
ulatory approval. Therefore, the challenge for
national governments is to determine how much
of the healthcare budget to allocate for cancer,
what portion, if any, should be borne by the pa-
tient and what is the minimum value that should be
offered by a new cancer drug.
8. The Role of Pharmacoeconomics in
Oncology
What is evident over the past 20 years is an
increase in the number of cancer-related eco-
nomic evaluations and health technology assess-
ment (HTA) reports appearing in the medical lit-
erature.[56] Pharmacoeconomic evaluations are an
important component of the overall process of for-
mulary decision making.[55] However, they may
have an additional and perhaps more valuable
role in estimating or negotiating the cost of the
drug based on societal value thresholds. Pharmaco-
economics has been used in this role for a few
cancer drugs assessed by NICE for the English
NHS. NICE was able to secure price reductions
from manufacturers of erlotinib, lenalidomide and
sunitinib based on cost effectiveness.[60] How-
ever, what has not been extensively examined is
the estimation of drug price before a product re-
ceives regulatory approval.
There is one example in the cancer supportive
care literature where decision analysis modelling
was used to estimate drug cost before the product
was launched. In that study, Dranitsaris and
Leung[61] sought to estimate a unit cost of an or-
ally administered neurokinin (NK)-1 receptor an-
tagonist, a new class of drugs indicated for the
prevention of chemotherapy-related emesis. Clin-
ical data on emesis control were obtained from a
randomized phase II trial that evaluated emesis
rates following the addition of an investigational
NK-1 antiemetic (by mouth twice daily) for 5 days
to a control group (a single dose of granisetron
and dexamethasone before cisplatin-based chemo-
therapy). Costs were obtained from a Canadian
cancer centre, and health state utilities for the
various health outcomes associated with emesis
control were collected from a sample of oncology
nurses. The product had not been approved for
clinical use, so the investigators developed a deci-
sion analysis model to estimate a unit cost for the
drug using a predefined threshold of $Can20 000
per QALY gained as the measure of ‘good value
for money’.[62]
The findings suggested that the product would
have a cost per QALY gained at the $Can20 000
threshold if it were priced at $Can6.60 per dose,
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or $Can13.20 daily (year 2003 values).[61] In
hindsight, there are some important limitations
to this study. The threshold for economic value at
$Can20 000 per QALY gained is unrealistically
low in the current oncology setting. Furthermore,
it could be argued that value thresholds for sup-
portive care agents should be lower than for
drugs that improve survival because gains in life-
years tend to have a larger impact on the overall
cost per QALY calculation.
Nevertheless, the study did demonstrate that a
systematic process could be used to estimate a
reasonable range of prices before a product be-
comes commercially available. The advantages of
this technique are that it is relatively straightfor-
ward to perform, is transparent and the decision
model can be easily applied to other jurisdictions
such as lower income countries using local cost
data and thresholds for economic value. Such
information can be of value to both drug manu-
facturers and formulary committees because it
would facilitate negotiations for identifying an
optimal price for a given jurisdiction.
8.1 Defining Value
Value represents a composite measure of drug
utility consisting of clinical, economic and QOL-
related attributes. Although it is an imperfect
measure, the QALY as part of the ICER analysis
attempts to incorporate all three of these product
attributes into a single outcome. One of the major
challenges against the use of pharmacoeconomic
modelling for estimating a drug cost before pro-
duct launch is in establishing the threshold for
value within a given country. As an illustration,
the UK NICE has established a threshold for
drug coverage at d30 000 per QALY gained.[55] In
the Netherlands, the unofficial threshold is
h18 000 per QALY.[56] In many other jurisdic-
tions a $US50 000 cost per QALY threshold has
been used,[62] which was based on a 1982 valua-
tion and is now equivalent to approximately
$US197 000 per QALY in year 2007 values (after
a 5.5% annual adjustment in healthcare inflation).[63]
However, the $US50 000 threshold continues to
be used and quoted in the pharmacoeconomic
literature. One approach to address this dilemma
would be for formulary committees to establish
their own local thresholds for accepting new
drugs through a review of their national human
life valuation literature or through the use of fo-
cus groups involving the key stakeholders.
Notwithstanding this, a key problem in using
such thresholds is that the wealth of an individual
country is not taken into consideration. To ad-
dress this, the WHO has proposed to use multi-
ples of a country’s per capita GDP to establish
thresholds for economic value.[63-65] Products less
than or equal to the per capita GDP would be
considered very cost effective, one to three times
would be cost effective and more than three
times would be cost ineffective.[63] Using South
Africa as an illustration (i.e. per capita GDP =
$US10 000), the three-time threshold for cost ef-
fectiveness of new anticancer drugs would be
approximately $US30 000 per QALY gained.[66]
For a lower income country such as India (per
capital GDP = $US3000),[66] the cost per QALY
gained threshold would be $US9000. In contrast,
the threshold for economic value for a high-income
country such as Norway would be $US150 000
per QALY gained.[66] Therefore, the cost for the
same drug would be proportionally less in India,
higher in Norway and intermediate in South
Africa.
The use of thresholds based on per capita
GDP in combination with pharmacoeconomic
modelling to establish a value-based price for a
new drug is an intriguing approach and could set
the foundation for improving global patient ac-
cess because wealthier nations would be expected
to pay more for drugs and would subsequently
subsidize the developing world. However, this ap-
proach would only be applicable in countries that
have socialized healthcare systems and would
also depend on the manufacturer’s willingness to
launch their product in less developed countries.
9. Improving Patient Access to New
Cancer Drugs: Current and Future
Strategies
Over the last decade, the number of new can-
cer patients has continued to rise.[3,4] But more
encouragingly, the number of cancer-related deaths
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has stabilized over the same time period (table I).
At least part of this reduction in cancer-related
mortality has been attributed to new cancer drugs
such as the ones described in this review.[14,20,28]
The initial success of these targeted therapies will
ensure the continued development and approval
of more such agents. Therefore, the combination
of more patients alive with cancer and more new
cancer drug approvals will continue to elevate
total drug expenditures.
Rising drug costs should also be of concern to
the pharmaceutical industry and other key stake-
holders because they are easily identifiable by
government agencies with a mandate to reduce
costs. Governments may mandate price controls
on the pharmaceutical industry in order to con-
tain drug expenditures. This has recently been the
case in Europe. At the time of writing of this article,
Greece and Spain have mandated price cuts of up
to 23% for branded products.[68,69] The German
Government has followed a similar example,
where healthcare plans will now be allowed to
negotiate a discounted price for the product after
the first year.[70] As part of the new law, discounts
of up to 16%will take effect, as will a ban on price
increases for branded products. The final nego-
tiated discounted price will be based on the ben-
efits offered by the product. Therefore, the intent
is to make economic evaluations an integral part
of price negotiations with manufacturers.[70]
These developments were foreseen by Dr Steve
Harr, a Morgan Stanley research analyst who
warned the pharmaceutical industry in 2005 that
excessive drug costs could be bad for business
because they could trigger government controls,
hurting the industry in the long term.[71] Dr Harr
stated that ‘‘soaring cancer-drug prices, generat-
ing fat profit margins, aren’t sustainable.’’[71]
Some large pharmaceutical companies did heed
Dr Harr’s advice and have implemented price
caps and patient assistance programmes for some
products in order to avoid price controls. As a
recent example, AstraZeneca fixed the UK price
of gefitinib at d12200, irrespective of the duration
of treatment, and there will be no charge for pa-
tients who are treated for less than 3 months.[72]
In addition to price cap programmes that limit
drug expenditures and improve access, risk-
sharing partnerships between the pharmaceutical
industry and national healthcare systems may
also improve patient access to innovative new
treatments.[73] However, such agreements need
careful planning before implementation. In a re-
cent article by Towse and Garrison,[74] key fac-
tors associated with the success of risk-sharing
agreements were discussed. For risk-sharing agree-
ments to become more prevalent with high-cost
pharmaceuticals, a workable process for collecting
post-launch effectiveness data must be developed
and adequately funded, and a binding contract
between the payer and the pharmaceutical com-
pany must be created to address issues such as
drug price adjustments and rebates following
the availability of new post-launch evidence.
Towse and Garrison[74] indicated that risk-sharing
Table I. Number of new cases and deaths in selected cancers
2002–6 (adapted from Stark,[67] with permission)
EU25 +CH+ IS +NO and
events
2002 (n) 2006 (n) Change
(%)
All cancers except skin
Cases 2138 700 2351 100 9.93
Deaths 1 188 100 1192 500 0.37
Breast
Cases 277300 328 600 18.51
Deaths 89 900 87200 -2.97
Colorectal
Cases 283600 307 000 8.27
Deaths 142 400 142 700 0.20
Lung female
Cases 60 500 73500 21.46
Deaths 54 300 65800 21.11
Lung male
Cases 199900 198 100 -0.86
Deaths 182 100 175 200 -3.80
Prostate
Cases 201700 311 100 54.25
Deaths 69 300 70300 1.48
Stomach
Cases 92 200 81600 -11.46
Deaths 70 200 58400 -16.76
Uterus
Cases 85 900 84900 -1.17
Deaths 26 700 24200 -9.49
CH=Switzerland; EU25 =25 European countries; IS = Iceland;
NO =Norway.
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partnerships are, in principle, attractive options
that may increase patient access to new drugs and
help contain costs. However, until more evidence
is collected from the current programmes, it will
be difficult to determine if they will represent a
real solution to challenges in drug access.
A final approach that may help contain costs,
enhance outcomes and facilitate the appropriate
access of cancer drugs is better patient selection.
For example, the therapeutic benefit of cetux-
imab appears to be limited to CRC patients with
KRAS wild-type tumours, which make up ap-
proximately 60% of the CRC population.[47,48]
Limiting cetuximab to KRAS wild-type tumours
will help contain costs and ensure that the drug is
being used in those patient subgroups where the
economic value is optimized.
Notwithstanding this, improved drug access
should not be limited to patients in wealthy na-
tions but rather a goal that is extended to all so-
cieties globally. There is an obvious concern that
new targeted therapies are beyond the financial
means of patients in the developing world. One
approach that could address this need would be
to use the pharmacoeconomic modelling tech-
niques described earlier along with the value
thresholds proposed by the WHO (i.e. less than
three times the per capita GDP) to estimate a
value-based drug price for lower income coun-
tries prior to its introduction. The pharmaceuti-
cal manufacturer would then launch at the lower
price on the strict and enforceable condition that
the drug will not be exported to a wealthier na-
tion (i.e. the phenomenon know as parallel trade)
by an intermediary for the intention of profit
making. For instance, parallel trade could be ad-
dressed through a centralized single-source drug
distribution process, along with a preauthorized
list of prescribers.
Reducing drug prices to lower levels would
improve patient access in less developed coun-
tries. However, central to the pricing debate and
the issue of increased access is the matter of com-
mercial viability based on themanufacturer’s cost
of goods and operational overhead expense. It is
unclear whether manufacturers would realize
greater short-term benefit from a scenario in
which the drug is sold at a high price to a few
people, versus one where the drug is sold at a
lower cost but to a much larger group of people.
However, in the long term, it seems likely that
pharmaceutical manufacturers will have to adapt
their business models to better address the unmet
needs of developing countries where high-
volume, low-price therapies will predominate.
10. Conclusions
The new targeted therapies have contributed
to an important advance in cancer care. How-
ever, the high costs of these drugs are limiting
patient access in many parts of the world. There-
fore, a new paradigm needs to be developed in
collaboration with all of the key stakeholders.
The new system must reward drug innovation,
enhance global patient access and, above all, be
sustainable. The application of pharmacoeconomic
modelling techniques in combination with value
thresholds based on the wealth of a nation is one
approach that may contribute to enhanced pa-
tient access.
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3.2    International drug pricing issues 
 NICE of the UK has taken a leading role in indirect price negotiations with 
drug manufacturers.  NICE has been very active in the development of patient 
access schemes that have effectively resulted in price reductions, while leaving the 
list price untouched.  As an illustration, AstraZeneca fixed the price of gefitinib at 
12,200 GBP, irrespective of the duration of treatment, and there will be no charge for 
patients who are treated for less than three months (NICE, 2010).  From the 
manufacturer’s point of view, retaining the list price of a drug has important 
implications across Europe. 
 In the pharmaceutical industry, parallel trade occurs when drug prices are 
highly variable between countries because of price regulation.  In these situations, a 
wholesaler in a lower price country would be able to achieve a better price by selling 
the product “in a high-price country” rather than on the domestic market of the 
original country.  As an illustration, prices of branded drugs in Greece tend to be the 
lowest in the European Union.  Therefore, a wholesaler in Greece would be able to 
buy a drug at a lower price and then sell it at a substantial profit in Germany, where 
drug prices tend to be the higher (Arfwedson, 2004).  Parallel trade is of concern to 
the pharmaceutical industry because it can have a major effect on profits.  But more 
importantly, parallel trade also undermines intellectual property and can act as a 
disincentive for investment in research and development.  The consequences of 
parallel trade could hurt patients in the long term because it curtails innovation.  
Therefore, the pharmaceutical industry strives to maintain comparable drug prices 
across Europe.  As a result, the patient access schemes negotiated by NICE on 
behalf of the National Health Services do not affect the list price of the drug. 
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 The third factor that could have an impact on global drug prices is the 
Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS).  This 
is an international agreement that establishes minimum standards for all forms of 
intellectual property, including pharmaceuticals.  TRIPS requires member states to 
provide strong protection for intellectual property rights (WHO, 2000).  However, 
disagreements can develop.  The most prominent conflict in the case of 
pharmaceuticals has been with the selling of AIDS drugs in Africa at prices 
comparable to Western countries.  African governments would not afford to pay 
higher prices and this led to an international outcry by patient advocacy groups.  
Eventually, there was a loosening of the agreement which allowed countries to 
export life-saving drugs to developing countries at a lower cost in times of a national 
health care crisis.  Alternatively, TRIPS allows the government of the country in need 
to issue a compulsory license, which would enable local production of the patented 
drug (Shashikant, 2005).  This has already occurred with some AIDS drugs and may 
be extended to cancer products is the launch prices are deemed excessive by a 
national government. Therefore, the pharmaceutical industry needs to exercise care 
in establishing the launch price in a less developed country.  Early dialogue under 
the framework of a “fair” and “affordable” price is encouraged to avoid local 
manufacturing of a new and clinically important cancer drug. 
 
3.3  Conclusions 
 The literature review provided evidence to support the clinical use of selected 
targeted therapies.  However, clinical efficacy does not necessarily translate into cost 
effectiveness.  As highlighted in the review article, several of the drugs, particularly 
bevacizumab and cetuximab which are both approved for use in mCRC, have been 
shown through PE studies to be cost ineffective (Tappenden et al., 2007; Mittmann 
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et al., 2009).  The primary driver behind such conclusions has been the high price of 
these agents, which is several times higher than traditional chemotherapy (Schrag et 
al., 2004).  The impact of these high prices has been to deny or limit patient access 
to these important agents because national health care systems around the world 
are refusing to reimburse (NICE, 2010).  This is unacceptable for patients, but the 
challenge is to determine a final drug price that offers value and is affordable to a 
national health care system.  Therefore, a new paradigm needs to be developed that 
is transparent and potentially acceptable to all of the key stakeholders.  The new 
system must reward drug innovation, enhance global patient access and above all 
be sustainable.  The application of PE modeling techniques in combination with 
value thresholds based on the wealth of a nation is one approach that may 
contribute to enhanced and sustainable patient access. 
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CHAPTER 4 
FORMULARY DECISION MAKING IN THE ERA OF TARGETED THERAPIES 
 
4.1 Introduction 
 Drug formulary committees worldwide face tremendous challenges associated 
with the high cost of the new targeted anticancer agents.  They must identify 
strategies that will make these drugs available to patients within the confines of a 
limited drug budget.  The chapter begins with a presentation of trends in global 
health care expenditures with a focus on the rising cost of pharmaceuticals.  The 
impacts of these trends are illustrated followed by a discussion on how governments 
around the world have responded.  The chapter also describes the role of health 
technology assessment in deciding on which cancer drugs to add to a national drug 
formulary.  The concept of pharmacoeconomics and how it is applied to the field of 
oncology in then presented.  A definition of the concept of “value”, as how it relates 
to reimbursement decisions for oncology drugs is then provided. 
 
4.2 The rising cost of pharmaceuticals 
 Total spending on pharmaceuticals has been increasing rapidly, well beyond the 
rate of inflation (Orszag and Ellis, 2007; Jackevicius et al., 2009).  In many countries, 
drug expenditures in general have also outpaced total health care spending and 
higher drug prices have been a contributing factor (Figure 4.1) – (Organization for 
Economic Co-operation and Development, 2005).  Contributing causes include an 
ageing population, a more aggressive treatment culture, availability of more effective 
and higher priced drugs that have replaced medical procedures previously requiring 
hospitalization and increased use of preventive medicines (Hoffman et al.,  2009; 
Guo et al.,  2008).  Rising drug costs have now become a global concern as 
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institutionalized health care systems struggle to offer modern treatments within 
limited budgets.  Some view this as threatening the health care systems that are 
integral to the modern social contract (Prescribing Caution, 2005). 
 
 
 
Figure 4.1.  Annual growth in drug and total health care expenditures: 1998 to 2003 
 
 The main components of health care costs consist of expenditures for hospitals, 
physician fees and pharmaceuticals.  Of these, curtailing spending on drugs is the 
easiest and perhaps most politically acceptable target for cost containment 
initiatives.  Many reasons are offered for the mounting political and fiscal pressure 
being brought to bear: high prices, opaque processes for the evaluation of 
pharmaceutical efficacy, shoddy or biased research, a culture that emphasizes 
marketing over efficacy and safety, and too close relations between regulators 
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representing the public interest and the corporations that they regulate.  At root, the 
key unknown is the overall value that a new drug offers society.   
 To address rising drug costs, nationalized health care systems have responded in 
different ways.  The United Kingdom (UK), Canada and Australia have used cost 
effectiveness ratios developed by agencies such as the National Institute of Clinical 
Excellence (NICE), the Pan Canadian Oncology Drug Review Program and the 
Australian Pharmaceutical Benefits Advisory Committee as a basis to limit or deny 
access to underperforming drugs (Wilking and Jonsson, 2005).  Several other 
European countries also consider cost effectiveness data to some degree.  In 
contrast, the United States the Agency for Healthcare Research and Quality does 
not possess direct influence on formulary listing decisions.  However, drug access is 
sometimes managed by the creation of payment tiers shifting more of the cost of 
expensive drugs to the patient in commercial and government drug plans (Faden, 
2009)
 Risk sharing programs where national health care systems only reimburse drug 
costs for patients responding to treatment are also being created (de Pouvourville, 
2006).  As a recent example, AstraZeneca recently fixed the price of the anticancer 
agent gefitinib at 12,200 GBP, irrespective of the duration of treatment, and there will 
be no charge for patients who are treated for less than three months (Church, 2010).
. 
  
Other examples of cost containment strategies include price cap schemes that limit 
annual expenditures for certain high cost drugs and, in a more positive light, the use 
of validated predictive markers (such as the human epidermal growth factor 
receptor-2 for trastuzumab) where the drug is reimbursed in specific patient 
subgroups who are most likely to derive optimal benefit (Piccart-Gebhart et al., 
2005).  Such initiatives have helped to reduce drug expenditures, but demographics 
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have caused absolute drug expenditures to continue to rise (Dranitsaris et al.,  
2011). 
 As an immediate response, several countries in Europe have now mandated 
price controls.  In Spain and Greece, the respective governments recently 
announced price cuts of up to 30% of branded products (Spain announces big price 
cuts, 2010; Greece price cuts, 2010).  Annual drug expenditures in Spain were 
approximately 12.5 billion euros in 2009, a 4.4% increase from the previous year.  
Therefore, it was projected that these price cuts would save the national health care 
system 1.3 billion euros.  France has also announced drug funding restrictions for 
both brand and generic products (FiercePharma, 2010). 
 Government mandated cuts of branded drugs do not serve patients in the long 
term because such actions will only serve as a disincentive for pharmaceutical 
companies to invest in new drug discovery.  Furthermore, companies may withdraw 
their products and choose to not launch new drugs in the future.  All of these factors 
will further limit patient access to new agents.  A better alternative to such actions 
would be to set product price based on several factors such as performance under a 
controlled clinical trial setting, a nation’s ability to pay a price premium for 
exceptional products, how uniformly income is distributed within a given country, and 
the overall cost effectiveness of the product measured against some reasonable 
societal value threshold.  A review of the oncology literature has revealed that such 
alternatives encompassing all of these factors have not been explored. 
 
 
4.3 Formulary approval of new drugs to treat cancer 
Once a cancer drug receives regulatory approval, a process of formulary decision 
making is initiated in most developed countries.  For a product to receive 
reimbursement, it must be seek approval for formulary entry at a national or regional 
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level.  This process involves a review of the safety and efficacy data and an 
assessment of the product’s budget impact.  In some jurisdictions such as the United 
Kingdom, Canada, Australia and several countries in Europe, a health technology 
assessment (HTA) with an associated pharmacoeconomic (PE) evaluation is 
required (Figure 4.2) - (National Centre for Pharmacoeconomics, 2011).  For 
products to achieve formulary access, the HTA process must confirm/verify safety 
and efficacy against the current standard of care and the PE evaluation must verify 
the products cost effectiveness (Drummond et al.,  2007; Wilking and Jonsson, 2007).  
Products deemed by the HTA authority to be cost ineffective usually receive a negative 
recommendation for formulary listing (Drummond et al.,  2007; Wilking and Jonsson, 
2005). 
 
 
Figure 4.2.  The role of pharmacoeconomic evaluations in Europe on 2011, Source: 
National Centre for Pharmacoeconomics, Ireland, 2011. 
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 There are several agencies around the world that are actively involved in 
performing PE evaluations as part of a formal HTA process in order to provide 
advice on new oncology products.  An HTA database maintained by the Swedish 
Council of Health Technology Assessment was reviewed to determine changes in 
the number of annual HTA reports related to cancer (Wilking and Jonsson, 2007).  
What has been evident over the past 20 years was the sharp increase in the number 
of cancer related economic evaluations appearing in the medical literature.  In 1991, 
there were no cancer related PE publications contained within the HTA database.  
However by 2005, there were no cancer related HTA reports added to the database 
(Figure 4.3). 
 It is also interesting to note that a majority of the publications were from the 
United Kingdom, Canada, the Netherlands, Sweden, and Australia; countries where 
a full economic analysis is required before a reimbursement decision for a new drug 
is made (Wilking and Jonsson, 2007; Ganfi et al.,  2003; Glennie et al.,  1999).  
Since the targeted therapies are available at costs substantially higher that traditional 
chemotherapy, HTAs and associated PE evaluations are now routinely undertaken 
(Dranitsaris et al.,  2011). 
 
 
 
 
 
 
Figure 4.3. Number of cancer health technology assessment reports from 1991 to 
2005 (Wilking and Jonsson, 2005) 
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4.4   The role of pharmacoeconomics in oncology 
 During the formulary decision making process, drug cost is an important factor.  
Cost, however, is a crude measure of the value of a new anticancer drug.  A 
comprehensive PE study is warranted before a new agent becomes available for 
clinical use.  The basic premise of PE evaluations is to compare the costs and 
consequences of alternative pharmaceutical interventions, and to determine which 
treatment offers the best value for limited resources. 
 With respect to oncology drugs, CUA can be complex but is the most common 
method used because it considers cost, overall survival and quality of life differences 
between two competing therapies (Goodwin et al.,  1998, Canadian 2006).  Once the 
analysis is completed, the outcome of a CUA is an incremental cost per QALY 
gained when one treatment is used in place of another.  At this point, a formulary 
committee needs to make a value decision on the final incremental cost per QALY 
ratio.  If the reported incremental cost per QALY ratio is acceptable relative to a pre-
established benchmark for economic value, then the product can be added to the 
drug formulary (Hillner and Smith, 2009). 
 There are four mains types of 
PE evaluations:  (1) cost-benefit analysis (CBA) expresses years of life gained in 
monetary terms; (2) cost-minimisation analysis (CMA) compares costs of competing 
strategies which yield the same clinical outcomes; (3) cost-effective analysis (CEA) 
determines a ratio of cost to effectiveness (measured on some natural unit such as 
life years gained), and is expressed as dollars per outcome gained; (4) cost-utility 
analysis (CUA) compares quality-adjusted life-years (QALYs) gained with 
incremental costs of two competing interventions (Drummond et al.,  2005).   
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4.5   Estimating drug price with pharmacoeconomic modeling 
 PE evaluations provide an important component to the overall process of 
formulary decision making.  However, they may have an additional and perhaps 
more valuable role in estimating or negotiating a drug price with manufacturers 
based on societal value thresholds.  PE has been used in this role for a few cancer 
drugs assessed by NICE of the United Kingdom.  NICE was able to secure price 
reductions from manufacturers for the cancer drugs erlotinib, lenalidomide and 
sunitinib based on cost effectiveness thresholds and PE modeling (Church, 2009).  
However, what has not been extensively examined is the estimation of drug price 
before the product receives regulatory approval. 
 There is a single example in the cancer care literature where PE modeling was 
used to estimate drug price before a product was approved by regulatory authorities.  
In that study, Dranitsaris and Leung sought to estimate a unit price of an orally 
administered neurokinin-1 (NK-1) receptor antagonist, a new class of drugs indicated 
for the prevention of emesis from chemotherapy (Dranitsaris and Leung, 2004).  
Clinical data on emesis control were obtained from a randomized phase II trial which 
evaluated emesis rates following the addition of an investigational NK1 antiemetic 
(by mouth twice daily) for 5 days to a control group consisting of a single dose of 
granisetron and dexamethasone before cisplatin-based chemotherapy.  Cost was 
obtained from a Canadian cancer centre, and health state utilities for the various 
health outcomes associated with emesis control were collected from a sample of 
oncology nurses.  The product had not been approved for clinical use, so the 
investigators developed a decision analysis model to estimate a unit price for the 
drug using a predefined threshold of $Can 20,000 per QALY gained as the measure 
of “good value for money” (Dranitsaris and Leung, 2004). 
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 The findings suggested that the product would have a cost per QALY gained at 
the $Can 20,000 threshold if it were priced at $Can 6.60 per dose, or $Can 13.20 
daily (2003 Canadian dollars).  In the sensitivity analysis, the unit price of the new 
antiemetic could increase to $Can 20.32 per dose if the granisetron and 
dexamethasone prophylaxis were extended to three days post chemotherapy (that 
is, the standard of care).  In hindsight, there are some important limitations to this 
study.  The threshold for economic value at $Can 20,000 per QALY gained is 
unrealistic in today’s oncology setting, and the phase II randomized trial did add the 
investigational NK-1 antagonist to an appropriate duration of granisetron and 
dexamethasone treatment.  Nevertheless, the study did demonstrate that a 
systematic process could be used to estimate a reasonable range of prices before a 
product becomes commercially available.  The advantages of this technique are that 
it is relatively straightforward to perform, transparent and the decision model can be 
easily applied to other jurisdictions using local cost data and thresholds for economic 
value.  Such information could be used by drug manufacturers and formulary 
committees to facilitate negotiations for optimal pricing in a given jurisdiction. 
 
4.6 Defining value 
 One of the major challenges against the use of PE modeling for estimating drug 
price is in establishing the threshold for value within a given country.  As an 
illustration, NICE of the United Kingdom has established the threshold for drug 
coverage at £30,000 per quality adjusted life year (QALY) gained (Drummond et al.,  
2007).  In the Netherlands, the unofficial threshold is € 18,000 per QALY (Wilking 
and Jonsson, 2005).  In many other jurisdictions, a $ 50,000 cost per QALY threshold 
has been used (Laupacis, 1992), based on a 1982 valuation for renal dialysis, which 
is now equivalent to approximately $ 197,000 per QALY in 2007 U.S. dollars (after a 
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5.5% adjustment in health care inflation) – (Hillner and Smith, 2009).  One approach 
to address this dilemma would be for formulary committees to establish their own 
local thresholds for accepting new drugs through a review of their national human life 
valuation literature. 
 Notwithstanding, a key problem in using any such thresholds is that the wealth of 
an individual country is not taken into consideration.  To address this, the World 
Health Organization (WHO) has proposed to use multiples of a country’s per capita 
gross domestic product (GDP) to establish thresholds for economic value (Hillner 
and Smith, 2009; Murray et al.,  2000; Sarin, 2008).  Products less than or equal to 
the per capita GDP would be considered very cost effective, one to three times 
would be cost effective and more than three times would be cost ineffective (Hillner 
and Smith, 2009).  Using South Africa as an illustration (that is, per capita GDP = 
$US 10,000 or R 71,000), the three time threshold for cost effectiveness of new 
anticancer drugs would be approximately $US 30,000 per QALY gained (World Fact 
Book, 2010).  For a lower income country such as India (per capital GDP = $US 
3,100), the cost per QALY gained threshold would be $US 9,300.  In contrast, the 
threshold for economic value for a high income country such as Norway would be 
$US 150,000 per QALY gained.  The use of thresholds based on per capita GDP 
with PE modeling to establish a value-based price for a cancer drug is novel 
because it incorporates product attributes such as disease response, survival, quality 
of life improvements and of equal importance, a country’s ability to pay. 
 
4.7   Current models for drug pricing 
 Before applying PE modeling for estimating a cost effective drug price, it is 
important to understand the techniques that pharmaceutical companies use 
determine a final drug price.  This is a difficult undertaking because drugs are not like 
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consumer goods.  Patients often receive their medication through a hospital or in a 
retail setting, and the prescriber is usually not involved in the financial transaction.  
Hence, the prescriber often does not know the acquisition cost of the drug.  
Pharmaceuticals are also considered to be “negative goods” because in many 
cases, the patient would rather not take the drug and the rationale or necessity for 
the prescription administration is often unknown (Kolassa et al.,  2009).  In addition, 
the patient may not recognize or gain satisfaction from health status improvement 
when a drug’s effectiveness pertains to ‘silent killers’ such as hypertension or 
hyperlipidemia.  These and other factors supposedly lead to pricing “models” for 
pharmaceuticals that are very different than those used for other consumer goods 
such as cars and television sets. 
 The process of drug pricing is complex and involves multiple steps such as 
identification of the product’s value proposition, creation of financial models outlining 
the burden of disease, assessment of the reimbursement environment, willingness-
to-pay thresholds with payers and prescribers in the market place and the 
development of an overall pricing strategy for the life cycle of the product (Nagle et 
al.,  2011; Kolassa et al.,  2009).  This approach is sound in principle, yet may lead 
to a price that is not acceptable to payers because it may be considerably higher 
relative to the current standard of care, without clear evidence of substantial clinical 
benefit. 
 To apply current pricing models, data about perceived value are collected through 
willingness to pay surveys or conjoint analyses involving patients, payers or 
physicians (Kolassa et al.,  2009).  However, willingness to pay surveys determine 
price points and measure intention but do not necessarily reflect the actions patients 
or payers will take when ultimately faced with the decision.  Respondents in such 
surveys often involve physicians, who are often far removed from the decision to add 
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the drug to the formulary or to purchase it.  Patients and payers may also consider 
different product value attributes to those of physicians.  As an illustration, patients 
may place higher value on an oral agent versus an intravenously administered drug 
because the former avoids a visit to the physician’s office.  In contrast, physicians 
practicing in the United States may place a higher value on the intravenous product if 
it translates into rapid symptom control coupled with increased revenue for which 
they can bill. 
 Pharmaceutical companies also develop return on investment (ROI) models to 
determine a final launch price of a product (Nagle et al.,  2011; Kolassa et al.,  2009).  
Time-to-market greatly affects ROI models because they are based on the long and 
expensive pre-market investment period, followed by a relatively short period of 
revenue generation, which has been estimated to be 12 to 13 years (Scherer, 2004).  
Patent life is typically 20 years from the time of filing a submission, which is usually 
done before clinical testing on humans begins.  All of these factors tend to drive the 
launch price of a product upwards as the industry attempts to maximize revenue 
within a shortened commercialization period.  This is often done without extensive 
consideration of the value that a new drugs offers in terms of improved efficacy, 
overall survival and reduction of downstream health care costs (Schrag, 2004; Fojo 
and Grandy, 2009).  Furthermore, the current pricing models do not routinely 
consider the wealth of a nation, or the extent of income dispersion among the 
population.  The net impact of these factors has been to increase in the price of 
drugs, particularly for diseases such as cancer (Schrag, 2004).  Therefore, new 
approache that a linked to product performance, economic efficiency and a country’s 
ability to pay premium prices are needed for estimating the launch price of new 
drugs. 
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4.8   Conclusions 
 The new targeted therapies have contributed to an important advance in cancer 
care.  However, their high costs are limiting patient access as health care systems 
around the world attempt to contain rising health care expenditures by limiting or 
rejecting the use of new agents. Therefore, a new paradigm for determine a fair 
value based drug price is needed, which can then be the starting point for initiating 
dialogue between the key stakeholders. The new system must reward drug 
innovation, enhance global patient access to important agents and above all be 
sustainable.  The application of PE modeling techniques in combination with value 
thresholds based on the wealth of a nation is one approach that can be used to 
estimate a final drug price.  In this study, PE modeling techniques were used to 
create a value based pricing index for new drugs in mCRC.  It was created from data 
collected in Canada, Spain, South Africa, Malaysia and India.  The final index could 
then be used to estimate appropriate drugs prices based on societal value 
thresholds, the survival benefit offered by a new drug, per capita GDP and income 
dispersion for a given country. 
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CHAPTER 5 
RESEARCH METHODS 
 
5.1 Introduction 
 This chapter presents the methodology used to undertake the study and meet the 
overall objectives.  This includes a description of the reference countries, the 
development of the PE model that was used to undertake the analysis, the source of 
the clinical, utility and economic data that was used to populate the model in each 
country and the value thresholds that were used to estimate a value based price for 
each of the reference countries.  The final part of the methods section describes the 
statistical techniques that were used to develop the value based pricing index for 
new drugs in mCRC. 
 
5.2 Reference countries 
 Data were collected from the following five countries: Canada, Spain, South 
Africa, Malaysia and India with the per capita GDPs ranging from $US 39,000 to $US 
3,100 (R 286,000 to R 22,000) respectively (see Table 5.1). Country selection was 
based on both cultural factors such as religion/beliefs about health, economic 
considerations (that is, the GDP per capita) and the type of health care system 
employed (only public versus a mix of public and private).  With the range of per 
capita GDPs being from $US 3,100 to $US 39,000, approximately 140 countries 
worldwide would be encompassed thereby expanding the potential application of the 
pricing index (World Fact Book, 2010). 
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Table 5.1.  Description of reference countries 
Country Population GDP per Capita
($US) 
1,2,4 Gini 
Coefficient
Health Care 
System 2 
Canada 
 
Spain 
 
Malaysia 
 
South Africa 
 
India 
33 million 
 
45 million 
 
28 million 
 
49 million 
 
1.1 billion 
$ 39,000 (R 286,000) 
 
$ 35,000 (R 257,000) 
 
$ 14,800 (R 105,080) 
 
$ 10,000 (R 70,600) 
 
$ 3,100 (R 22,000) 
32.6 
 
34.7 
 
49.2 
 
57.8 
 
36.8 
Public only 
 
Public-private mix 
 
Public-private mix 
 
Public-private mix 
 
Public-private mix 
 
1The World Fact Book, 2010.  2The cost per QALY value threshold for estimating a value 
based price for that country was three times the per capita GDP for that country. 
3The Gini coefficient is a measure of income dispersion.  A value of 0 represents absolute 
equality, and a value of 100 is absolute inequality (De Maio et al.,  2007). 4
 
$1U.S. = R7.10, 
as of December, 2010. 
5.3 Cost utility analysis 
 There are multiple PE methodologies such as cost minimization, cost benefit and 
cost effectiveness analysis available and some are more appropriate than others for 
a given drug.  With respect to oncology products, cost utility analysis (CUA) can be 
complex but is the most common method used because it considers cost, overall 
survival and quality of life differences between two competing therapies (Goodwin, 
1998).  In contrast, cost minimization analysis (CMA) is a simpler approach for 
measuring the economic value of alternative cancer therapies.  The primary 
requirement for a CMA is that all clinical outcomes such as overall survival, drug 
toxicity and quality of life (measured as health state utilities) be equivalent 
(Drummond et al.,  1995).  However, such occurrences are uncommon in oncology.  
Two drugs, even with equivalent survival often have differences in safety and 
methods of administration, the most inconvenient of which affects patient 
preferences and utilities. 
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 Therefore, the clinical, economic and respondent utility data collected in each 
country were combined for a CUA comparing the cost effectiveness of a hypothetical 
“new drug” when added to the standard chemotherapy for mCRC to chemotherapy 
alone over a range of gains in overall survival relative to a series of drug prices.  This 
approach is sound and has been successfully used by the candidate in the 
estimation of optimal drug price before the launch of a product that is now 
comerically available (Dranitsaris and Leung, 2004).  Therefore, the analysis allowed 
the estimation of a unit price for a targeted cost per QALY gain. 
 
5.4  Pharmacoeconomic model development 
 mCRC was chosen because several new anticancer agents have been approved 
in this disease site but their high cost has led to their outright refusal for 
reimbursement by some government payers (Mittmann et al.,  2009; NICE, 2010).  
The clinical and economic outcomes for mCRC were modelled using the principles of 
decision analysis.  The current standard of care for the first line treatment of mCRC 
is oxaliplatin in combination with infusional 5-fluorouracil (FOLFOX).  In patients who 
have disease progression or intolerable toxicity, second line irinotecan in 
combination with infusional 5-fluorouracil (FOLFIRI) is a recommended treatment 
(Price et al.,  2010; Barugel et al.,  2009).  Data from a large randomised trial also 
verified that sequential schedules of FOLFOX and FOLFIRI (or the reverse order) 
are equally effective and have thus emerged as the first and second line standard of 
care for patients with mCRC (Tournigand et al.,  2004).  The addition of an anti-
vascular endothelial growth factor (VEGF) such as bevacizumab during 
chemotherapy for mCRC has also been recommended by clinical guidelines 
(Engstrom et al.,  2008). 
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 A decision model for the sequential treatment of mCRC with FOLFOX (± an anti-
VEGF agent – the “new drug” in this study) and then followed by FOLFIRI upon 
disease progression was created with the DATA model building program, developed 
by Treeage Software Inc. (Figure 5.1).  The analytic timeframe was from the first 
cycle of FOLFOX chemotherapy until death.  The primary outcome for measuring 
successful initial therapy was clinical benefit, defined as complete tumour response 
(CR), partial response (PR) or stable disease (SD) based on the Response 
Evaluation Criteria
 The model began at the decision node (square) where the first line treatment 
choice would be either FOLFOX + “the new drug (bevacizumab)” or FOLFOX alone 
(Figure 5.1 and 5.2).  During the first two cycles of chemotherapy, patients would be 
assessed for intolerable toxicity. For those patients with severe toxicity, first line 
therapy would be discontinued in its entirety and second line FOLFIRI would be 
offered until disease progression. Upon progression, all patients would receive best 
supportive care until death.  In contrast, patients who do not experience severe 
toxicity from first line FOLFOX (± “the new drug”) would also receive treatment until 
disease progression.  They would then be offered second line FOLFIRI alone and 
the new drug would be discontinued.  Upon progression, all patients would receive 
best supportive care until death (Table 5.2).  To simplify the modeling, epidermal 
growth factor receptor (EGFR) inhibitors such as cetuximab in mCRC patients with 
KRAS ild type tumours were not considered.  Furthermore, such agents would be 
available to both treatments options in the model, so their inclusion would not impact 
the final results. 
 in Solid Tumors [Therasse et al.,  2000]).  Three clinical 
oncologists (one from Canada, the United Kingdom and South Africa) who had 
experience in colorectal cancer evaluated the face and content validity of the model. 
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Figure 5.1.  Decision analysis model for the treatment of metastatic colorectal cancer. 
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Figure 5.2.  Fully rolled back decision analysis model with individual payoffs. 
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aAs presented in each branch of the decision analysis model. b
 
A quality of life score for a health 
state between 0 and 1, with 0 = death and 1 = optimal health. Abbreviations: FOLFOX = 
oxaliplatin+ infusional 5-FU. FOLFIRI = irinotecan + infusional 5-FU, BSC = best supportive care 
5.5   Clinical data 
 The clinical data required to populate the model consisted of early treatment 
discontinuations because of toxicity, achievement of clinical benefit (that is, non 
progressive disease), duration of clinical benefit, risk of cancer related death during 
active treatment and number of chemotherapy cycles administered. These data were 
obtained through a literature search of randomized trials evaluating FOLFOX (± 
bevacizumab) in the first line setting and second line FOLFIRI in the treatment of 
mCRC.  A literature search of Medline, Embase and the Cochrane databases was 
performed from 2000 through 2010 for human clinical studies involving FOLFOX, 
FOLFIRI and bevacizumab as first and second line therapy in mCRC.  The primary 
objective of the review was to identify the most up-to-date clinical data for populating the 
model. Care was taken to avoid inclusion of duplicate publications.   
 
5.6   Collection of cost and utility data to populate the model for each country 
 Direct medical cost data to populate the model were collected from large cancer 
centers in each of the reference countries.  Public payer costs were used for those 
countries where public health care was available.  Health care resource use included 
costs for drug acquisition, preparation and administration, patient monitoring, side 
effects management and all related physician fees.  Palliative care costs for terminally ill 
cancer patients were obtained from the palliative care literature in the respective 
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countries (Batiste-Gomez et al 2006; Uys et al, 2002).  The health-related utility 
estimates were individual preferences for the alternative health outcomes as described 
in the model (Figure 5.1).  In the current study, quality adjusted life years (QALYs) were 
measured as "healthy month equivalence" using the Time Trade-Off (TTO) technique 
(Torrance, 1987; Gafni, 1997). 
 The TTO is a preference based approach designed to measure a respondent’s 
preferences and quality of life (QOL) for alternative health states.  After background 
information is presented on a particular health state (e.g. a cancer that is not responding 
to treatment) and the time period within that state, respondents are asked to trade 
length of life in the poorer health state for a lesser period of time in a state of optimal 
health and quality of life (Torrance, 1987; Gafni, 1997).  As an illustration, a respondent 
may prefer to live 6 months of optimal health rather than the 12 months with a 
progressive non-responding cancer.  Under this scenario, the utility associated with 
having a non-responding cancer for 12 months would be 0.5 (that is, 6 / 12) on a scale 
between 0 and 1, where 0 represents death and 1 is a state of optimal quality of life.  In 
the economic model, all of the possible outcomes (i.e. health states) were valued this 
way and then used to weight the time spent in each health state in terms of QOL. 
 Intuitively, the ideal population for measuring health states utilities and treatment 
preferences should be cancer patients with the disease in question who are in a position 
to receive the new treatment.  However, it has been recommended in the Canadian 
Guidelines for Economic Evaluations and by the Panel on Cost-Effectiveness in Health 
and Medicine of the United States that treatment preferences be measured from 
members of the general public who are potential candidates of the new medical 
intervention (Canadian Agency for Drugs and Technology in Health, 2006; Russell et al, 
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1996).  However based on our experience, members of the general public have difficulty 
in understanding cancer related understanding utility questionnaires.  As a compromise, 
a patient surrogate group consisting on oncology nurses and pharmacists was used to 
provide insight from both the perspective of the patient and members of the general 
public.  There is also evidence in the oncology literature to suggest that nurses are 
suitable patient surrogates for objective outcomes, and that utility estimates derived 
from such a sample do not substantially alter the findings of cost utility studies (Ortega 
et al., 1996; Leung et al., 1999)
 Potential respondents were approached and were asked to participate in the study.  
If they were interested, respondents were presented information on the background, 
aims and objective to the study.  They were also assured that complete confidentiality 
would be maintained and their names would not appear in any report or publication 
arising from this research.  After informed consent was obtained, each participant was 
interviewed for 30 to 45 minutes by trained local field investigators.  Respondents were 
presented with information on FOLFOX, bevacizumab and FOLFIRI consisting of the 
methods of administration, efficacy and the side effects reported in the literature 
(Appendix 1 and 2).  The interview was then continued with a description of the 16 
health states and the length of time a patient would live in each health state (Figure 
5.1). The respondents were then asked how many months of "optimal health" they 
considered being equivalent to the time spent in each of the less than optimal health 
states described in the model.  These measures were then used to weigh each branch 
.  Therefore, a patient surrogate sample consisting of 24 
oncology nurses and pharmacists from each of the five countries provided utility values 
for the model.  With a sample of 24 respondents for each country, healthy month 
equivalence was measured with a precision of ± 1.0 month, with a 95% probability. 
57 
 
of the model by the quality of life experienced by a patient living through that time 
period.  An identical process was used for each of the 16 outcomes (Figure 5.1). 
 A standardised questionnaire supported by printed interview tools with graphical 
displays was used to facilitate the participant’s understanding of the Time Trade-off 
technique (Appendix 1 and 2). To minimize the framing effect, all pathways were 
presented in a consistent manner pictorially.  Demographic data were also collected 
from each participant, and consisted of years of oncology and colorectal cancer 
experience, involvement in the development of systemic treatment guidelines for 
colorectal cancer, familiarity with the cost of anticancer drugs and family history of 
colorectal cancer. 
 
5.7 Estimating a value based drug price for each country 
 The clinical, economic and respondent utility data from each country were then 
combined into a cost-utility analysis to estimate a price per dose for the “new drug” in 
the first line treatment of mCRC.  The base case analysis assumed that the addition of 
the new drug to standard chemotherapy would provide a survival benefit of 1.4 months 
as reported for bevacizumab (Saltz et al., 2008).  The primary objective of the analysis 
was to estimate a price for the “new drug” using a targeted incremental cost of three 
times the per capita GDP for each of the five countries (see Table 5.1).  Indirect costs 
were not included because there was no data available on the association between 
bevacizumab usage and indirect cost avoidance.  Future costs and benefits were not 
discounted because of the short time periods involved.  However, the stability of the 
baseline results for each country was evaluated by a one-way sensitivity analysis.  This 
consisted of substituting the 95% confidence intervals (CI) for the health-state utilities as 
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well as variations in the overall survival benefit and costs of care.  The overall survival 
benefit from the “new drug” was also increased by approximately two and four times 
(that is, to 3 and 6 months) to account for gains that are considered clinically relevant 
for new drugs in mCRC.  Costs of care were also varied by ± 15% to capture any 
potential differences across the reference country. 
 
5.8 Development of an index for estimating drug price 
 After application of the PE model for a cost utility analysis, the evaluation in each 
country provided three price points for the “new drug” that were linked to the associated 
gains in survival (that is, 1.4, 3 and 6 months).  A multivariable regression analysis, 
which was adjusted for clustering on the variable “country”, was then conducted with 
“drug price” as the dependent variable and survival gain, per capita GDP and the Gini 
coefficient, which is a measure of income dispersion (a value of 0 represents absolute 
equality, and 100 is absolute inequality) as independent variables.  Given the small 
sample size consisting of only 15 price points in total from the five countries, 
nonparametric bootstrapping was applied. Resampled data (1000 iterations) were used 
to generate bootstrap estimates of the regression coefficients of the multivariable 
model.  All of the statistical analyses were performed using Stata, release 11.0 (Stata 
Corp., College Station, Texas, USA). 
 
5.9 Ethical considerations 
 The study protocol and all associated questionnaires were reviewed and approved 
by the Research Ethics Committee (Human) (REC-H) of the Nelson Mandela 
Metropolitan University.  Respondents (that is, nurses and pharmacists) were not 
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interviewed until informed consent was received.  Respondents were also assured that 
complete confidentiality would be maintained and their names would not appear in any 
publication arising from this research.  The study followed the principles of the Helsinki 
Declaration (World Medical Association, 2002). 
 
5.10 Study limitations 
The clinical outcomes for the “hypothetical new drug” were estimated based on the 
clinical data from bevacizumab, targeted therapy that is currently approved for use in 
mCRC.  However, it is uncertain how generalizable the data for this agent will be for 
drugs currently in clinical development.  These limitations were evaluated in the 
sensitivity analysis. Oncology nurses and pharmacists were used as patient surrogates 
in the utility assessments.  Even though all respondents had oncology experience, they 
may not fully understand the impact that new therapies will have on a patient’s quality of 
life.  Another limitation is related to the economic parameters that were considered.  Only 
direct health care and drug-related expenditures were included and indirect costs (e.g. 
patient travel to the clinic, lost productivity) secondary to drug toxicity or disease 
progression were not considered in the analysis.  This may decrease the final estimated 
price for the drug.  A major advantage of the final pricing index is the ability to apply it to 
approximately 140 countries whose per capita GDP falls within the range evaluated in 
this study.  However, external validation in other countries outside of our GDP range is 
warranted. 
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5.11 Conclusions 
 This chapter presented the methodology used to collect the data, build the PE model 
and then generate the point estimates from each of the five countries that were needed 
to develop the final pricing index.  The method for estimating the price points was a 
standard cost utility approach, but it was unique because the outcome was a final price 
for a predetermined value threshold as oppose to a cost per QALY gained.  With the 
price points from each country, multivariate analysis was then used to develop the final 
index that can be used to estimate a final price using three key independent variables; 
survival gain, per capita GDP and income dispersion.  In chapter six, the results of the 
pricing analysis from the five countries are presented followed by the final value based 
pricing index. 
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CHAPTER 6 
RESULTS 
6.1 Introduction 
 This chapter presents the seven scientific papers that were generated from this 
research.  At the writing of the thesis, seven of seven papers have been accepted for 
publication in peer reviewed journals.  The first paper was a review of the literature, 
which was presented in chapter two of this thesis.  The second, third, fourth, fifth and 
sixth papers describe the PE modeling results for Canada, India, Spain, Malaysia and 
South Africa.  The seventh paper, which presents the final value based pricing index for 
new drugs in mCRC, was accepted for publication in the European Journal of Cancer 
(Impact factor 4.4).  This paper received fast track publication (submitted February 21, 
2011 and accepted without revision on March 14, 2011).  There was also an 
accompanying editorial to the paper, which has been included below.  In addition to the 
publications, a total of six abstracts from this research were accepted for presentation at 
professional meetings.  This consisted of one oral presentation 13th
 
 annual meeting of 
the International Society of Pharmacoeconomics and Outcomes Research (Prague, 
2010) and five poster presentations.  One of the posters was presented at the annual 
meeting of the American Society of Clinical Oncology (Chicago, 2011). 
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Improving patient access to
cancer drugs in India: Using
economic modeling to estimate a
more affordable drug cost based
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Background: Using multiples of India’s per capita gross domestic product (GDP) as the
threshold for economic value as suggested by the World Health Organization (WHO),
decision analysis modeling was used to estimate a more affordable monthly cost in India
for a hypothetical new cancer drug that provides a 3-month survival benefit to Indian
patients with metastatic colorectal cancer (mCRC).
Methods: A decision model was developed to simulate progression-free and overall
survival in mCRC patients receiving chemotherapy with and without the new drug. Costs
for chemotherapy and side-effects management were obtained from both public and
private hospitals in India. Utility estimates measured as quality-adjusted life-years (QALY)
were determined by interviewing twenty-four oncology nurses using the Time Trade-Off
technique. The monthly cost of the new drug was then estimated using a target threshold
of US$9,300 per QALY gained, which is three times the Indian per capita GDP.
Results: The base-case analysis suggested that a price of US$98.00 per dose would be
considered cost-effective from the Indian public healthcare perspective. If the drug were
able to improve patient quality of life above the standard of care or survival from 3 to 6
months, the price per dose could increase to US$170 and US$253 and offer the same
value.
Conclusions: The use of the WHO criteria for estimating the cost of a new drug based on
economic value for a developing country like India is feasible and can be used to estimate
a more affordable cost based on societal value thresholds.
Keywords: Drug pricing, Cost analysis, Chemotherapy, Value
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India is a culturally diverse country occupying approximately
2.4 percent of the world’s land area, but supporting 17.5 per-
cent of the global population (13). With a population of 1.17
billion people, it is the world’s second most populous coun-
try after China (20). The majority of the people live in small
villages where agriculture and associated activities predom-
inate. Based on a 2001 census, approximately 72 percent of
the population lives in 638,000 villages across the country
(20).
The healthcare system in India consists of both
government-financed public hospitals and private institu-
tions. In 2002, there were 15,393 hospitals in India with ap-
proximately two-thirds being public (23). However, because
of chronic under-funding, most public healthcare facilities
are only able to offer basic care. Therefore, the better funded
private sector provides approximately 60 percent of all com-
prehensive outpatient care in India and up to 40 percent of
all inpatient care (22;23). To gain access to private hospitals,
patients must have health insurance or they must pay out of
pocket. Unfortunately, only approximately 11 percent of the
population has any form of health insurance, and this is of-
ten inadequate (23). Patients with sufficient private insurance
have better access to modern health care, but only 1 percent
of the Indian population fall into this category. Since so few
patients have adequate health insurance, personal funds have
to be used to obtain treatment. In one report, it was estimated
that out of pocket payments for medical care accounted for
98.4 percent of total healthcare expenditures (23).
Given the lack of adequate health insurance, only ap-
proximately 50 million Indians (i.e., 4.2 percent of the popu-
lation) are able to afford modern medicines, which are avail-
able at comparable costs to the United States and Europe
(22;23). To increase patient access to new and vital drugs,
the Indian government has created an essential drugs list.
When drugs are added to this list, the government imposes
price controls to ensure that these vital agents become af-
fordable to the population. Under a new policy originally
proposed in 2006, the government revealed its intention to
increase the number of essential drugs for price control from
79 to 354, which would bring almost a third of the phar-
maceutical industry under such control (22;23). Given their
high cost, cancer drugs are likely to be affected by this pol-
icy (11). This would no doubt create tension between for-
eign drug firms who want to sell their products at an ade-
quate margin to ensure a profit and the government’s desire
to increase patient access to new agents. To address this
impasse, new drug pricing strategies need to be found that
will ensure the commercial viability of innovative therapies
while making such agents affordable to the extended Indian
population.
One approach that may facilitate the identification of an
optimal list price would be through the application of phar-
macoeconomic (PE) modeling techniques. The basic premise
of PE evaluations is to compare the costs and consequences
of a new drug to determine if it offers the best value for
money relative to the standard of care (1;11). Such analyses
are usually undertaken after the unit cost of the drug has
been set following regulatory approval. However, PE may
have an additional and perhaps more valuable role in esti-
mating or negotiating the price of the drug based on societal
value thresholds. PE has been used in this capacity for the
evaluation of numerous biologics, including novel oncologic
agents assessed by Institute of Clinical Excellence (NICE)
for the United Kingdom (UK) (4). This approach can also
be used to estimate a more affordable price of a drug for the
Indian healthcare setting.
Quality-adjusted life-years, or QALYs, are a way of mea-
suring the impact of disease. They include both the quality
and the quantity of life lived and are used to quantify the
relative benefit of two competing medical interventions. One
of the major challenges against the use of PE modeling for
estimating drug cost is in setting the value threshold for a
given country. As an illustration, NICE of the UK has estab-
lished a threshold for drug coverage at £30,000 per QALY
gained (8). In many other jurisdictions, a US$50,000 cost
per QALY threshold has been used (17); which was based on
a 1982 valuation (15). A problem in using such thresholds
is that the wealth of the individual country is not taken into
consideration. To address this, the World Health Organiza-
tion (WHO) has proposed to use multiples of a country’s per
capita gross domestic product (GDP) to establish thresholds
for economic value (15;19;26). Products less than or equal to
the per capita GDP would be considered very cost-effective,
one to three times would be cost-effective and more than
three times would be cost-ineffective (15). For a country
like India (i.e., per capita GDP = $US3,100) (2), the three
times threshold for cost-effectiveness of new anticancer ther-
apies would be approximately US$9,300 per QALY gained.
In contrast, the threshold for economic value for a higher
income country such as Norway would be US$150,000 per
QALY gained. Therefore, the list price for a drug sold in India
would be substantially less than the list price in Norway, and
these price figures would be proportional to their respective
national per-capita GDP.
The use of thresholds based on per capita GDP in com-
bination with PE modeling to establish a value-based price
for a drug is an interesting approach, because it could set the
foundation for improving global patient access. Wealthier na-
tions would then be expected to pay more for drugs and these
higher revenues would subsequently subsidize access for the
developing world. To illustrate the application of this drug
pricing strategy, decision analyses modeling was used in the
current study to estimate the price per dose of a hypothetical
new cancer drug that would provide an overall survival bene-
fit of 3 months over the standard of care. Clinical data for the
case study are based on a combination of bevacizumab plus
chemotherapy in a first-line treatment setting of metastatic
colorectal cancer (mCRC) (3). Bevacizumab was chosen be-
cause it has a high acquisition cost and its economic value
has been questioned in recent PE studies (28;29).
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METHODS
Economic Model
mCRC was chosen for this analysis because the sequential
use of specific chemotherapy regimens is well established.
In patients with mCRC, randomized trials have demonstrated
that irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) in com-
bination with infusional 5-fluorouracul (5-FU) and leucov-
orin are highly active and superior to the previous standard of
5-FU/leucovorin alone (5;14). Data from a large randomized
trial also verified that sequential schedules of FOLFOX and
FOLFIRI (or the reverse order) are equally effective and have
thus emerged as the first- and second-line standard of care
for patients with mCRC (32). Clinical practice guidelines
also recommend the addition of an anti-vascular endothelial
growth factor (VEGF) such as bevacizumab at some point
during chemotherapy for mCRC (9). FOLFOX, FOLFIRI,
and bevacizumab are all available in India, but access is lim-
ited by a patient’s ability to pay.
A decision model for the sequential treatment of mCRC
with FOLFOX (± an anti-VEGF) followed by FOLFIRI
upon disease progression was developed with the DATA
software (Treeage Software Inc.) (Supplementary Figure 1,
which can be viewed online at www.journals.cambridge.
org/thc2011003). The analytic timeframe was from the first
cycle of FOLFOX chemotherapy until death, and an Indian
healthcare system perspective (both public and private) was
taken. The primary outcome for measuring successful initial
therapy was clinical benefit, defined as either complete tumor
response (CR), partial response (PR), or stable disease (SD)
based on the Response Evaluation Criteria in Solid Tumors
[RECIST]) (30). Three clinical oncologists, each with expe-
rience in treating colorectal cancer, evaluated the face and
content validity of the model.
The model began at the decision node (square) where
the first-line treatment choice would be either FOLFOX +
“the new drug” or FOLFOX alone (Supplementary Figure 1).
During the first two cycles of chemotherapy, patients would
be assessed for intolerable toxicity. For those patients with
severe toxicity, first-line therapy would be discontinued in
its entirety and second-line FOLFIRI would be offered un-
til disease progression. Upon progression, all patients would
receive best supportive care until death. In contrast, patients
who did not experience severe toxicity from first-line FOL-
FOX (± “the new drug”) would continue receiving treat-
ment until disease progression. They would then be offered
second-line FOLFIRI alone and the new drug would be dis-
continued. Upon progression, all patients would receive best
supportive care until death (Supplementary Figure 1).
Clinical Data
The clinical data required to populate the model consisted of
early treatment discontinuations because of toxicity, achieve-
ment of clinical benefit, duration of clinical benefit, risk
of cancer-related death during active treatment, and num-
ber of chemotherapy cycles administered. These data were
obtained through a literature search of randomized trials eval-
uating FOLFOX (± bevacizumab) in the first-line setting and
second-line FOLFIRI in the treatment of mCRC. Two ran-
domized trials were identified that provided the required data
for the decision model (Table 1) (25;32).
Estimation of Treatment Costs
The duration of investigation ran from the start of first and
second-line sequential chemotherapy therapy until death.
Costs for anticancer drugs, materials, patient monitoring and
other related hospital resources (e.g., laboratory and diag-
nostic tests) were obtained from two private and two public
institutions. The costs collected in the study were in Indian
Rupees and then converted to US$ per the currency conver-
sion prevailing in 2010 (conversion factor 1 US$ = 45 Indian
Rupees).
Patient Preferences for Alternative Health
States
The health-related quality of life values measured in the anal-
ysis were patient preferences for alternative health outcomes,
as depicted in the decision analysis model. In the current
study, quality-adjusted progression-free periods were mea-
sured as “healthy months equivalent” for the time spent in
each outcome of the decision model using the Time Trade-
Off (TTO) technique (12;31). The scores in months were
then converted to utility measures between 0 and 1, where
0 represented death and 1 was a state of perfect health or
optimal quality of life.
Intuitively, the ideal population for measuring health
state utilities and treatment preferences should be cancer
patients with the disease in question who are in a position
to receive the new treatment. However, it has been recom-
mended in the Canadian Guidelines for Economic Evalua-
tions and by the Panel on Cost-Effectiveness in Health and
Medicine of the United States that treatment preferences be
measured from members of the general public who are poten-
tial candidates of the new medical intervention (1;24). As a
compromise in this study, a patient surrogate group was used
that would provide insight from both the perspective of the
patient and members of the general public because the latter
sample often has difficulty in understanding utility question-
naires. Therefore, a patient surrogate sample consisting of
twenty-four oncology nurses provided utility values for the
model. With a sample of twenty-four respondents, healthy
month equivalence was measured with a precision of ± 1.0
month, with a 95 percent probability. Such a sample has been
successfully used by our group in several economic evalua-
tions of cancer drugs (6;7;18). There is also evidence in the
oncology literature suggesting that nurses are suitable patient
surrogates for objective outcomes and that utility estimates
derived from such a sample do not substantially alter the
findings of cost-utility studies (18;21).
?
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Table 1. Published Randomized Trials Providing Clinical Data to Populate the Economic Model
Reference Treatment arms Clinical outcomes
Saltz et al. (2008) FOLFOX/XELOX + Disease progression = 29%
bevacizumab Median PFS = 9.4 months
Median duration of response = 8.45 months
Treatment discontinuations = 30%
Death during treatment = 2%
Serious side effects (grade III/IV) = 16%
Specific grade III/IV side effects
Deep vein thrombosis = 8%
Diarrhea = 18%
Bleeding = 2%
Neutropenia = 50%
FOLFOX/XELOX + Disease progression = 47%
placebo Median PFS = 8.0 months
Median duration of response = 7.4 months
Treatment discontinuations = 20%
Death during treatment = 1%
Serious side effects (grade III/IV) = 8%
Specific grade III/IV side effects
Deep vein thrombosis = 5%
Diarrhea = 11%
Bleeding = 1%
Neutropenia = 44%
Tournigand et al. Second Line FOLFIRI Disease progression = 51%
(2004) Death during treatment = 3%
Median PFS = 10.9 months
Median number of cycles = 6
Note. PFS, progression-free survival; OS, overall survival; FOLFOX, oxaliplatin in combination with infusional
5-fluorouracul; FOLFIRI, irinotecan in combination with infusional 5-fluorouracul.
After informed consent was obtained, each participant
was interviewed for 30 to 45 minutes by trained local field
investigators. Respondents were presented with information
on FOLFOX, bevacizumab, and FOLFIRI consisting of the
methods of administration, efficacy, and the side effects re-
ported in the literature (25;32). Bevacizumab was not iden-
tified by name but simply referred to as the “new drug.” The
interview was then continued with a description of the sixteen
health states, and the length of time a patient would live in
each health state (Supplementary Figure 1). The respondents
were then asked how many months of “optimal health” they
considered being equivalent to the time spent in each of the
less than optimal health states described in the model. These
measures were then used to weigh each branch of the model
by the quality of life experienced by a patient living through
that time period.
Cost-Utility Analysis
The clinical, economic, and respondent preference data were
then combined into a cost-utility analysis of the “new drug”
for the first-line treatment of mCRC. The base-case analy-
sis assumed that the addition of the “new drug” to standard
chemotherapy would provide a survival benefit of 3 months.
The primary objective of the analysis was to estimate an
appropriate price per dose for the “new drug” by using the
target benchmark cost of US$9,300 per QALY gained, which
is three times the Indian per capita GDP. Indirect costs were
not included because there were no data available on the asso-
ciation between bevacizumab usage and indirect cost avoid-
ance. Future costs and benefits were not discounted because
of the short time periods involved. However, the stability of
the baseline results was evaluated by a comprehensive sensi-
tivity analysis. This consisted of substituting the 95 percent
confidence intervals (CI) for the health-state utilities as well
as variations in the overall survival benefit, costs of care, and
the target threshold for economic value in India. Individual
analyses were conducted from both the public and private
healthcare perspective.
RESULTS
Clinical outcomes data and costs used to populate the model
are presented in Tables 1 and 2. The economic data revealed
that expenses for chemotherapy, side-effect management,
and best supportive care are considerably lower in the public
than the private system in India. This may be a reflection of
the modest level of care offered to patients in public hospitals
and of the ability of the private sector to mark up the cost of
goods and health services.
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Table 2. Hospital Costs for the Treatment of Metastatic Colorectal Cancer in India
Recourse item Public hospitals Private hospitals
FOLFOX chemotherapya US$238 / cycle US$664 / cycle
FOLFIRI chemotherapyb US$301 / cycle US$691 / cycle
Cost for a permanent chemotherapy discontinuation because of toxicityc US$23.73 US$556
Cost to administer the “new drug” after FOLFOX chemotherapy US$4.60 US$11.50
Cost of best supportive cared US$29.98/month US$162/month
Note. FOLFOX, oxaliplatin in combination with infusional 5-fluorouracul; FOLFIRI, irinotecan in combination with infusional
5-fluorouracul.
aOxaliplatin in combination with infusional 5-fluorouracul. Cost per cycle includes resources for drug administration and routine
patient monitoring. In the hospitals that provided data for this study, patients are admitted for two days to receive the chemotherapy.
bIrinotecan in combination with infusional 5-fluorouracul.
cPatients would be admitted for 3 days for the management of side effects and for reassessment.
dAfter failing two lines of chemotherapy, patients would receive best supportive care on an outpatient basis until death.
The second component required for the cost-utility anal-
ysis was health state utilities for the time period spent in each
of the 16 health states (Supplementary Figure 1). Utilities
for each outcome were estimated from a sample of twenty-
four oncology nurses. There were thirteen respondents from
private hospitals and the remainder were from public insti-
tutions. The sample had an average of 5.4 years of direct
oncology experience (range, 3–15 years) and all had experi-
ence in the treatment of colorectal cancer patients. In addi-
tion, 22 of 24 (91.7 percent) respondents had direct clinical
experience in the administration and follow-up care associ-
ated with FOLFOX (mean years = 4.8) and FOLFIRI (mean
years = 3.2) chemotherapy. However, only 9 of 24 (37.5 per-
cent) had experience with the newer targeted therapies such
as bevacizumab and cetuximab.
The health state utilities from the oncology nurses are
presented in Supplementary Table 1, which can be viewed
online at www.journals.cambridge.org/thc2011003. The re-
sults suggested that patient utilities were influenced by the
severity of drug toxicity, the likelihood of achieving a re-
sponse to chemotherapy and the risk of rapid cancer death.
The health states with the lowest utilities (i.e., branches 4 and
12 of the model, Supplementary Figure 1) were those where
first-line therapy had to be stopped because of severe toxicity,
the patient then had an early progression during second-line
treatment followed by a rapid cancer death. It was also inter-
esting to note that, in all of the related scenarios, comparative
branches that included treatment with the “new drug” tended
to have lower health state utilities (Supplementary Table 1).
This is likely related to the additional side effects that would
occur with the addition of an anti-VEGF agent like beva-
cizumab to chemotherapy (Table 1).
Cost Utility Analysis for the Public
and Private Healthcare Systems
The outcomes data from the clinical trial, the estimated costs
associated with each treatment and the health state utility
estimates were combined into the cost-utility analysis. The
price per dose of the “new drug” was then varied until the
incremental cost-effectiveness ratio reached a threshold of
US$9,300 per QALY gained. Using this approach from the
public healthcare system perspective, the base-case analysis
suggested that a price of US$98.00 would be considered cost-
effective for India according to the WHO criteria (15;19;26).
A series of one-way sensitivity analyses were then con-
ducted using the upper 95 percent CI for the health state
utilities, variations in treatment costs, overall survival ben-
efit, and the targeted cost per QALY threshold. When the
costs of therapy were varied by ± 15 percent, the results
were relatively stable (Table 3). The two biggest factors to
impact the base-case findings were the health state utilities
associated with the new drug and the overall survival gain.
The monthly drug price rose to US$170 when the upper 95
percent CI of the health state utilities for the new drug were
applied to the model. Similarly, increasing the overall sur-
vival benefit from 3 to 6 months allowed the monthly drug
price to increase to $U.S.253 while retaining the same value.
These findings indicate that the two most important factors
driving the cost-effectiveness of any new cancer drug is its
ability to significantly improve quality and quantity of life.
While bevacizumab is available in India, its purchase
price is approximately US$2184 per dose for an average
mCRC patient, which is similar to the price charged in the
United States and Europe. As a result, only patients with ad-
equate insurance and or sufficient personal resources would
have access to this drug. A sensitivity analysis was conducted
where the current price of bevacizumab was applied to the
model. The results revealed that the incremental cost per
QALY gained would be greater than US$200,000. When a
US$50,000 cost per QALY threshold was used instead of the
WHO criteria, the price per dose of the new drug rose to
US$770.00. In summary, the sensitivity analyses suggested
that a price of approximately US$98.00 for a new drug that
would prolong patient survival by 3 months would be con-
sidered cost-effective in India.
A similar series of analysis was conducted with cost
data collected from private hospitals. Unlike the results from
the public system, we were unable to find a price per dose
for the new drug that would result in a US$9,300 cost per
?
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Table 3. Sensitivity Analysis on the Unit Price per Dose for the “New Drug”
Sensitivity maneuvre Public hospitals Private hospitals
Base-casea US$98.00 Not reached
Upper 95% CI of health state utilities for chemotherapy + the “new drug” US$170 US$48.00
Changing cost of FOLFOX chemotherapy by ±15% US$93 to US$107 Not reached
Changing cost of FOLFIRI chemotherapy by ±15% US$99 to US$103 Not reached
Changing cost of BSC cost by ±15% US$97 to US$99 Not reached
Changing cost of ADR cost by ±15% US$97 to US$99 Not reached
Changing survival benefit of the “new drug” from 3 to 6 months US$253 US$130
Changing survival benefit of the “new drug” from 3 to 1 month Not reached Not reached
Using the current cost of bevacizumab (US$2184 per dose) in India Not reached Not reached
Setting the threshold for cost-effectiveness at US$50,000 per QALY gained US$770 US$650
Note. CI, confidence interval; FOLFOX, oxaliplatin in combination with infusional 5-fluorouracul; FOLFIRI, irinotecan in combination
with infusional 5-fluorouracul; BSC, best supportive care; ADR, adverse drug reaction costs; QALY, quality-adjusted life-year.
aFor a target threshold of US$9,300 per QALY when the new drug is added to FOLFOX chemotherapy.
QALY gained (Table 3). Under most of the sensitivity sce-
narios evaluated, a price for the “new drug” could also not
be found (Table 3). The only exception was when the upper
95 percent CI of health state utilities for chemotherapy + the
“new drug” were used. This allowed the price of the drug
to be US$48.00. The main reason behind these results was
the fact that the addition of an effective new drug would in-
crease the total number of chemotherapy cycles administered.
This would drive up the costs and overcome any incremen-
tal benefit in quality of life and overall survival. However,
the intent of the WHO criteria for cost-effectiveness is its
application towards publicly funded healthcare systems. The
criteria seem to provide a reasonable threshold for estimating
the cost-effectiveness of a new drug in a developing country
like India.
DISCUSSION
In this study, decision analysis was used to estimate the price
of a hypothetical new drug that provides a 3-month survival
benefit when added to chemotherapy in the first-line treat-
ment of mCRC. The primary analysis was conducted from
the Indian public healthcare system perspective using the
WHO criteria for cost-effectiveness. In the base-case analy-
sis and in most of the scenarios evaluated, a price per dose
of approximately US$98.00 was suggested by the data as
being cost-effective. The price of the drug could increase to
US$253 per month if the survival benefit were to approach
6 months. However, in the treatment of solid tumor patients
with metastatic disease, a 6-month survival gain is rarely
achieved. Most new cancer drugs approved for use over the
past 3 years have not been able to improve survival beyond
3 months (10;16;25;33).
The findings of this study suggest that the WHO criteria
for cost-effectiveness can be applied to a developing country
like India for estimating an appropriate price which may be
more affordable to the public healthcare system. Reducing
drug acquisition prices to these levels would improve pa-
tient access. However, central to the pricing debate is the
matter of commercial viability based on the manufacturer’s
cost of goods and operational overhead expense. It is unclear
whether manufacturers would realize greater short-term ben-
efit from a scenario where the drug is sold at a high price to
a few people (as with bevacizumab in India), versus a case
where the drug is sold at a lower cost but to a much larger
group of people. In India, only 50 million people of a pop-
ulation of 1.17 billion are able to afford modern medicines
(22;23). Could a reasonable level of profit be achieved if a
drug were to become more affordable to the remaining 1.165
billion?
An exercise to identify a price point where revenue be-
tween the two scenarios reaches equivalence is a worthy anal-
ysis to undertake. However, if the status quo is maintained,
then one of two possible outcomes may materialize. The
Indian government may issue a compulsory license, which
would enable local production of the patented drug. This is
possible under the Trade Related Intellectual Property Rights
agreement of the World Trade Organization and has already
occurred with some HIV drugs (27). Alternatively, the gov-
ernment may mandate price controls by adding a new cancer
agent to the Essential Drugs List (22;23). Either way, total
revenues for the product would be compromised.
One of the challenges faced by the pharmaceutical in-
dustry in making a drug available at a lower price in less-
developed countries is the phenomenon known as parallel
trade. In this situation, the drug is imported to a wealthier
nation by an intermediary for the intention of profit making.
Cooperation between the global pharmaceutical industry and
the government of the developing nation will be needed to
make a lower price policy viable. A strict and enforceable
system would have to be developed that would reduce the
likelihood of parallel trade. One approach could be through
a centralized single source drug distribution process along
with a preauthorized list of prescribers. Notwithstanding, the
PE modeling approach presented in this paper along with the
WHO criteria for cost-effectiveness can be a useful tool in
identifying an optimal drug price for all of the key stakehold-
ers. The proposed methodology will also focus negotiations
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on cost-effectiveness and value based pricing as opposed to
intellectual property litigation and mandated price controls.
There are several limitations in the application of this
technique. Our modeling exercise was theoretical. For the
proposed methodology to be viable, complete data from ran-
domized trials on a drug by drug basis is required. One of the
limitations of using the per capita GDP for value based pric-
ing is that it represents a national average and does not con-
sider income dispersion. For our modeling strategy to be ap-
plied, a new drug must demonstrate either an improvement in
QOL over the standard of care or a survival of sufficient mag-
nitude to identify a final price point for cost-effectiveness.
However, many of the newer oncology drugs have not been
able to demonstrate such benefits (10;16;25;33). Lastly, in-
direct costs such as time off work secondary may be relevant
in this setting, but were not considered in this analysis.
CONCLUSIONS
Modern cancer medicines are often out of reach for many
patients in developing countries. To help improve patient ac-
cess, a process to estimate an optimal drug price based on
predetermined thresholds of societal value is presented. The
advantages of this technique are that it is relatively straight-
forward to perform, transparent, and the modeling can be
easily applied to any jurisdiction using local cost data. Such
information can be of value to both drug manufacturers and
governments because it would facilitate value based drug
price negotiations. However, the challenge would be to iden-
tify an ideal list price that would strike a balance between
that which patients/governments can afford to pay and the
commercial viability of the product.
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Abstract
Background. Several European governments have recently mandated price cuts in drugs to reduce health care spend-
ing. However, such measures without supportive evidence may compromise patient care because manufacturers may
withdraw current products or not launch new agents. A value-based pricing scheme may be a better approach for
determining a fair drug price and may be a medium for negotiations between the key stakeholders. To demonstrate this
approach, pharmacoeconomic (PE) modeling was used from the Spanish health care system perspective to estimate a
value-based price for bevacizumab, a drug that provides a 1.4-month survival benefit to patients with metastatic colo-
rectal cancer (mCRC). The threshold used for economic value was three times the Spanish per capita GDP, as recom-
mended by the World Health Organization (WHO).
Methods. A PE model was developed to simulate outcomes in mCRC patients receiving chemotherapy bevacizumab.
Clinical data were obtained from randomized trials and costs from a Spanish hospital. Utility estimates were determined
by interviewing 24 Spanish oncology nurses and pharmacists. A price per dose of bevacizumab was then estimated using a
target threshold of E78,300 per quality-adjusted life year gained, which is three times the Spanish per capita GDP.
Results. For a 1.4-month survival benefit, a price of E342 per dose would be considered cost effective from the Spanish
public health care perspective. The price may be increased to E733 or E843 per dose if the drug were able to improve
patient quality of life or enhance survival from 1.4 to 3 months.
Conclusions. This study demonstrated that a value-based pricing approach using PE modeling and the WHO criteria for
economic value is feasible and perhaps a better alternative to government mandated price cuts. The former approach
would be a good starting point for opening dialog between European government payers and the pharmaceutical
industry.
Keywords
Drug pricing, Europe, cost analysis, chemotherapy, value
Introduction
Cancer remains a global issue due to its eﬀect on
human quantity and quality of life. It was reported
that in 2008, there were approximately 7.4 million
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cancer deaths from the disease, which was approxi-
mately 13% of all cause mortality.1 In 25 European
countries, cancer was responsible for 16.7% of all
disability adjusted life years lost, which ranked third
after mental illness and cardiovascular disease.2
However, one of the positive developments in cancer
management over the past decade is that overall patient
mortality is no longer increasing but has stabilized and
has even decreased in some tumor sites.3–5
A contributing factor has been the introduction of
new oncology products.4,5 These agents, which include
trastuzumab, rituximab, imatinib, and bevacizumab
target speciﬁc components of the cancer cell and are
usually better tolerated than conventional chemother-
apy.6,7 However, an important attribute of these new
agents is their price is substantially higher than older
anticancer drugs. In a recent editorial, the annual price
for a full course of therapy for the targeted agents erlo-
tinib, sorafenib, bevacizumab, and cetuximab was esti-
mated to be $U.S.15,752, $U.S.34,373, $U.S.80,352,
and $U.S.90,816, respectively.8 This can compromise
patient access to new drugs in both private and publicly
funded health care systems.9 It was also reported that
over 90% of new FDA cancer drug approvals in
the last 4 years had prices that exceed $20,000 for a
12-week course of therapy.10 The impact of these
rising drug prices has been to strain cancer care bud-
gets. From 1993 to 2004, total European expenditures
for oncology drugs increased seven times from E840
million to E6170 million.5 Similar trends have also
been reported in the US where cancer drug expendi-
tures increased from $3 billion in 1997 to $11 billion
in 2004.10 In many countries, drug expenditures in
general have also outpaced total health care spending
and higher drug prices have been a contributing
factor (Figure 1).
Countries, particularly in Europe have responded in
diﬀerent ways to address rising drug expenditures.
Greece, France, and Spain have mandated govern-
ment price controls of up to 23% for branded prod-
ucts.11–13 The Italian Medicines Agency also
announced possible cuts of up to 40% for selected
cancer drugs that failed to meet expectations under a
‘pay for performance’ program.14 The United
Kingdom (UK) and Germany have taken a step
further and are planning to introduce a value-based
pricing scheme for new products. In Germany, the
new law that should take eﬀect in 2011 will allow
the national health plans to negotiate a discounted
price for the product after the ﬁrst year following
product launch.15 As part of the new law, brand
name pharmaceutical companies will be allowed to
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Figure 1. Annual growth in drugs expenditures and in total health care expenditures: 1998 to 2003.
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set the price in the ﬁrst year. After that time, the
company will need to demonstrate the drug’s beneﬁts
in order to maintain that price. If this has been not
achieved, insurance companies will be permitted to
negotiate a price reduction. The ﬁnal price will be
based on the magnitude of beneﬁt oﬀered by the prod-
uct both within a clinical trial and following approval.
Therefore, the objective is to make cost beneﬁt anal-
yses part of price negotiations.
Following the German example, the government of
the UK has also proposed a new value-based pricing
scheme for drugs.16 In the UK, there is legislation that
regulates proﬁt but not price. It is not clear what the
new scheme will look like, but new product pricing will
likely be based on the incremental cost per quality-
adjusted life year (QALY) gained threshold, which is
30,000 in the UK.17 This threshold, which is equiva-
lent to approximately $U.S.50,000 was based on a 1982
valuation for kidney transplantation.18,19 Several coun-
tries in Europe use comparable thresholds for drug
formulary decision making. However, a problem in
using such thresholds is that the wealth of an individual
country is not taken into consideration. To overcome
this drawback, the World Health Organization (WHO)
has recommended to use multiples of a country’s per
capita gross domestic product (GDP) to establish value
thresholds for drug cost eﬀectiveness.19–21 Based on the
WHO criteria, products more than three times the per
capita GDP would be cost ineﬀective.19 Using Spain as
an illustration (i.e., per capita GDP¼ $U.S.33,700), the
threshold for cost eﬀectiveness of new cancer drugs
would be $U.S.101,100 or E78,300 per QALY.22 This
is a higher one but perhaps more appropriate threshold
for assessing the economic value of modern cancer
drugs.
The use of thresholds based on per capita GDP in
combination with pharmacoeconomic (PE) modeling to
establish a value-based price for a cancer drug is novel
because it incorporates product attributes such as
disease response, survival, and quality of life improve-
ments. To demonstrate its application, PE modeling
was used to estimate the price of bevacizumab, a drug
that provides a survival beneﬁt to patients with meta-
static colorectal cancer (mCRC) when added to ﬁrst
line chemotherapy.23 Bevacizumab was chosen because
its economic value has been questioned in recent PE
studies making it a candidate for government mandated
price cuts.24,25 The analysis was conducted from the
Spanish health care perspective because this is one of
the countries where government mandated price con-
trols are currently being imposed. Therefore, we seek to
demonstrate that a value-based approach to estimate a
drug price using per capita GDP thresholds is feasible
and a better alternative to government imposed price
controls.
Methods
Development of PE model
A decision model for the treatment of mCRC was
developed with DATA software (Treeage Software
Inc., Williamstown, MA, USA). The analytic time-
frame was from cycle one of ﬁrst line chemotherapy
until death and a Spanish health care system perspec-
tive was taken. Oxaliplatin in combination with infu-
sional 5-ﬂuorouracil (FOLFOX) is a recommended
standard of care for the ﬁrst line treatment of
mCRC.26 If treatment related toxicity or disease
progression develops, then irinotecan in combination
with infusional 5-ﬂuorouracil (FOLFIRI) is a recom-
mended second line treatment.27,28 It has also been
demonstrated from a large randomized trial that
sequential schedules of FOLFOX and FOLFIRI
(or the reverse order) are equally eﬀective and are
now the ﬁrst and second line standards of care for
patients with mCRC.28 Clinical practice guidelines
also recommend the addition of an anti-vascular endo-
thelial growth factor such as bevacizumab with either
ﬁrst or second line chemotherapy for mCRC.29
Using these treatment algorithms, a PE model was
developed for the sequential treatment of mCRC with
FOLFOX (bevacizumab) followed by FOLFIRI upon
disease progression (Figure 2). The primary outcome of
the model was the achievement of successful therapy
deﬁned as complete tumor response (CR), partial
response (PR), or stable disease during and following
active therapy. However, all outcomes of the PE model
resulted in eventual death, which is the ultimate conse-
quence in this patient population. The face and content
validity of the model was evaluated by three clinical
oncologists who had experience in CRC.
The model began at the decision node where a
selection for ﬁrst line therapy would have to be made
between FOLFOX+‘the new drug (bevacizumab)’ or
FOLFOX alone (Figure 2). During the ﬁrst two cycles
of chemotherapy, patients would be assessed for
intolerable toxicity. In cases of severe toxicity, ﬁrst
line therapy would be permanently discontinued and
second line FOLFIRI would be oﬀered until disease
progression or treatment-related death. When disease
progression occurs, best supportive care would be
oﬀered until death. Treatment would be continued
until disease progression in patients who tolerate ﬁrst
line FOLFOX (‘the new drug’). This would then be
followed by second line FOLFIRI but the new drug
would be discontinued. Upon progression following
second line FOLFIRI, all patients would receive best
supportive care until death (Figure 2). Epidermal
growth factor receptor inhibitors such as cetuximab in
mCRC patients with KRAS wild-type tumors were not
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considered because we did not want to over complicate
the modeling. Furthermore, such agents would be avail-
able to both treatments options in the model, so their
inclusion would not impact the ﬁnal results.
Clinical data
The relevant clinical data to populate the model
consisted of early treatment discontinuations due to
toxicity, the achievement of clinical beneﬁt (CR, PR,
or disease stabilization), duration of clinical beneﬁt,
risk of cancer-related death during active treatment
and the number of chemotherapy cycles administered.
To obtain these data, a literature search of Medline,
Embase, and the Cochrane databases was per-
formed from 2000 through 2010 for human clinical
studies involving FOLFOX, FOLFIRI, and bevacizu-
mab as ﬁrst and second line therapies in mCRC.
The main objective of the review was to identify the
most up-to-date clinical data for populating the
model. Care was taken to avoid inclusion of duplicate
publications.
Estimation of treatment costs
The analytic time period for this investigation was from
the start of ﬁrst and then second line sequential chemo-
therapy until disease progression and eventual death.
Costs for anticancer drugs, materials for drug delivery,
patient monitoring, and other related hospital resources
(e.g., laboratory and diagnostic tests) were obtained
from a Spanish hospital. Palliative care costs for termi-
nally ill cancer patients were obtained from the Spanish
palliative care literature.30 All costs in the current study
were reported in 2010 Euros. Costs from previous years
were converted into 2010 estimates using the Spanish
consumer price index for health care.
Treatment preferences and health state utilities
Using the Time Trade-oﬀ technique, quality-adjusted
life periods were measured as ‘healthy months equiva-
lent’ for the time spent in each outcome of the decision
model (Figure 2).31,32 Healthy month equivalence
scores measure patient utilities for a given health
state. A lower healthy month equivalence for the total
FOLFOX+New drug
Severe ADRs. D/C regimen,
offer FOLFIRI alone
30%
Disease progress, BSC until death – 5 months later
51% –2 months+3 months
Clinical benefit (CR+PR+SD), cont regimen
46% –2 months+4 months
Cancer death –2 months later
3%
Disease progress, offer 2nd line FOLFIRI until death
29% –2 months+4 months
Clinical benefit (CR+PR+SD), continue regimen
69% – 8.5 months
Cancer death within 2 months
2%
Disease progress, BSC until death-5 months later
51% –2 months+3 months
Clinical benefit (CR+PR+SD), continue regimen
46% –2 months+4 months
Clinical benefit (CR+PR+SD), continue regimen
57% – 7.4 months
Cancer death –2 months later
3%
Cancer death within 2 months
1%
Disease progress, offer 2nd line FOLFIRI until death –5
months later
47% –2 months+4 months
mCRC patient
No severe ADRs, continue
regimen
70%
FOLFOX alone
Severe ADRs, D/C regimen,
offer FOLFIRI alone
20%
No severe ADRs, continue
chemo
80%
Offer BSC until death –22
months later
95%
Cancer death –2 months
later
5%
Offer 2nd line FOLFIRI
until death –24 months
later
95%
Cancer death –2 months
later
5%
Offer BSC until death –22
months later
95%
Cancer death –2 months
later
5%
Offer 2nd line FOLFIRI
until death –24 months
later
95%
Cancer death –2 months
later
5%
Figure 2. Decision analysis model for the treatment of metastatic CRC.
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time spent in a given health state suggests poorer qual-
ity of life during that time period (e.g., a time period
where a cancer progression occurs). The scores in
months were then converted to utility measures
between 0 and 1, where 0 represented death and
1 was a state of perfect health or optimal quality of
life. The healthy month equivalence was also converted
into QALYs by dividing by 12 months and then
entered into the associated branches of the decision
analysis model.
Intuitively, the ideal population for measuring
health states utilities and treatment preferences should
be cancer patients with the disease in question who are
in a position to receive the new treatment. However, in
this study, oncology nurses and pharmacists were used
as a patient surrogate sample because it was felt that
terminally ill mCRC patients would have diﬃculty in
understanding the Time Trade-oﬀ technique. There is
also some evidence in the oncology literature to suggest
that nurses and pharmacists can be suitable patient
surrogates for objective outcomes, and that utility
estimates derived from such a sample do not substan-
tially alter the ﬁndings of cost utility studies.33 With a
sample of 24 respondents, healthy month equivalence
was measured with a precision of 1.0 month, with
a 95% probability.
After informed consent was obtained, each partici-
pant was interviewed for 15–30min by trained local
investigator. Respondents were presented with infor-
mation on FOLFOX, bevacizumab, and FOLFIRI
consisting of the methods of administration, eﬃcacy,
and the side eﬀects reported in the literature. The inter-
view was then continued with a description of the
16 health states and the length of time a patient
would live in each health state (Figure 2). The respon-
dents were then asked how many months of ‘optimal
health’ they considered being equivalent to the time
spent in each of the less than optimal health states
described in the model. These measures were then
used to weigh each branch of the model by the quality
of life experienced by a patient living through that time
period. An identical process was used for each of the
16 outcomes (Figure 2). A standardized questionnaire
supported by printed interview tools with graphical
displays was used to facilitate the participant’s under-
standing of the Time Trade-oﬀ technique. To minimize
the framing eﬀect, all pathways were presented in a
consistent manner pictorially.
Value-based pricing analysis for the Spanish health
care system
A cost utility analysis was undertaken to estimate a
value-based price for the ‘new drug’ in the ﬁrst line
treatment of mCRC. The initial analysis assumed
that the addition of the ‘new drug (bevacizumab)’
to ﬁrst line oxaliplatin-based chemotherapy would
provide a survival beneﬁt of 1.4 month as reported
in the literature.34 The primary outcome of interest
was to estimate a price per dose for the ‘new drug’
using a targeted incremental cost of E78,300 per
QALY gained, which is three times the Spanish per
capita GDP.22 The evaluation did not include indirect
costs because such data were not available for beva-
cizumab. In addition, future costs and beneﬁts were
not discounted because of the short-time periods
involved. However, the stability of the baseline results
was evaluated by a one-way sensitivity analysis. This
consisted of substituting the 95% conﬁdence intervals
(CI) for the health state utilities as well as variations
in the overall survival beneﬁt and costs of care.
Speciﬁcally, the survival gain was varied to 3 and
6 months from the baseline of 1.4 month. Costs
were changed by 15% to account for variations in
costs across Spain.
Results
The literature search identiﬁed the relevant randomized
trials to populate the PE model (Table 1). The ﬁrst trial
evaluated FOLFOX or a clinically similar regimen
XELOX (capecitabine plus oxaliplatin) bevacizumab
in the ﬁrst line treatment of mCRC.34 A total of
1401 patients were randomized to receive FOLFOX/
XELOX+bevacizumab (n¼ 699) or FOLFOX/
XELOX+placebo (n¼ 701). Median progression free
survival was 9.4 months in the bevacizumab group
compared to 8.0 months with placebo (HR¼ 0.83;
p¼ 0.023). This resulted in a 1.4-month survival
gain in favor of bevacizumab. Overall, 30% of
patients in the bevacizumab group required a
permanent treatment discontinuation because of
adverse events compared to 20% in the control
(Table 1).
Data on the safety and eﬃcacy of second line
FOLFIRI following ﬁrst line FOLFOX were obtained
from a randomized sequential trial reported by
Tournigand et al.28 Patients were randomized to receive
sequential FOLFOX followed by FOLFIRI upon
progression or the reverse sequence (Table 1). There
was no signiﬁcant diﬀerence in progression free
and overall survival (FOLFOXFOLFIRI¼ 21.5 vs.
FOLFIRIFOLFOX¼ 20.6months; p¼ 0.99) between
the two sequences.28 With second line FOLFIRI, 51%
of patients experienced disease progression for an overall
progression free survival of 2.5 months, respectively.28
Approximately, 3% of patients died within the ﬁrst
60 days of second line FOLFIRI (Table 1).
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Estimation of treatment costs
From the unit cost estimates in Spain, the cost per cycle
of FOLFOX was estimated to be E825. However,
before the ﬁrst cycle of FOLFOX, the protocol start-
up costs were estimated to be approximately E221
(Table 2). The costs per cycle for FOLFIRI were
slightly less at E665 with the associated start-up costs
being E239. Additional costs required to populate the
model which included costs for the management of
severe toxicity, administration of the ‘new drug,’ and
best supportive care are presented in Table 3. These
estimates were then incorporated into the PE model
for the subsequent pricing analysis.
Health state utility assessments
Health state utilities for the time period spent in each of
the 16 health outcomes were the second component
required for the analysis (Figure 2). Utilities for
Table 1. Published randomized trials providing clinical data to
populate the economic model
Reference Treatment arms Clinical outcomes
Saltz FOLFOX/XELOX Disease progression¼ 47%
et al.34 + placebo Median PFS¼ 8.0 months
Median duration of
response¼ 7.4 months
Overall survival¼ 21.3 months
Treatment discontinuations¼ 20%
Death during treatment¼ 1%
Serious side effects
(grade III/IV)¼ 8%
Specific grade III/IV side effects
Deep vein thrombosis¼ 5%
Diarrhea¼ 11%
Bleeding¼ 1%
Neutropenia¼ 44%
FOLFOX/XELOX Disease progression¼ 29%
+ bevacizumab Median PFS¼ 9.4 months
Median duration of
response¼ 8.45 months
Overall survival¼ 19.9 months
Treatment discontinuations¼ 30%
Death during treatment¼ 2%
Serious side effects
(grade III/IV)¼ 16%
Specific grade III/IV side effects
Deep vein thrombosis¼ 8%
Diarrhea¼ 18%
Bleeding¼ 2%
Neutropenia¼ 50%
Tournigand Second Disease progression¼ 51%
et al.28 Line FOLFIRI Death during treatment¼ 3%
Median PFS¼ 10.9 months
Median number of cycles¼ 6
Abbreviations: PFS¼ progression-free survival, OS¼ overall survival,
FOLFOX¼ oxaliplatin in combination with infusional 5-fluorouracil, and
FOLFIRI¼ irinotecan in combination with infusional 5-fluorouracil.
Table 3. Hospital costs for the treatment of metastatic CRC
in Spain
Recourse item Hospital cost
FOLFOX chemotherapya E825/cycle
FOLFIRI chemotherapyb E665/cycle
Cost for a permanent chemotherapy
discontinuation because of toxicityc
E1778
Cost to administer the ’new drug’
after FOLFOX chemotherapy
E62.76
Cost of best supportive cared E1654/month
aOxaliplatin in combination with infusional 5-fluorouracil. Cost per cycle
includes resources for drug administration and routine patient
monitoring.
bIrinotecan in combination with infusional 5-fluorouracil.
cPatients would be admitted for 3 days for the management of side effects
and for reassessment. The principle side effects that would lead to the
discontinuation of therapy would be febrile neutropenia and grade III/IV
diarrhea.
dFrom Gomex-Batiste.30
Table 2. Mean cost per cycle of FOLFOX and FOLFIRI
Resource Itema FOLFOX FOLFIRI
Drug acquisitiona E521 E421
Ancillary drugsb E129.73 E59.84
Preparation and administrationc E85.75 E57.66
Patient monitoringd E88.69 E126.32
Protocol start-up costse E221.16 E239.09
Total cost per cycle E825 E665
aAssuming a 60-kg patient with a body surface area of 1.6m2.
bIncludes standard premedication and antiemetics.
cIncludes materials, supplies, personnel, chemotherapy unit stays, and
physician visits.
dStandard laboratory and diagnostic tests.
eThese costs are a one-time cost in order to prepare the patient for the
associated chemotherapy protocol. In the case of FOLFOX and FOLFIRI,
preparations and materials for infusional 5-fluorouracil made up the bulk
of the costs. For the economic analysis, the start-up costs were only
applied once over the estimated median number of cycles delivered,
thus avoiding double counting.
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each outcome were estimated from a sample of
24 respondents, consisting of oncology nurses (n¼ 7)
and pharmacists (n¼ 17). The sample had a mean age
of 38.2 years, an average of 10.9 years of direct oncol-
ogy experience (range 0.1–40 years) and all but two had
experience in the treatment of CRC patients. In addi-
tion, 22 of 24 (91.2%) respondents had direct clinical
experience in the preparation/administration and
follow-up care associated with FOLFOX (mean
years¼ 6.1) and FOLFIRI (mean years¼ 5.4) chemo-
therapy. Furthermore, 100% and 95.8% had experi-
ence with the newer targeted therapies bevacizumab
and cetuximab. Lack of drug cost knowledge could
aﬀect treatment preferences. Respondents were asked
to state their knowledge of costs for modern oncology
drugs. The ﬁndings revealed that 91.7% were ‘very
familiar’ or ‘somewhat familiar’ with the cost of drugs
used to treat cancer. The ﬁnal series of demographic
questions focused on respondent’s family history of
CRC. Eleven of 24 (45.8%) subjects had a positive
family history for CRC.
The health state utilities from the respondents are
presented in Table 4. The results suggested that patient
utilities were most inﬂuenced by the severity of side
eﬀects and the speed of disease progression. The
health states with the lowest utilities (i.e., branches 1,
4, 9, and 12 of the model – Figure 2) were those where
ﬁrst line therapy had to be stopped because of severe
toxicity, the patient then had an early progression
during second line treatment followed by cancer
death a few months later. The branches with among
the highest utilities (i.e., branches 7 and 15) were
those where the patient tolerated the treatment,
responded to ﬁrst line therapy and then went on to
receive maximum cycles. However, an unexpected
ﬁnding was that the two scenarios of rapid cancer
death within 2 months of starting chemotherapy
(i.e., branches 8 and 16) were associated with high
health state utilities (Table 4). The interpretation of
this latter ﬁnding is that in cases of terminal disease,
respondents may not be averse to a rapid death that
would avoid prolonged pain and suﬀering.
Alternatively, some respondents with only a short
time to live may not be willing to trade length of life
because they would want some time to settle their
aﬀairs and say good bye to loved ones.
Another observation was that branches which
included treatment with the ‘new drug’ had comparable
health state utilities to those where chemotherapy alone
was given (Table 4). The hypothesis is that respondents
were more concerned with achieving a disease response
than the inconvenience and added risk of toxicity with
the ‘new drug.’ Therefore, they were willing to endure
toxicity from the addition of the new drug if it were to
prolong life.
Value-based pricing analysis
Using the cost and utility data collected from the
Spanish respondents along with a value threshold of
E78,300 per QALY gained, the PE model was used to
estimate a price for bevacizumab that would be consid-
ered cost eﬀective. Assuming that bevacizumab would
provide a 1.4-month survival beneﬁt when added to
FOLFOX chemotherapy, it could be priced at E342
per dose and be considered cost eﬀective from the
Spanish health care system perspective according to
the WHO criteria.19–21 This is substantially lower
than the current price of bevacizumab which is greater
than E900 per dose for a 60-kg patient.
The stability of the base case price point was tested
with a series of one-way sensitivity analyses. These
consisted of using the lower and upper 95%CI of the
health state utilities, variations (15%) in the cost of
chemotherapy, best supportive care, and the manage-
ment of side eﬀects from anticancer therapy. In addi-
tion, the overall survival beneﬁt of adding the new drug
to FOLFOX chemotherapy was changed to 3 and
6 months, respectively. The results indicated that vari-
ations in the above costs had only minor eﬀects on
the overall price point for the new drug (Table 5).
However, variations in the utilities and in the survival
beneﬁt did have a substantial eﬀect on the price point.
The drug price rose to E733 when the upper 95%CI
of the health state utilities for the new drug were
applied to the model. In contrast, the price point for
cost eﬀectiveness was reduced to E318 when the lower
95%CI was used (Table 5). Similarly, increasing the
overall survival beneﬁt to 3 and 6 months allowed the
drug price to increase to E843 and E2138 while retain-
ing the same level of cost eﬀectiveness. When the
survival beneﬁt was reduced to only 1 month, the
price of the ‘new drug’ would have to be $342 per
dose in order to achieve a cost per QALY of
E78,300. To summarize, the major factors that would
aﬀect the economic value of a new drug for mCRC
would be its ability to improve patient quality of life
and overall survival by at least 3 months.
Discussion
The price of pharmaceuticals, particularly anticancer
agents have been increasing more rapidly than any
other component of health care.35,36 Rising drug costs
have now become a global concern as public systems
struggle to oﬀer modern treatments within a limited
health care budget. Some view this as threatening the
health care systems that are integral to the modern
social contract itself.8,37 Therefore, a new process for
estimating drug price based on reasonable thresholds
for economic value is required. Such thresholds should
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Table 4. Health state utilities derived using the Time Trade-off technique
Sixteen health outcomes evaluated in the decision model
Time in
health statea
Utility estimateb
[mean (95%CI)]
FOLFOX+ ‘new drug’! FOLFIRI! BSC until death
Branch #1: Stopped FOLFOX+ the ‘new drug’ after two cycles due to side effects and was then treated
with FOLFIRI for four cycles. There was disease progression. The patient received BSC and died 6
months later.
10 months 0.53 (0.46–0.60)
Branch #2: Stopped FOLFOX+ the ‘new drug’ after two cycles due to side effects and was then treated
with FOLFIRI. There was a response to FOLFIRI and the patient went on to receive eight cycles. Upon
progression, the patient received BSC and died 22 months later.
28 months 0.65 (0.57–0.87)
Branch #3: Stopped FOLFOX+ the ‘new drug’ after two cycles due to side effects and was then treated
with FOLFIRI. There was a response to FOLFIRI and the patient went on to receive eight cycles. Upon
progression, the patient received BSC and died 2 months later.
8 months 0.67 (0.58–0.76)
Branch #4: Stopped FOLFOX+ the ‘new drug’ after two cycles due to side effects and was then treated
with FOLFIRI for two cycles. However, the patient died due to cancer progression within the first 2
months.
4 months 0.52 (0.42–0.62)
Branch #5: Tolerated side effects but had disease progression after four cycles of FOLFOX+ the ‘new
drug.’ The patient was then treated with FOLFIRI for four cycles but the disease did not respond. The
patient received BSC and died 2 months later.
6 months 0.61 (0.55–0.68)
Branch #6: Tolerated side effects and responded FOLFOX+ the ‘new drug.’ The patient went on to
receive a total of 17 cycles of first line therapy. Upon progression, the patient went on to receive six
cycles of FOLFIRI. Upon progression, the patient received BSC and died 21 months later.
29 months 0.69 (0.61–0.76)
Branch #7: Tolerated side effects and responded FOLFOX+ the ‘new drug.’ The patient went on to
receive a total of 17 cycles of first line therapy. Upon progression, the patient went on to receive two
cycles of FOLFIRI but died 2 months later.
11 months 0.81 (0.74–0.89)
Branch #8: Tolerated side effects and but had disease progression after two cycles of FOLFOX+ the ‘new
drug.’ The patient died due to the cancer 1 month later.
2 months 0.84 (0.75–0.94)
FOLFOX! FOLFIRI! BSC until death
Branch #9: Stopped FOLFOX after two cycles due to side effects and was then treated with FOLFIRI for
four cycles. There was disease progression. The patient received BSC and died 6 months later.
10 months 0.54 (0.47–0.62)
Branch #10: Stopped FOLFOX after two cycles due to side effects and was then treated with FOLFIRI.
There was a response to FOLFIRI and the patient went on to receive eight cycles. Upon progression,
the patient received BSC and died 22 months later.
28 months 0.66 (0.59–0.74)
Branch #11: Stopped FOLFOX after two cycles due to side effects and was then treated with FOLFIRI.
There was a response to FOLFIRI and the patient went on to receive eight cycles. Upon progression,
the patient received BSC and died 2 months later.
8 months 0.68 (0.59–0.77)
Branch #12: Stopped FOLFOX after two cycles due to side effects and was then treated with FOLFIRI for
two cycles. However, the patient died due to cancer progression within the first 2 months.
4 months 0.53 (0.43–0.63)
Branch #13: Tolerated side effects but had disease progression after four cycles of FOLFOX. The patient
was then treated with FOLFIRI for four cycles but the disease did not respond. The patient received
BSC and died 2 months later.
6 months 0.61 (0.55–0.68)
Branch #14: Tolerated side effects and responded FOLFOX. The patient went on to receive a total of 15
cycles of first line therapy. Upon progression, the patient went on to receive six cycles of FOLFIRI.
Upon progression, the patient was offered BSC and died 21 months later.
32 months 0.65 (0.57–0.73)
Branch #15: Tolerated side effects and responded FOLFOX. The patient went on to receive a total of 15
cycles of first line therapy. Upon progression, the patient went on to receive two cycles of FOLFIRI but
died 2 months later.
11 months 0.80 (0.72–0.87)
Branch #16: Tolerated side effects and but had disease progression after two cycles of FOLFOX. The
patient died due to cancer progression 1 month later.
2 months 0.84 (0.75–0.94)
Abbreviations: FOLFOX¼ oxaliplatin + infusional 5-FU. FOLFIRI¼ irinotecan + infusional 5-FU, BSC¼ best supportive care.
aAs presented in each branch of the decision analysis model.
bA quality of life score for a health state between 0 and 1, with 0¼ death and 1¼optimal health.
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consider the wealth of a nation but at the same time
provide price points for new agents that would provide
a return of investment to the innovating company.
In this study, we present a process that uses PE
modeling along with the WHO criteria for economic
value to determine price points for new cancer drugs.
Using mCRC patients from Spain as our case study, we
demonstrated that prices ranging from E843 to E2138
would be considered cost eﬀective for a new drug that is
able to improve survival by 3–6 months, respectively.
Considering a drug like bevacizumab which provided
the clinical data for the case study, the price estimates
generated suggest that it has priced excessively, given
the modest 1.4-month survival gain and the lack of
quality of life data in mCRC patients.
Our proposed approach to drug pricing has several
advantages such as improved transparency to many
stakeholders and also the ability to link product perfor-
mance to price. We would also argue that it is prefer-
able to current draconian measures such as mandated
government price controls which may compromise
patent care and threaten innovation.11–13 In the very
least, our proposed value-based pricing approach
provides the starting point for committed negotiations
between payers and the pharmaceutical industry.
There are a number of limitations in the application
of this technique that have to be discussed. For our
modeling strategy to be applied, a new drug must
demonstrate either an improvement in quality of life
over the standard of care or a survival of suﬃcient
magnitude to identify a ﬁnal price point that would
be commercially viable for the manufacturer. Our
modeling exercise was theoretical using simple decision
analysis. For the proposed methodology to be viable,
complete data from randomized trials on a drug by
drug basis are required to conduct more robust
economic modeling such as Markov processes.
We used oncology nurses and pharmacists to provide
the utility data. Even though there are data suggesting
that such a sample provides acceptable data for cost
utility studies,33 mCRC patients would have been pref-
erable. The objective of our analysis was to provide a
systematic process that would make important drugs
available to patients at a price that is considered to be
cost eﬀective. This does not necessarily mean that
annual drug expenditures will be contained. True ther-
apeutic innovation requires an investment by society.
Therefore, increased spending for innovative drugs
should be expected and planned for by formulary com-
mittees. The budgetary planning process is also compli-
cated and many other factors such as price cuts from
the manufacturer during a drugs life cycle and the exis-
tence of lower priced alternatives need to be considered.
At the time of the publication, price cuts of up to 30%
for oxaliplatin and irinotecan were implemented in
Spain. However in our sensitivity analysis, the lowest
range in the cost of these drugs that we considered was
15%. Nevertheless, reductions of oxaliplatin and irino-
tecan costs of up to 30% would have only had a mini-
mal impact on our base case results because such costs
were not major drivers in estimating the ﬁnal price
points for cost eﬀectiveness.
Conclusions
A value-based pricing approach using PE modeling and
the WHO criteria for economic value is feasible and a
better alternative to government mandated price cuts.
The former approach would also be a good starting
point for opening dialogue between government
payers and the pharmaceutical industry because it
would link drug price to overall product performance.
Funding source
This study was not supported by external funding but
part of a PhD thesis.
Table 5. Sensitivity analysis on the unit price for the ‘new drug.’
Sensitivity manoeuvrea Price per dose
Base case E342
Lower and upper 95%CI of health state utilities for chemotherapy + the ‘new drug’ E318 to E733
Changing cost of FOLFOX chemotherapy by 15% E323 to E361
Changing cost of FOLFIRI chemotherapy by 15% E340 to E344
Changing cost of BSC cost by 15% E282 to E402
Changing cost of ADR cost by 15% E339 to E345
Changing survival benefit of the ‘new drug’ from 1.4 to 3 months E843
Changing survival benefit of the ‘new drug’ from 1.4 to 6 months E2138
Abbreviations: FOLFOX¼Oxaliplatin in combination with infusional 5-fluorouracil, FOLFIRI¼ Irinotecan in combination with infusional 5-fluorouracil,
BSC¼ best supportive care, and ADR¼ adverse drug reaction costs.
aFor a target threshold of E78,300 per QALY when the new drug is added to FOLFOX chemotherapy.
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overall survival did not exceed 6 months [7]. With the emergence of
agents like bevacizumab and cetuximab, overall survival in combi-
nation with first line fluorouracil-based chemotherapy has now
exceeded 20 months [9,10]. Therefore as a society, we must deter-
mine what we are willing to pay for a life year gained [6].
Quality adjusted life years (QALYs) are a way of measuring the
total impact of a disease such as cancer. They include both quality
and the quantity of life and are used to quantify the relative benefit
of two competing medical interventions. Through the application
of pharmacoeconomic (PE) analysis, the incremental cost per
QALY gained between a new treatment and the standard of care is
then determined, which is then followed by a funding decision
[11]. Such evaluations are typically conducted once a new product
is approved for clinical use and the price per dose has been set.
However, PE may have an additional and perhaps more valuable
role in estimating or negotiating the price of the drug based on
societal value thresholds and before it becomes commercially
available. PE has been used for negotiating a final price for a few
cancer drugs assessed by the National Institute of Clinical Excel-
lence (NICE) of the United Kingdom (UK) [12]. Hence, this
approach can also be used to estimate a value-based price for the
drug prior to regulatory approval.
One of the major challenges against the use of PE analysis for
estimating a value-based drug price is in establishing the threshold
for value within a given country. Many nations have been reluctant
to publicly state such a figure because of the ethical issue of
placing a monetary value on human life. To address this, the World
Health Organization (WHO) has proposed to use multiples of a
country’s per capita gross domestic product (GDP) to establish
thresholds for economic value [13–15]. Products less than or equal
to the per capita GDP would be considered very cost-effective, one
to three times would be cost-effective and more than three times
would be cost-ineffective [13]. Using Canada as an illustration (i.e.
per capita GDP = $US39 000), the three-time threshold for cost-
effectiveness of new anticancer drugs would be approximately
$US117 000 per QALY gained [16]. For a lower income country
such as India (per capital GDP = $US3100), the cost per QALY
gained threshold would be $US9300.
The use of thresholds based on per capita GDP in combination
with PE modelling to establish a value-based price for a drug is
an interesting approach because it would determine a final price
based on the attributes of the product in terms of disease
response, survival and quality of life benefits. To illustrate the
application of this drug pricing strategy, PE modelling was used
in the current study to estimate the price of bevacizumab, a
cancer drug that is commercially available. However in this
analysis, bevacizumab was defined as the ‘new drug’. The clini-
cal scenario for the case study was bevacizumab in combination
with the first line chemotherapy for treatment of mCRC [17].
This agent was chosen because it has a high acquisition price and
its economic value has been questioned in recent PE studies
[18,19].
Methods
Economic model
The clinical and economic outcomes for mCRC were modelled
using the principles of decision analysis. mCRC was chosen
because the sequential use of specific chemotherapy regimens is
well established. The current standard of care for the first line
treatment of mCRC is oxaliplatin in combination with infusional
5-fluorouracil (FOLFOX). In patients who have disease progres-
sion or intolerable toxicity, second line irinotecan in combination
with infusional 5-fluorouracil (FOLFIRI) is a recommended treat-
ment [20,21]. Data from a large randomized trial also verified that
sequential schedules of FOLFOX and FOLFIRI (or the reverse
order) are equally effective and have thus emerged as the first and
second line standard of care for patients with mCRC [22]. The
addition of an anti-vascular endothelial growth factor (VEGF)
such as bevacizumab at some point during chemotherapy for
mCRC has also been recommended by clinical practice guidelines
[23].
A decision model for the sequential treatment of mCRC with
FOLFOX (an anti-VEGF agent) and then followed by FOLFIRI
upon disease progression was developed with the DATA software
(Treeage Software Inc., Williamstown, MA, USA) (Fig. 1). The
analytic timeframe was from the first cycle of FOLFOX chemo-
therapy until death and a Canadian health care system perspective
was taken. The primary outcome for measuring successful initial
therapy was clinical benefit, defined as complete tumour response
(CR), partial response (PR) or stable disease (SD) based on the
Response Evaluation Criteria in Solid Tumors. Three clinical
oncologists who had experience in colorectal cancer evaluated the
face and content validity of the model.
The model began at the decision node (square) where the first
line treatment choice would be either FOLFOX + ‘the new drug
(bevacizumab)’ or FOLFOX alone (Fig. 1). During the first two
cycles of chemotherapy, patients would be assessed for intoler-
able toxicity. For those patients with severe toxicity, first line
therapy would be discontinued in its entirety and second line
FOLFIRI would be offered until disease progression. Upon pro-
gression, all patients would receive best supportive care until
death. In contrast, patients who do not experience severe toxicity
from first line FOLFOX (‘the new drug’) would also receive
treatment until disease progression. They would then be offered
second line FOLFIRI alone and the ‘new drug’ would be discon-
tinued. Upon progression, all patients would receive best sup-
portive care until death (Fig. 1). To simplify the modelling,
epidermal growth factor receptor (EGFR) inhibitors such as
cetuximab in mCRC patients with KRAS wild-type tumours
were not considered. Furthermore, such agents would be avail-
able to both treatments options in the model, so their inclusion
would not impact the final results.
Clinical data
The clinical data required to populate the model consisted of early
treatment discontinuations because of toxicity, achievement of
clinical benefit (CR + PR + SD), duration of clinical benefit, risk
of cancer-related death during active treatment and number of
chemotherapy cycles administered. These data were obtained
through a literature search of randomized trials evaluating
FOLFOX (bevacizumab) in the first line setting and second line
FOLFIRI in the treatment of mCRC. A literature search of
Medline, Embase and the Cochrane databases was performed from
2000 to 2010 for human clinical studies involving FOLFOX,
FOLFIRI and bevacizumab as first and second line therapy in
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mCRC. The primary objective of the review was to identify the
most up-to-date clinical data for populating the model. Care was
taken to avoid inclusion of duplicate publications.
Estimation of treatment costs
The analytic time period for this investigation was from the start of
first and second line sequential chemotherapy until disease pro-
gression and a Canadian health care system perspective was taken.
To estimate the direct overall cost of a cycle of FOLFOX and
FOLFIRI, a series of quantitative interviews were conducted with
oncology nurses and pharmacists who had experience in managing
colorectal cancer patients and in the preparation and administra-
tion of infusional 5-fluorouracil, oxaliplatin, irinotecan and beva-
cizumab in this patient population. Overall, 12 health care
professionals from three distinct cancer centres (four from each
centre) were interviewed to determine the direct resource require-
ments for FOLFOX, FOLFIRI and bevacizumab. For each chemo-
therapy protocol, a standardized data collection form was used to
collect such items as drug dosage, materials and pharmacy time
required for chemotherapy preparation, prophylactic medication,
laboratory and diagnostic tests, physician visits, nursing time to
administer treatment and all other relevant hospital resource
requirements.
In addition to direct costs for drug acquisition, preparation,
administration and monitoring, ancillary health care resources
required by these patients were also quantified. These include
costs for interventions to manage grade III/IV side effects, pallia-
tive care costs such as radiation for bone pain, blood transfusions
and recombinant erythropoietin for severe anaemia (in some
patients), analgesics for pain control and physician costs. In addi-
tion, it was assumed that all patients would receive home health
care visits or hospice care. These additional data were obtained
from the three colorectal cancer oncologists through a standard-
ized data collection form.
Costs for drugs, materials and other related hospital resources
(e.g. laboratory and diagnostic tests) were obtained from the
University Health Network, 2010. Physician’s fees for service
were obtained from the Schedule of Benefits: Physician Services
under the Health Insurance Act, Ontario Ministry of Health,
2008. Costs from non-Canadian sources were converted and
updated into 2010 Canadian dollars using the consumer price
index for health care as reported by Statistics Canada
($CAD1 = $US1, as of June 2010).
Disease progress, BSC until death – 5months later
Offer BSC until death
– 22 months later
Offer 2nd line FOLFIRI
until death – 24 months later
Cancer death – 2 months later
Disease progress, offer 2nd line FOLFIRI until death
Disease progress, BSC until death – 5 months later
Disease progress, other 2nd line FOLRIFI until death – 5 months later
Clinical benefit (CR + PR + SD), Con’t regimen
Clinical benefit (CR + PR + SD), Con’t regimen
Clinical benefit (CR + PR + SD), Con’t regimen
Clinical benefit (CR + PR + SD), Con’t regimen
Cancer death – 2 months later
Cancer death within 2 months
Cancer death – 2 months later
Cancer death within 2 months
Severe ADRs, D/C regimen,
offer FOLFIRI alone
Severe ADRs, D/C regimen,
offer FOLFIRI alone
No Severe ADRs, Con’t chemo
No Severe ADRs, Con’t regimen
FOLFOX +
New Drug
mCRC patient
FOLFOX only
70%
20%
80%
30%
2%
3%
1%
3%
95%
5%
Cancer death – 2 months later
5%
95%
Offer BSC until death
– 22 months later
Cancer death – 2 months later
5%
95%
Offer 2nd line FOLFIRI
until death – 24 months later
Cancer death – 2 months later
5%
95%
69% – 8.5 months
46% – 2 months + 4 months
51% – 2 months + 3 months
29% – 2 months + 4 months
51% – 2 months + 3 months
46% – 2 months + 4 months
47% – 2 months + 4 months
52% – 7.4 months
Figure 1 Decision analysis model for the treatment of metastatic colorectal cancer. ADR, adverse drug reaction costs; BSC, best supportive care; CR,
complete tumour response; D/C, discontinued; FOLFIRI, irinotecan in combination with infusional 5-fluorouracil; FOLFOX, oxaliplatin in combination
with infusional 5-fluorouracil; mCRC, metastatic colorectal cancer; PR, partial response; SD, stable disease.
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Treatment preferences and health state utilities
The health-related quality of life values measured in the analysis
were patient preferences for alternative health outcomes, as
depicted in the decision analytic model (Fig. 1). In the current
study, quality-adjusted life periods were measured as ‘healthy
months equivalent’ for the time spent in each outcome of the
decision model using the Time Trade-off technique [24,25].
Healthy month equivalence scores measure patient utilities for a
given health state. A lower healthy month equivalence for the total
time spent in a given health state suggests poorer quality of life
during that time period (e.g. a time period when a cancer progres-
sion occurs). The scores in months were then converted to utility
measures between 0 and 1, where 0 represented death and 1 was a
state of perfect health or optimal quality of life. Gains in healthy
month equivalence were also converted into QALYs by dividing
by 12 months and then entered into the associated branches of the
decision analysis model.
Intuitively, the ideal population for measuring health state utili-
ties and treatment preferences should be cancer patients with the
disease in question who are in a position to receive the new
treatment. However, it has been recommended in the Canadian
Guidelines for Economic Evaluations and by the Panel on Cost-
Effectiveness in Health and Medicine of the United States that
treatment preferences be measured from members of the general
public who are potential candidates of the new medical interven-
tion [11,26]. However based on our experience, members of the
general public have difficulty in understanding cancer-related
utility questionnaires. As a compromise, a patient surrogate group
was used that would provide insight from both the perspective of
the patient and members of the general public. There is also evi-
dence in the oncology literature to suggest that nurses are suitable
patient surrogates for objective outcomes, and that utility estimates
derived from such a sample do not substantially alter the findings
of cost utility studies [27,28]. Therefore, a patient surrogate
sample consisting of 24 oncology nurses provided utility values
for the model. With a sample of 24 respondents, healthy month
equivalence was measured with a precision of1.0 month, with a
95% probability.
After informed consent was obtained, each participant was
interviewed for 30 to 45 minutes by trained local field investiga-
tors. Respondents were presented with information on FOLFOX,
bevacizumab and FOLFIRI consisting of the methods of adminis-
tration, efficacy and the side effects reported in the literature. The
interview was then continued with a description of the 16 health
states and the length of time a patient would live in each health
state (Fig. 1). The respondents were then asked how many months
of ‘optimal health’ they considered being equivalent to the time
spent in each of the less than optimal health states described in the
model. These measures were then used to weigh each branch of the
model by the quality of life experienced by a patient living through
that time period. An identical process was used for each of the 16
outcomes (Fig. 1).
A standardized questionnaire supported by printed interview
tools with graphical displays was used to facilitate the participant’s
understanding of the Time Trade-off technique. To minimize the
framing effect, all pathways were presented in a consistent manner
pictorially. Demographic data were also collected from each par-
ticipant, and consisted of years of oncology and colorectal cancer
experience, involvement in the development of systemic treatment
guidelines for colorectal cancer, familiarity with the cost of anti-
cancer drugs and family history of colorectal cancer.
Value-based pricing using cost utility analysis
The clinical, economic and respondent utility data were then com-
bined into a cost–utility analysis to estimate a price per dose for the
‘new drug’ in the first line treatment of mCRC. The base case
analysis assumed that the addition of the bevacizumab to standard
chemotherapy would provide a survival benefit of 1.4 months (vide
infra). The primary objective of the analysis was to estimate a
price for the ‘new drug’ using a targeted incremental cost of
$US117 000 per QALY gained, which is three times the Canadian
per capita GDP [16]. Indirect costs were not included because
there was no data available on the association between bevaci-
zumab usage and indirect cost avoidance. Future costs and benefits
were not discounted because of the short time periods involved.
However, the stability of the baseline results was evaluated by a
one-way sensitivity analysis. This consisted of substituting the
95% confidence intervals (CI) for the health state utilities as well
as variations in the overall survival benefit and costs of care.
Overall survival was increased by approximately two and four
times to account for gains that are considered clinically relevant
for new drugs in mCRC. Costs of care were varied by 15% to
capture any potential differences across the country.
Results
Two randomized trials were identified that provided the required
data for the decision model (Table 1). The first trial evaluated
FOLFOX or a clinically similar regimen XELOX (capecitabine
plus oxaliplatin) bevacizumab in the first line treatment of
mCRC [10]. A total of 1401 patients were randomized to
receive FOLFOX/XELOX + bevacizumab (n = 699) or FOLFOX/
XELOX + placebo (n = 701). The interaction between FOLFOX
and XELOX on the primary clinical endpoint was not statistically
significant (P = 0.70) thereby justifying the combining of patients
who received FOLFOX and XELOX [10]. Median progression
free survival was 9.4 months in the bevacizumab group compared
to 8.0 months with placebo (Hazard = 0.83; P = 0.023) resulting in
a survival gain of 1.4 months (P = 0.077). Overall, 30% of patients
in the bevacizumab group required a permanent treatment discon-
tinuation because of adverse events compared to 20% in the
control (Table 1). Approximately 2% and 1% of patients died
during treatment with bevacizumab and placebo (Table 1).
Data on the safety and efficacy of second line FOLFIRI follow-
ing first line FOLFOX was obtained from a randomized sequential
trial reported by Tournigand et al. [22]. Patients were randomized
to receive sequential FOLFOX followed by FOLFIRI upon pro-
gression or the reverse sequence (Table 1). There was no
significant difference in progression free and overall survival
(FOLFOX–FOLFIRI = 21.5 vs. FOLFIRI–FOLFOX = 20.6
months; P = 0.99) between the two sequences [22]. With second
line FOLFIRI, 51% of patients experienced disease progression
for an overall progression free survival of 2.5 months, respectively
[22]. Approximately 3% of patients died within the first 60 days of
second line FOLFIRI (Table 1).
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Estimation of treatment costs
A total of 12 respondents with experience in chemotherapy admin-
istration in patients with mCRC were interviewed to estimate the
resource utilization. Among the 12 respondents, the median dura-
tion of chemotherapy experience in mCRC was 14.6 years
(range = 5 to 33 years). Respondents for the interviews were
selected from three different cancer centres to ensure a wide range
of treatment settings. All 12 respondents had direct experience
with FOLFOX, FOLFIRI and bevacizumab.
The resource requirement data for each protocol collected
through the case report forms were then combined with the unit
cost estimates to determine the cost per cycle. FOLFOX at
$CAD2121 had the lowest cost per cycle followed by FOLFIRI at
$CAD684 (Table 2). Additional costs required to populate the
model which included costs for the management of severe toxicity,
administration of the bevacizumab and best supportive care are
presented in Table 3. These estimates were then incorporated into
the decision model for the subsequent pricing analysis.
Health state utility assessments
The second component required for the cost–utility analysis was
health state utilities for the time period spent in each of the 16
health states (Fig. 1). Utilities for each outcome were estimated
Table 2 Mean cost per cycle of FOLFOX and FOLFIRI
Resource item* FOLFOX ($CAD) FOLFIRI ($CAD)
Drug acquisition* 1530.00 179.00
Ancillary drugs† 163.10 89.13
Preparation and
administration‡
339.19 331.36
Patient monitoring§ 88.70 84.42
Protocol start up costs¶ 199.07 213.63
Total cost per cycle (95%CI) 2121 (1919–2326) 684 (601–768)
*Assuming a 60-kg patient.
†Includes standard premedication and antimetics.
‡Includes materials, supplies, personnel, chemotherapy unit stays and
physician visits.
§Standard laboratory and diagnostic tests.
¶These costs are a one-time cost in order to prepare the patient for the
associated chemotherapy protocol. In the case of FOLFOX and FOLFIRI,
preparations and materials for infusional 5-fluorouracil made up the bulk
of the costs. For the economic analysis, the start-up costs were only
applied once over the estimated median number of cycles delivered.
Thus avoiding double counting.
FOLFOX, oxaliplatin in combination with infusional 5-fluorouracil;
FOLFIRI, irinotecan in combination with infusional 5-fluorouracil.
Table 1 Published randomized trials providing
clinical data to populate the economic model
Reference Treatment arms Clinical outcomes
Saltz et al.,
(2008) [10]
FOLFOX/XELOX +
bevacizumab
Disease progression = 29%
Median PFS = 9.4 months
Median duration of response = 8.45 months
Overall survival = 21.3 months
Treatment discontinuations = 30%
Death during treatment = 2%
Serious side effects (grade III/IV) = 16%
Specific grade III/IV side effects
Deep vein thrombosis = 8%
Diarrhea = 18%
Bleeding = 2%
Neutropenia = 50%
FOLFOX/XELOX +
placebo
Disease progression = 47%
Median PFS = 8.0 months
Median duration of response = 7.4 months
Overall survival = 19.9 months
Treatment discontinuations = 20%
Death during treatment = 1%
Serious side effects (grade III/IV) = 8%
Specific grade III/IV side effects
Deep vein thrombosis = 5%
Diarrhea = 11%
Bleeding = 1%
Neutropenia = 44%
Tournigand et al.,
(2004) [23]
Second Line
FOLFIRI
Disease progression = 51%
Death during treatment = 3%
Median PFS = 10.9 months
Median number of cycles = 6
PFS, progression free survival; FOLFOX, oxaliplatin in combination with infusional 5-fluorouracil;
FOLFIRI, irinotecan in combination with infusional 5-fluorouracil; XELOX, capecitabine plus
oxaliplatin.
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from a sample of 24 respondents, consisting of oncology nurses
(n = 12) and pharmacists (n = 12). The sample had a mean age of
41.3 years and an average of 11.1 years of direct oncology expe-
rience (range 0–23 years) and all but one had experience in the
treatment of colorectal cancer patients. In addition, 20 of 24
(83.3%) respondents had direct clinical experience in the admin-
istration and follow-up care associated with FOLFOX (mean
years = 4.9) and FOLFIRI (mean years = 4.8) chemotherapy. Fur-
thermore, 83.3% and 58.3% had experience with the newer tar-
geted therapies bevacizumab and cetuximab. Lack of drug cost
knowledge could affect treatment preferences. Respondents were
asked to state their knowledge of costs for modern oncology drugs.
The findings revealed that 91.7% were ‘very familiar’ or ‘some-
what familiar’ with the cost of drugs used to treat cancer. The final
series of demographic questions focused on respondent’s family
history of colorectal cancer. The findings revealed that 3 of 24
(12.5%) subjects had a positive family history for colorectal
cancer. Therefore, the above data suggests that the respondent
sample was well informed about mCRC and able to provide mean-
ingful health state utility estimates.
The health state utilities from the oncology nurses are presented
in Table 4. The results suggested that patient utilities were most
influenced by the severity of side effects, the speed of disease
progression and the risk of rapid cancer death. The health states
with the lowest utilities (i.e. branches 4, 8, 12 and 16 of the model
– Fig. 1) were those where first line therapy had to be stopped
because of severe toxicity, and the patient then had an early pro-
gression during second line treatment followed by rapid cancer
death. It was also interesting to note that in all of the related
scenarios, branches that included treatment with the ‘new drug’
had comparable health state utilities to those where chemotherapy
alone was given (Table 4). The interpretation is that respondents
were more concerned with achieving a disease response than the
inconvenience and the added risk of toxicity with the ‘new drug’.
Therefore, they were willing to endure added toxicity from the
addition of the ‘new drug’.
Value-based pricing analysis
The outcomes data from the clinical trial, the estimated costs
associated with each treatment and the health state utility estimates
were combined for a value-based pricing analysis. The price for
one dose of the ‘new drug’ was then varied until the incremental
cost-effectiveness ratio reached a threshold of $CAD117 000 per
QALY gained. Using this approach from the public health care
system perspective, the base case analysis suggested that a price
per dose of $CAD830 would be considered cost-effective for
Canada according to the WHO criteria [13–15].
A series of one-way sensitivity analyses were then conducted
using the upper 95% CI for the health state utilities, variations in
treatment costs and overall survival benefit. When the costs of
chemotherapy, best supportive care and side effects management
were varied by 15%, the impact on the base case finding was
negligible (Table 5). The two biggest factors to impact the base
case findings were the health state utilities associated with the
‘new drug’ and the overall survival gain. The price rose to
$CAD1560 per dose when the upper 95% CI of the health state
utilities for the new drug were applied to the model. Increasing the
overall survival benefit from 1 to 3 and then 6 months allowed the
drug price to increase to $CAD2180 and $CAD3430 while pro-
viding the same cost per QALY.
Bevacizumab is available in Canada and the price is approxi-
mately $CAD2250 per dose (7.5 mg kg-1 for a 60 kg patient at a
price of $CAD5.00 mg kg-1) for an average mCRC patient. A
sensitivity analysis was conducted where the current price of beva-
cizumab was applied to the model. The results revealed that the
incremental cost per QALY gained would be $CAD224 000, well
above the $CAD117 000 WHO recommended threshold. In
summary, the sensitivity analyses suggested that a price of
approximately $CAD830 per dose for a ‘new drug’ that would
prolong patient survival by 1.4 months would be considered cost-
effective in Canada using the WHO criteria for value. This price
could be adjusted upwards if a new drug was able to enhance
patient quality of life or extend survival to 3 or 6 months.
Discussion
In many countries around the world, health care costs have been
rising beyond the rate of inflation [29,30]. The main components
of health care expenditures are costs for physicians, hospital ser-
vices and pharmaceuticals. Among these three, the latter is an
identifiable and easy source for initial cost containment initiatives.
This has certainly been the case in many European countries, as
they struggle to contain rising health care costs. In Spain and
Greece, the respective governments recently legislated price cuts
of up to 23% of branded products [31,32]. Annual drug expendi-
tures in Spain were approximately 12.5 billion euros in 2009, a
4.4% increase from the previous year [32]. Therefore, it was pro-
jected that these price cuts would save the national health care
system 1.3 billion euros [32]. France has also announced price cuts
for both branded and generic products [33]. However, more con-
Table 3 Hospital costs for the treatment of metastatic colorectal cancer
in Canada
Recourse item Public hospitals
FOLFOX chemotherapy* $CAD2121/cycle
FOLFIRI chemotherapy† $CAD684/cycle
Cost for a permanent chemotherapy
discontinuation because of toxicity‡
$CAD2312
Cost to administer the ‘new drug’ after
FOLFOX chemotherapy
$CAD60.50
Cost of best supportive care§ $CAD1233/month
*Oxaliplatin in combination with infusional 5-fluorouracul. Cost per cycle
includes resources for drug administration and routine patient
monitoring.
†Irinotecan in combination with infusional 5-fluorouracil.
‡Patients would be admitted for 3 days for the management of side
effects and for reassessment. The main toxicities leading to a discon-
tinuation were assumed to be either febrile neutropenia of grade III/IV or
diarrhoea.
§After failing two lines of chemotherapy, patients would receive best
supportive care on an outpatient basis until death. These resources
were obtained from a survey of three medical oncologists and consisted
of monthly patient needs such as radiation therapy, blood transfusions,
analgesics and home care.
FOLFOX, oxaliplatin in combination with infusional 5-fluorouracil;
FOLFIRI, irinotecan in combination with infusional 5-fluorouracil.
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cerning to the pharmaceutical industry is that Germany and the UK
plan to introduce a value-based drug pricing scheme where the
final price will be linked to the clinical and economic value that the
drug offers to society [34,35].
In the UK for instance, there is legislation that regulates profit but
not prices. It is not clear what the new scheme will look like, but new
product pricing will likely be based on the therapeutic value that it
brings to patients and the National Health Service because part of
the proposal was to reform NICE and move to a system of value-
based pricing [35]. If administered by NICE, it is likely that this new
pricing scheme will revolve around the incremental cost per QALY
where the current value-based threshold is £30 000 per QALY
Table 4 Health state utilities derived using the Time Trade-off technique
Sixteen health outcomes evaluated in the decision model
Time in health
state* (months)
Utility estimate†
[mean (95% CI)]
FOLFOX + ‘new drug’ → Folfiri → BSC until death
Branch #1: Stopped FOLFOX + the ‘new drug’ after 2 cycles due to side effects and was then treated
with FOLFIRI for 4 cycles. There was disease progression. The patient received BSC and died 6
months later.
10 0.61 (0.54–0.68)
Branch #2: Stopped FOLFOX + the ‘new drug’ after 2 cycles due to side effects and was then treated
with FOLFIRI. There was a response to FOLFIRI and the patient went on to receive 8 cycles. Upon
progression, the patient received BSC and died 22 months later.
28 0.63 (0.55–0.72)
Branch #3: Stopped FOLFOX + the ‘new drug’ after 2 cycles due to side effects and was then treated
with FOLFIRI. There was a response to FOLFIRI and the patient went on to receive 8 cycles. Upon
progression, the patient received BSC and died 2 months later.
8 0.65 (0.57–0.73)
Branch #4: Stopped FOLFOX + the ‘new drug’ after 2 cycles due to side effects and was then treated
with FOLFIRI for 2 cycles. However, the patient died due to cancer progression within the first 2
months.
4 0.47 (0.37–0.88)
Branch #5: Tolerated side effects but had disease progression after 4 cycles of FOLFOX + the ‘new
drug’. The patient was then treated with FOLFIRI for 4 cycles but the disease did not respond. The
patient received BSC and died 2 months later.
6 0.61 (0.51–0.72)
Branch #6: Tolerated side effects and responded FOLFOX + the ‘new drug’. The patient went on to
receive a total of 17 cycles of first line therapy. Upon progression, the patient went on to receive 6
cycles of FOLFIRI. Upon progression, the patient received BSC and died 21 months later.
29 0.72 (0.63–0.81)
Branch #7: Tolerated side effects and responded FOLFOX + the ‘new drug’. The patient went on to
receive a total of 17 cycles of first line therapy. Upon progression, the patient went on to receive 2
cycles of FOLFIRI but died 2 months later.
11 0.69 (0.62–0.76)
Branch #8: Tolerated side effects and but had disease progression after 2 cycles of FOLFOX + the ‘new
drug’. The patient died due to the cancer one month later.
2 0.44 (0.32–0.56)
FOLFOX → FOLFIRI → BSC until death
Branch #9: Stopped FOLFOX after 2 cycles due to side effects and was then treated with FOLFIRI for 4
cycles. There was disease progression. The patient received BSC and died 6 months later.
10 0.64 (0.57–0.70)
Branch #10: Stopped FOLFOX after 2 cycles due to side effects and was then treated with FOLFIRI.
There was a response to FOLFIRI and the patient went on to receive 8 cycles. Upon progression, the
patient received BSC and died 22 months later.
28 0.63 (0.55–0.72)
Branch #11: Stopped FOLFOX after 2 cycles due to side effects and was then treated with FOLFIRI.
There was a response to FOLFIRI and the patient went on to receive 8 cycles. Upon progression, the
patient received BSC and died 2 months later.
8 0.69 (0.62–0.76)
Branch #12: Stopped FOLFOX after 2 cycles due to side effects and was then treated with FOLFIRI for
2 cycles. However, the patient died due to cancer progression within the first 2 months.
4 0.49 (0.38–0.60)
Branch #13: Tolerated side effects but had disease progression after 4 cycles of FOLFOX. The patient
was then treated with FOLFIRI for 4 cycles but the disease did not respond. The patient received
BSC and died 2 months later.
6 0.62 (0.51–0.72)
Branch #14: Tolerated side effects and responded FOLFOX. The patient went on to receive a total of 15
cycles of first line therapy. Upon progression, the patient went on to receive 6 cycles of FOLFIRI.
Upon progression, the patient was offered BSC and died 21 months later.
32 0.68 (0.56–0.80)
Branch #15: Tolerated side effects and responded FOLFOX. The patient went on to receive a total of 15
cycles of first line therapy. Upon progression, the patient went on to receive 2 cycles of FOLFIRI but
died 2 months later.
11 0.71 (0.64–0.78)
Branch #16: Tolerated side effects and but had disease progression after 2 cycles of FOLFOX. The
patient died due to cancer progression one month later.
2 0.44 (0.32–0.56)
*As presented in each branch of the decision analysis model.
†A quality of life score for a health state between 0 and 1, with 0 = death and 1 = optimal health.
FOLFOX, oxaliplatin in combination with infusional 5-fluorouracil; FOLFIRI, irinotecan in combination with infusional 5-fluorouracil; BSC, best
supportive care.
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gained, which is equivalent to approximately $US50 000 [36]. This
latter threshold for value, which was based on a 1982 valuation, is
now equivalent to approximately $US197 000 per QALY in 2007
US dollars (after a 5.5% annual adjustment in health care inflation)
[13]. However, the $US50 000 threshold continues to be used and
quoted in the PE literature. If the new value-based pricing scheme
proposed by the UK government will revolve around the use of PE
modelling and a cost per QALY gained, a more up to date value
threshold will need to be identified.
To provide insight on alternative value thresholds, we used the
criteria for value recommended by the WHO. The advantage of
using the proposed WHO threshold is that the wealth of an indi-
vidual country is taken into consideration. Therefore, the price for
the same drug would be proportionally less in lower income coun-
tries compared to wealthier nations. In this study, we assessed the
feasibility of our proposed value-based pricing scheme to estimate
a price for bevacizumab, a drug that provides a 1.4-month survival
benefit when added to chemotherapy in the first line treatment of
mCRC.
The primary analysis was conducted from the Canadian public
health care system perspective using the WHO criteria for cost-
effectiveness. In the base case analysis and in most of the scenarios
evaluated, a price of approximately $CAD830 per dose was sug-
gested by the data as being cost-effective. If the drug were able to
improve patient quality of life above the standard of care or sur-
vival from 1.4 to 3 months, the drug price could increase to
$CAD1560 and $CAD2180 and still be considered cost-effective.
These findings indicate that the two most important factors driving
the cost-effectiveness of any new cancer drug is its ability to
significantly improve quality and quantity of life. Therefore, these
should be the primary and secondary end points of randomized
trials of new cancer agents because they are the two main drivers
for optimizing drug price.
What is interesting to note is that the outcomes generated in this
study are approximately 60% lower than the current price of beva-
cizumab in Canada (i.e. $CAD2250 per dose). Had a value-based
pricing scheme using theWHO value thresholds been applied to this
agent, a substantially lower price would have been proposed by
government payers. Such a price would have at least been the
starting point for negotiations between public payers and the manu-
facturer. This would be preferable to government mandated price
cuts that are currently ongoing in many European countries. Not-
withstanding, a price less than $CAD1000 per dose may be unten-
able for newer anticancer drugs currently under investigation
because research and development (R&D) costs for bringing a
product to market now exceed $CAD800 million [37]. Therefore, it
is unlikely that a value-based pricing scheme will be able to
mandate such large price reductions without affecting investment
into R&D.
There are a number of limitations in the application of this
technique that have to be discussed. Our modelling exercise was
theoretical using simple decision analysis and applied to a drug that
is already comerically available. For the proposed methodology to
be viable, complete data from randomized trials on a drug by drug
basis is required to conduct more robust economic modelling such
as Markov processes. mCRC patients who have KRAS wild-type
tumours would be offered EGFR inhibitors (e.g. cetuximab) fol-
lowing first line chemotherapy [38]. However, the inclusion of these
agents would have unnecessarily complicated the model and would
not have altered the final results. Many of the newer cancer drugs
such as bevacizumab, cetuximab and panitumumab that have been
introduced into clinical practice for mCRC have not demonstrated
a significant improvement in patient quality of life and their survival
benefit has been less than 3 months [20,39,40]. For our modelling
strategy to provide drug prices that are commercially viable for the
manufacturer, a new drug must demonstrate either an improvement
in quality of life over the standard of care or a survival of sufficient
magnitude (i.e. at least 3 months).
Conclusions
The intent of our analysis was to provide a systematic process that
would make important cancer drugs available at prices that are
considered to be cost-effective. This does not necessarily mean
that annual drug expenditures will be contained. True therapeutic
innovation requires an investment by society. Therefore, increased
spending for innovative drugs should be expected and planned for
by formulary committees. The use of the WHO criteria for setting
value thresholds is feasible, but it does not necessarily ensure the
commercial viability of the product in the reference country.
Therefore, the final threshold used for value-based pricing should
have input from all of the key stakeholders.
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ABSTRACT 
Background:  Decision analysis (DA) is commonly used to perform economic 
evaluations of new pharmaceuticals.  Using multiples of Malaysia’s per capita 2010 
GDP as the threshold for economic value as suggested by the World Health 
Organization (WHO), DA was used to estimate a price per dose for bevacizumab in 
Malaysia, a drug that provides a 1.4 month survival benefit in metastatic colorectal 
cancer (mCRC). 
Methods: A decision model was developed to simulate progression free and overall 
survival in mCRC patients receiving chemotherapy with and without bevacizumab.  
Costs for chemotherapy and side effects management were obtained from both public 
and private hospitals in Malaysia.  Utility estimates measured as QALYs were 
determined by interviewing 24 oncology nurses using the Time Trade-Off technique.  
The price per dose was then estimated using a target threshold of $44,400 per quality-
adjusted life year gained, which is three times the Malaysian per capita GDP. 
Results:  A cost effective price for bevacizumab could not be reached because of the 
short survival benefit provided.  If the drug were able to improve survival from 1.4 to 3 or 
6 months, then the price per dose could be $U.S.567 and $U.S.1,258 and be 
considered cost effective according to the WHO criteria. 
Conclusions:  The use of decision modelling for estimating drug price is a powerful 
technique to ensure value for money.  Such information can be of value to both drug 
manufacturers and formulary committees because it would facilitate negotiations for 
value-based pricing in a given jurisdiction. 
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INTRODUCTION 
 The rapid growth of healthcare expenditures has led to increased interest in 
economic evaluations of healthcare programmes.1  This is particularly true for 
pharmaceuticals, which constitute a substantial portion of the healthcare budget.2  The 
basic premise of pharmacoeconomic evaluations is to compare the costs and 
consequences of alternative pharmaceutical interventions and determine which 
treatment offers the best value for money.3  There are several methods available to 
evaluate economic efficiency of health care interventions.3,4
Decision analysis modelling is a systematic process to assess appropriate courses 
of action in the presence of multiple uncertainties.
  All of the approaches 
measure costs in monetary terms, but differ in the way that consequences are 
evaluated. 
5  It is one of the most commonly used 
methods for conducting pharmacoeconomic evaluations (PE) and the outcomes are 
typically presented as the incremental cost per quality-adjusted life year (QALY) gained.  
This is then compared against the value threshold set by national formulary committees.  
As an illustration, the National Institute of Clinical Excellence (NICE) of the United 
Kingdom has established the threshold for drug coverage at £30,000 per QALY gained.6  
In the Netherlands, the unofficial threshold is €18,000 per QALY.7
To address this, the World Health Organization (WHO) has proposed to use 
multiples of a country’s per capita gross domestic product (GDP).
  However, these 
thresholds for economic value do not reflect the wealth of the nation. 
8,9  Based on the WHO 
criteria, products more than three times the GDP would be cost ineffective.8,9  Using 
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Malaysia as an illustration (i.e. per capita GDP for 2010 = $U.S.14,800), the threshold 
for cost effectiveness of new drugs would be $U.S.44,400 per QALY.
 Most PE are conducted with an established product price to estimate the cost per 
QALY gained.  However, PE analyses can also be very informative to determine a drug 
price given recommended thresholds for economic value.  To illustrate one application 
of PE for this purpose, we used decision analysis modeling to estimate a price for a 
cancer drug in Malaysia using the WHO criteria for cost effectiveness.  The drug 
selected as the case study was bevacizumab, an agent that provides a 1.4 month 
survival gain when added to first line chemotherapy in patients with metastatic 
colorectal cancer (mCRC).
10 
11  Bevacizumab was chosen because it has a high 
acquisition cost and its economic value has been questioned in recent PE studies.
 
12,13 
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METHODS   
Economic Model 
 
 mCRC was chosen for this analysis because the sequential use of specific 
chemotherapy regimens is well established.  In patients with mCRC, randomized trials 
have demonstrated that irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) in combination 
with infusional 5-fluorouracul (5-FU) and leucovorin are highly active and superior to the 
previous standard of 5-FU/leucovorin alone.14,15  Data from a large randomized trial also 
verified that sequential schedules of FOLFOX and FOLFIRI (or the reverse order) are 
equally effective and have thus emerged as the first and second line standard of care 
for patients with mCRC.16  Clinical practice guidelines also recommend the addition of 
an antivascular endothelial growth factor (VEGF) such as bevacizumab at some point 
during chemotherapy for mCRC.17
 The two most commonly used methods to model the clinical and economic 
consequences of cancer therapy are decision trees and Markov modelling.  The former 
method is most commonly used in situations where uncertainly arises once over a 
period of time.  However in cases where events occur repeatedly, Markov processes 
are better able to capture the uncertainties that are faced iteratively.
  FOLFOX, FOLFIRI and bevacizumab are all 
available in Malaysia. 
18 However, one of 
the disadvantages of Markov modelling is their need for a high level of detailed data.  To 
construct a Markov model of multiple cycles of FOLFOX and FOLFIRI, disease 
progression and toxicity data would be required for each cycle of chemotherapy.  
Unfortunately, such data was not available from the published clinical trials.  Since only 
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aggregate data were available (i.e. median number of cycle of chemotherapy), a 
decision tree approach was used for the current study. 
 A decision model for the sequential treatment of mCRC with FOLFOX (± an anti-
VEGF) followed by FOLFIRI upon disease progression was developed with the DATA 
software (Treeage Software Inc.) (Figure 1).  The analytic timeframe was from the first 
cycle of FOLFOX chemotherapy until death and a Malaysian health care system 
perspective (both public and private) was taken.  The primary outcome for measuring 
successful initial therapy was clinical benefit, defined as complete tumour response 
(CR), partial response (PR) or stable disease (SD) based on the Response Evaluation 
Criteria in Solid Tumors [RECIST
 The model began at the decision node (square) where the first line treatment choice 
would be either FOLFOX + “the new drug (bevacizumab)” or FOLFOX alone (Figure 1).  
During the first two cycles of chemotherapy, patients would be assessed for intolerable 
toxicity. For those patients with severe toxicity, first line therapy would be discontinued 
in its entirety and second line FOLFIRI would be offered until disease progression. Upon 
progression, all patients would receive best supportive care until death.  In contrast, 
patients who did not experience severe toxicity from first line FOLFOX (± “the new 
drug”) would continue receiving treatment until disease progression.  They would then 
be offered second line FOLFIRI alone and bevacizumab would be discontinued.  Upon 
progression, all patients would receive best supportive care until death (Figure 1).  
Epidermal growth factor receptor (EGFR) inhibitors such as cetuximab in mCRC 
patients with KRAS wild type tumours were not considered because we did not want to 
]). Three clinical oncologists, each with experience in 
treating colorectal cancer, evaluated the face and content validity of the model. 
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over complicate the modeling.  Furthermore, such agents would be available to both 
treatments options in the model, so their inclusion would not impact on the final results. 
 
Clinical Data 
 The clinical data required to populate the model consisted of early treatment 
discontinuations because of toxicity, achievement of clinical benefit (CR+PR+SD), 
duration of clinical benefit, risk of cancer related death during active treatment and 
number of chemotherapy cycles administered. These data were obtained through a 
literature search of randomized trials evaluating FOLFOX (± bevacizumab) in the first 
line setting and second line FOLFIRI in the treatment of mCRC.  Two randomized trials 
were identified that provided the required data for the decision model (Table 1).  The 
first trial evaluated FOLFOX or a clinically similar regimen XELOX (capecitabine plus 
oxaliplatin) ± bevacizumab in the first line treatment of mCRC.11  A total of 1,401 
patients were randomized to receive FOLFOX/XELOX + bevacizumab (n=699) or 
FOLFOX/XELOX + placebo (n=701).  The interaction between FOLFOX and XELOX on 
the primary clinical endpoint was not statistically significant (p=0.70) thereby justifying 
the decision to combine patients who received FOLFOX and XELOX.  Median 
progression free survival was 9.4 months in the bevacizumab group compared to 8.0 
months with placebo (HR=0.83; p=0.023) resulting in a 1.4 month survival benefit.11 
Overall, 30% of patients in the bevacizumab group required a permanent treatment 
discontinuation because of adverse events compared to 20% in the control (Table 1). 
Approximately 2% and 1% of patients died during treatment with bevacizumab and 
placebo (Table 1). 
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Data on the safety and efficacy of second line FOLFIRI following first line FOLFOX 
was obtained from a randomized sequential trial reported by Tournigand et al., (2004),  
Patients were randomized to receive sequential FOLFOX followed by FOLFIRI upon 
progression or the reverse sequence (Table 1).  There was no significant difference in 
progression free and overall survival (FOLFOX – FOLFIRI = 21.5 vs. FOLFIRI – 
FOLFOX = 20.6 mon; p=0.99) between the two sequences.16 With second line FOLFIRI, 
51% of patients experienced disease progression for an overall progression free 
survival of 2.5 months respectively.16
 
 Approximately 3% of patients died within the first 
60 days of second line FOLFIRI (Table 1). 
Estimation of Treatment Costs 
 Malaysia's healthcare system is composed of a public and private sector.  
Physicians are required to complete three years of service in public hospitals throughout 
the nation, ensuring there is adequate coverage for the general population.  With 
respect to drug access, patients treated under the private system typically have access 
to a greater selection of therapies than those managed under the public system.  
However, drug prices and costs for hospital resources tend to be higher in private than 
in public hospitals.  As results, an analysis was performed for patients treated under the 
public and private systems. 
 The duration of investigation ran from the start of first and second line sequential 
chemotherapy therapy until death. Health care resources and costs for anticancer 
drugs, materials, patient monitoring and other related hospital resources (e.g. 
laboratory, diagnostic tests and best supportive care) were obtained from two private 
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and two public health care institutions using a standardized data collection form.  The 
costs collected in the study were in Malaysian Ringgit (MYR) and then converted to $US 
as per the currency conversion prevailing in 2010 (conversion factor 1$US = 3.2 MYR, 
as of September, 2010). 
 
Patient Preferences for Alternative Health States 
 Quality adjusted life years or QALYs are a way of measuring the impact of disease 
on a patient.  They include both the quality and the quantity of life lived and are 
calculated by multiplying the survival gain by the overall utility benefit of one therapy 
over another.    The health-related quality of life (QOL) values measured in the analysis 
were patient preferences for alternative health outcomes, as depicted in the decision 
analysis model.  In the current study, quality-adjusted progression free periods were 
measured as "healthy months equivalent" for the time spent in each outcome of the 
decision model using the Time Trade-Off (TTO) technique.19  The scores in months 
were then converted to utility measures between 0 and 1, where 0 represented death 
and 1 was a state of perfect health or optimal quality of life. 
 The TTO technique is a preference based approach designed to measure 
respondent’s preferences and QOL for alternative health states.19 After background 
information is presented on a particular health state (e.g. a cancer that is not responding 
to treatment) and the time period within that state, respondents are asked to trade 
length of life in the poorer health state for a lesser period of time in a state of optimal 
health and QOL.  As an illustration, a respondent may prefer to live 4 months of optimal 
health rather than the 12 months confined to a wheel chair.  Under this scenario, the 
 
 
103 
 
utility associated with being in a wheel chair for 12 months would be 0.33 (i.e. 4 / 12) on 
a scale between 0 and 1, where 0 represents death and 1 is a state of optimal quality of 
life.  In the economic model, all of the possible outcomes were valued in this way and 
then used to weigh the time spent in each health state in terms of QOL. 
 Intuitively, the ideal population for measuring health state utilities and treatment 
preferences should be cancer patients with the disease in question who are in a position 
to receive the new treatment.  However, it has been recommended in the Canadian 
Guidelines for Economic Evaluations and by the Panel on Cost-Effectiveness in Health 
and Medicine of the United States that treatment preferences be measured from 
members of the general public who are potential candidates of the new medical 
intervention.5,20 As a compromise in this study, a patient surrogate group was used that 
would provide insight from both the perspective of the patient and members of the 
general public because the latter sample often has difficulty in understanding utility 
questionnaires.  There is also evidence in the oncology literature suggesting that nurses 
are suitable patient surrogates for objective outcomes, and that utility estimates derived 
from such a sample do not substantially alter the findings of cost utility studies.21,22  
Therefore, a convenience sample consisting of 24 oncology nurses provided utility 
values for the model.  With a sample of 24 respondents, healthy month equivalence was 
measured with a precision of ± 1.0 month, with a 95% probability. 
 After informed consent was obtained, each participant was interviewed for 30 to 45 
minutes by trained local field investigators.  Respondents were presented with 
information on FOLFOX, bevacizumab and FOLFIRI consisting of the methods of 
administration, efficacy and the side effects reported in the literature.  Bevacizumab was 
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not identified by name but simply referred to as the “new drug”.  The interview was then 
continued with a description of the 16 health states and the length of time a patient 
would live in each health state (Figure 1). The respondents were then asked how many 
months of "optimal health" they considered being equivalent to the time spent in each of 
the less than optimal health states described in the model.  These measures were then 
used to weigh each branch of the model by the QOL experienced by a patient living 
through that time period.  An identical process was used for each of the 16 outcomes 
(Figure 1).  The mean “healthy month equivalence” score for each outcome was then 
divided by 12 months to estimate the number of QALYs associated with that health 
state. 
 A standardized questionnaire supported by printed interview tools with graphical 
displays was used to facilitate the participant’s understanding of the Time Trade-off 
technique. To minimize the framing effect, all pathways were presented in a consistent 
manner pictorially.  Demographic data were also collected from each participant, and 
consisted of years of oncology and colorectal cancer experience, involvement in the 
development of systemic treatment guidelines for colorectal cancer, familiarity with the 
cost of anticancer drugs and family history of colorectal cancer. 
 
Cost Utility Analysis 
The clinical, economic and respondent preference data were then combined into a 
cost-utility analysis of bevacizumab to identify a price per dose that would be 
considered cost effective according to the WHO criteria.8,9  The base case analysis 
assumed that the addition of the bevacizumab to standard chemotherapy would provide 
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a survival benefit of 1.4 months.  The primary objective of the analysis was to estimate 
an appropriate price for the bevacizumab by using the target benchmark cost of 
$U.S.44,400 per QALY gained, which is three times the 2010 Malaysian per capita 
GDP.  Indirect costs were not included because there was no data available on the 
association between bevacizumab usage and indirect cost avoidance. Future costs and 
benefits were not discounted because of the short time periods involved.  However, the 
stability of the baseline results was evaluated by a comprehensive sensitivity analysis.  
This consisted of substituting the 95% confidence intervals (CI) for the health-state 
utilities as well as variations in the overall survival benefit, costs of care and the target 
threshold for economic value in Malaysia.  Costs of care were varied by ± 15% to 
capture any potential differences across the country.  Individual analyses were 
conducted for patients treated in public and private hospitals.   
 
RESULTS 
 Clinical outcomes data and costs used to populate the model are presented in 
Tables 1 and 2. The economic data revealed that expenses for chemotherapy, side 
effect management and best supportive care are lower in the public than the private 
health care system in Malaysia. This may be a reflection of a slightly lower level of care 
offered to patients in public hospitals and of the ability of the private sector to mark up 
the cost of goods and health services. 
 The second component required for the cost-utility analysis was health state utilities 
for the time period spent in each of the 16 health states (Figure 1).  Utilities for each 
outcome were estimated from a sample of 24 oncology nurses who consented to 
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participate in the study.  There were 14 respondents from public hospitals and the 
remainder were from private institutions.  The sample had an average of 3.4 years of 
direct oncology experience (range 2 – 8 years) and all had experience in the treatment 
of colorectal cancer patients.  In addition, all respondents had direct clinical experience 
in the administration and follow up care associated with FOLFOX (mean years = 2.2) 
and 92% had experience with FOLFIRI (mean years = 1.9) chemotherapy. Furthermore, 
22 of 24 (92%) had experience with the newer targeted therapies bevacizumab and 
cetuximab.  Lack of knowledge about the cost of drugs could affect treatment 
preferences.  Respondents were asked to state their knowledge of costs for modern 
oncology drugs.  The findings revealed that 100% were “very familiar” or “somewhat 
familiar” with the cost of drugs used to treat cancer.   The final series of demographic 
questions focused on respondent’s family history of colorectal cancer. The data 
revealed that only one of the 24 subjects had a positive family history for colorectal 
cancer. 
 The health state utilities from the oncology nurses are presented in Table 3.  The 
results suggested that patient utilities were influenced by the severity of drug toxicity, 
the likelihood of achieving a response to chemotherapy and the risk of rapid cancer 
death.  The health states with the lowest utilities (i.e. branches 11 and 16 of the model – 
Figure 1) were those where first line therapy had to be stopped because of severe 
toxicity, the patient then had an early progression during second line treatment followed 
by a rapid cancer death.  It was also interesting to note that in all of the related 
scenarios, comparative branches that included treatment with the “new drug” tended to 
have lower health state utilities (Table 3). This is likely related to the additional side 
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effects that would occur with the addition of an anti-VEGF agent like bevacizumab to 
chemotherapy (Table 1). 
 
Cost Utility Analysis for the Public and Private Hospital Systems 
 The outcomes data from the clinical trial, the estimated costs associated with each 
treatment and the health state utility estimates were combined into the cost-utility 
analysis.  The price for one dose of bevacizumab was then varied until the incremental 
cost-effectiveness ratio reached a threshold of $U.S.44,400 per QALY gained.  Using 
this approach from the public health care system perspective, the base case analysis 
suggested that a cost per dose that would achieve cost effectiveness according to the 
WHO criteria could not be reached because bevacizumab simply did not provide 
enough of a survival benefit in mCRC patients (Table 4).  Similar results were also 
identified when the analysis was undertaken from the perspective of private hospitals. 
A series of one-way sensitivity analyses were then conducted using the upper 
95%CI for the health state utilities, variations in treatment costs and the targeted cost 
per QALY threshold.  Identical results as in the base case analysis for both public and 
private hospitals were achieved.  A price per dose that would make bevacizumab cost 
effective could not be realized.  This was primarily driven by the modest survival benefit 
offered by bevacizumab in mCRC patients. 
The only situation where a cost effective price per dose was identified occurred when 
the survival gain was increased to 3 and 6 months.  When the survival benefit of 
bevacizumab was increased from 1.4 to 3 months, the cost per dose for public and 
private hospitals was estimated to be $U.S.567 and $U.S.490 respectively.  When the 
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survival gain was increased to 6 months, the price per dose of bevacizumab could 
increase further to $U.S.1,258 and $U.S.1,182 in both public and private institutions and 
be considered cost effective according to the WHO criteria.8,9  Therefore, the single 
biggest factor controlling the cost effectiveness of bevacizumab is the drug’s ability to 
increase overall survival. 
Bevacizumab is available in Malaysia and its purchase price is approximately 
$U.S.1,800 per dose (5 mg/kg) for an average 60 kg mCRC patient.  A sensitivity 
analysis was conducted where the current price of bevacizumab was applied to the 
model.  The results revealed that the incremental cost per QALY gained would be 
greater than $U.S.200,000 for both public and private institutions.  When a $U.S.50,000 
cost per QALY threshold was used instead of the WHO criteria, a cost effective price 
per dose could also not be achieved.  In summary, the sensitivity analyses suggested 
that bevacizumab is not a cost effective drug in Malaysia according to the WHO criteria.  
In order to achieve cost effectiveness, drug performance in terms of survival gain in 
mCRC patient will need to improve and the price would have to be reduced to between 
$U.S.500 to $U.S.1,300.  
 
 
 
109 
 
DISCUSSION 
 Decision analysis modeling is a powerful simulation technique widely used to 
perform cost-effectiveness evaluations of new drugs.  In such studies, the health 
services researcher develops a decision model comparing the new therapy to the 
current standard, incorporates into the analysis the costs and consequences of the two 
alternatives and then estimates the incremental cost per QALY gained with the new 
intervention.  If the cost per QALY is below a predetermined threshold, the conclusion is 
that the new treatment is cost effective and should be added to a hospital or national 
formulary.  
 Decision analysis is a useful tool that can also be used to estimate any unknown in 
the analysis.  The unknown in most published studies has been the incremental cost per 
QALY gained.  However, decision analysis can also be applied in the context of pricing 
a new drug before it is introduced to the market.  In this study, the latter process was 
used to estimate the cost of bevacizumab, a drug that provides a 1.4 month survival 
benefit when added to chemotherapy in the first line treatment of mCRC.11 
The analysis was conducted from both the Malaysian public and private health care 
system perspective using the WHO criteria for cost effectiveness. In the base case 
analysis and in most of the scenarios evaluated, a cost per dose resulting in cost 
effectiveness could not be identified because a 1.4 months survival gain was 
inadequate.  A final price was only realized when the survival gain from bevacizumab 
was artificially increased to at least three months.  When the current Malaysian price per 
dose (i.e. $U.S.2,622) for bevacizumab was evaluated, the drug was not considered to 
be cost effective according to the WHO criteria. 
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The findings of this study suggest that the WHO criteria for cost effectiveness can be 
applied to a country like Malaysia for estimating an appropriate price which may be 
more affordable to the national health care system and patients.  Furthermore, our 
results suggest that bevacizumab has been priced excessively high in Malaysia for the 
1.4 month survival benefit that it provides to mCRC patients.  For the drug to become 
cost effective, the price would have to be reduced and a new treatment algorithm would 
need to be identified that would increase survival to at least 3 months. 
There are a number of limitations in the application of this technique that need to be 
addressed.  Given the lack of data by cycle of chemotherapy, we constructed a decision 
tree instead of a Markov model to simulate the clinical and economic consequences of 
chemotherapy for mCRC.  The latter would have been preferable given its ability to 
incorporate the element of time.  For the proposed methodology to be viable, complete 
data from randomized trials on a drug by drug basis is required.  This is not always the 
case.  One of the limitations of using the per capita GDP for value based pricing is that it 
represents a national average and does not consider income dispersion.  Our study 
measured health state utilities from a sample of oncology nurses.  However, the 
external validity of our findings would have been enhanced if we had also included 
patients, family members and members of the general public.  For our modeling 
strategy to be applied, a new drug must demonstrate either an improvement in QOL 
over the standard of care or a survival of sufficient magnitude to identify a final price 
point for cost effectiveness.  In the case of bevacizumab, the drug simply did not 
provide enough of a survival benefit to identify a price that would be considered cost 
effective.  Lastly, indirect costs such as time off work secondary may be relevant in this 
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setting, but were not considered in this analysis because there was a lack of such data 
in the metastatic colorectal cancer literature.  Future modelling should consider their 
inclusion. 
 
CONCLUSIONS 
The current paper presents a systematic process to estimate drug cost based on pre-
determined thresholds for societal value.  The advantages of this technique are that it is 
relatively straightforward to perform, transparent and the decision model can be easily 
applied to other jurisdictions using local cost data.  Such information can be of value to 
both drug manufacturers and formulary committees because it would facilitate 
negotiations for optimal pricing in a given jurisdiction. 
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Table 1:  Published randomized trials providing clinical data to populate the economic 
model. 
Reference Treatment Arms Clinical Outcomes 
Saltz et al., (2008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tournigand et al., 
(2004) 
FOLFOX/XELOX + 
bevacizumab 
 
 
 
 
 
 
 
 
 
 
 
 
 
FOLFOX/XELOX + 
placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Second Line FOLFIRI 
Disease progression = 29% 
Median PFS = 9.4 mon 
Median duration of response =8.45 mon 
Overall survival = 21.3 mon 
 
Treatment discontinuations = 30% 
Death during treatment = 2% 
Serious side effects (grade III/IV) = 16% 
 
Specific Grade III/IV Side Effects 
Deep vein thrombosis = 8% 
Diarrhea = 18% 
Bleeding = 2% 
Neutropenia = 50% 
 
Disease progression = 47% 
Median PFS = 8.0 mon 
Median duration of response =7.4 mon 
Overall survival = 19.9 mon 
 
Treatment discontinuations = 20% 
Death during treatment = 1% 
Serious side effects (grade III/IV) = 8% 
 
Specific Grade III/IV Side Effects 
Deep vein thrombosis = 5% 
Diarrhea = 11% 
Bleeding = 1% 
Neutropenia = 44% 
 
 
Disease progression = 51% 
Death during treatment = 3% 
Median PFS = 10.9 mon 
Median number of cycles= 6 
 
Abbreviations: PFS = progression free survival, OS = overall survival, FOLFOX = oxaliplatin in 
combination with infusional 5-fluorouracul, FOLFIRI = irinotecan in combination with infusional 
5-fluorouracul. 
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Table 2:  Hospital costs for the treatment of metastatic colorectal cancer in Malaysia. 
Recourse Item Public Hospitals Private Hospitals 
FOLFOX chemotherapya 
 
$U.S.998 / cycle 
 
$U.S.1047 / cycle 
 
FOLFIRI chemotherapyb 
 
$ U.S.1395 / cycle 
 
$ U.S.1489 / cycle 
 
Cost for a permanent chemotherapy 
discontinuation because of toxicityc 
 
$ U.S.111.60 
 
 
$ U.S.241.80 
 
 
Cost to administer the “new drug” after 
FOLFOX chemotherapy 
 
$ U.S.18.60 
 
 
$ U.S.40.30 
 
 
Cost of best supportive cared $ U.S.156/month $ U.S.338/month 
 
aOxaliplatin in combination with infusional 5-fluorouracul.  Cost per cycle includes resources for 
drug administration and routine patient monitoring.  In the hospitals that provided data for this 
study, patients are admitted for two days to receive the chemotherapy. 
bIrinotecan in combination with infusional 5-fluorouracul. 
cPatients would be admitted for 3 days for the management of side effects and for 
reassessment. 
dAfter failing two lines of chemotherapy, patients would receive best supportive care on an 
outpatient basis until death. 
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Table 3.  Health state utilities derived using the Time Trade-Off technique. 
Sixteen Health Outcomes Evaluated 
in the Decision Model 
Time in 
Health Statea 
Utility Estimateb 
[mean (95%CI)] 
FOLFOX + “new drug” → Folfiri → BSC until death 
Branch #1:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI for 4 cycles.  There was disease progression.  
The patient received BSC and died 6 months later. 
 
Branch #2:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI.  There was a response to FOLFIRI and the 
patient went on to receive 8 cycles.  Upon progression, 
the patient received BSC and died 22 months later. 
 
Branch #3:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI.  There was a response to FOLFIRI and the 
patient went on to receive 8 cycles.  Upon progression, 
the patient received BSC and died 2 months later. 
 
Branch #4:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI for 2 cycles.  However, the patient died due to 
cancer progression within the first 2 months. 
 
Branch #5:  Tolerated side effects but had disease 
progression after 4 cycles of FOLFOX + the “new drug”.  
The patient was then treated with FOLFIRI for 4 cycles 
but the disease did not respond.  The patient received 
BSC and died 2 months later. 
 
Branch #6:  Tolerated side effects and responded 
FOLFOX + the “new drug”.  The patient went on to 
receive a total of 17 cycles of first line therapy.  Upon 
progression, the patient went on to receive 6 cycles of 
FOLFIRI.  Upon progression, the patient received BSC 
and died 21 months later. 
 
Branch #7:  Tolerated side effects and responded 
FOLFOX + the “new drug”.  The patient went on to 
receive a total of 17 cycles of first line therapy.  Upon 
progression, the patient went on to receive 2 cycles of 
FOLFIRI but died 2 months later. 
 
Branch #8:  Tolerated side effects and but had disease 
progression after 2 cycles of FOLFOX + the “new drug”.  
The patient died due to the cancerone month later. 
 
10 months 
 
 
 
 
28 months 
 
 
 
 
 
8 months 
 
 
 
 
 
4 months 
 
 
 
 
6 months 
 
 
 
 
 
29 months 
 
 
 
 
 
 
11 months 
 
 
 
 
 
2 months 
 
0.74 (0.65 - 0.83) 
 
 
 
 
0.80 (0.73 - 0.87) 
 
 
 
 
 
0.67 (0.61 - 0.73) 
 
 
 
 
 
0.74 (0.65 - 0.84) 
 
 
 
 
0.82 (0.76 - 0.89) 
 
 
 
 
 
0.81 (0.77 - 0.86) 
 
 
 
 
 
 
0.83 (0.79 - 0.87) 
 
 
 
 
 
0.75 (0.63 - 0.86) 
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Table 3.  Continued… 
FOLFOX → Folfiri → BSC until death 
Branch #9:  Stopped FOLFOX after 2 cycles due to side 
effects and was then treated with FOLFIRI for 4 cycles.  
There was disease progression.  The patient received 
BSC and died 6 months later. 
 
Branch #10:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI.  There 
was a response to FOLFIRI and the patient went on to 
receive 8 cycles.  Upon progression, the patient 
received BSC and died 22 months later. 
 
Branch #11:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI.  There 
was a response to FOLFIRI and the patient went on to 
receive 8 cycles.  Upon progression, the patient 
received BSC and died 2 months later. 
 
Branch #12:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI for 2 
cycles.  However, the patient died due to cancer 
progression within the first 2 months. 
 
Branch #13:  Tolerated side effects but had disease 
progression after 4 cycles of FOLFOX.  The patient was 
then treated with FOLFIRI for 4 cycles but the disease 
did not respond.  The patient received BSC and died 2 
months later. 
 
Branch #14:  Tolerated side effects and responded 
FOLFOX.  The patient went on to receive a total of 15 
cycles of first line therapy.  Upon progression, the 
patient went on to receive 6 cycles of FOLFIRI.  Upon 
progression, the patient was offered BSC and died 21 
months later. 
 
Branch #15:  Tolerated side effects and responded 
FOLFOX.  The patient went on to receive a total of 15 
cycles of first line therapy.  Upon progression, the 
patient went on to receive 2 cycles of FOLFIRI but died 
2 months later. 
 
Branch #16:  Tolerated side effects and but had disease 
progression after 2 cycles of FOLFOX.  The patient died 
due to cancer progression one month later. 
 
10 months 
 
 
 
 
28 months 
 
 
 
 
 
8 months 
 
 
 
 
 
4 months 
 
 
 
 
6 months 
 
 
 
 
 
32 months 
 
 
 
 
 
 
11 months 
 
 
 
 
 
2 months 
 
 
0.82 (0.75 - 0.82) 
 
 
 
 
0.81 (0.76 - 0.86) 
 
 
 
 
 
0.72 (0.66 - 0.79) 
 
 
 
 
 
0.75 (0.66 - 0.84) 
 
 
 
 
0.84 (0.76 - 0.92) 
 
 
 
 
 
0.91 (0.88 - 0.94) 
 
 
 
 
 
 
0.84 (0.79 - 0.90) 
 
 
 
 
 
0.75 (0.63 - 0.86) 
aAs presented in each branch of the decision model. bA quality of life score for a health state 
between 0 and 1, with 0 = death and 1 = optimal health. Abbreviations:   FOLFOX = Oxaliplatin 
+ infusional 5-FU. FOLFIRI = Irinotecan + infusional 5-FU, BSC = best supportive care. 
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Table 4.  Sensitivity analysis on the cost per dose of the “new drug”. 
Sensitivity Analysis1 Public Hospitals Private Hospitals 
Base case 
 
Upper 95%CI of health state utilities for 
chemotherapy + the “new drug” 
 
Changing cost of FOLFOX chemotherapy 
by ± 15% 
 
Changing cost of FOLFIRI chemotherapy 
by ± 15% 
 
Changing cost of BSC cost by ± 15% 
 
Changing cost of ADR cost by ± 15% 
 
Changing survival benefit of the “new drug” 
from 1.4 to 3 months 
 
Changing survival benefit of the “new drug” 
from 1.4 to 6 month 
 
Using the current cost of bevacizumab 
($U.S.1,800 per dose) in Malaysia 
 
Setting the threshold for cost effectiveness 
at $U.S.50,000 per QALY gained 
Not reached 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
Not reached 
 
$U.S.567 
 
 
$U.S.1,258 
 
 
Not cost effective 
 
 
Not reached 
 
Not reached 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
Not reached 
 
$U.S.490 
 
 
$U.S.1,182 
 
 
Not cost effective 
 
 
Not reached 
 
 
Abbreviations:   FOLFOX = Oxaliplatin in combination with infusional 5-fluorouracul.  FOLFIRI = 
Irinotecan in combination with infusional 5-fluorouracul.  BSC = best supportive care, ADR = 
adverse drug reaction costs. 
1For a target threshold of $U.S.44,400 per QALY when the new drug is added to FOLFOX 
chemotherapy. 
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Figure 1.  Decision analysis model for the treatment of metastatic colorectal cancer. 
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ABSTRACT 
Background:  One of the major barriers against patient access to new cancer drugs 
has been price.  We present a novel approach to estimate a value based price for new 
cancer drugs that considers the clinical benefits of the product and the wealth of a 
nation.  To demonstrate its application, pharmacoeconomic (PE) modeling was used to 
estimate a value based South African price for bevacizumab, a drug that improves 
survival in metastatic colorectal cancer (mCRC) patients by 1.4 months.  The threshold 
used for economic value used was 3 times the South African per capita gross domestic 
product (GDP), as recommended by the World Health Organization (WHO). 
Methods: A PE model was developed to simulate the outcomes in mCRC patients 
receiving chemotherapy ± bevacizumab.  Utility estimates were determined by 
interviewing 16 oncology nurses involved in the care of mCRC patients.  A price per 
dose of bevacizumab was then estimated using a target threshold of R219,000 per 
quality adjusted life year (QALY) gained, which is 3 times the South African per capita 
GDP. 
Results:  A cost effective price for bevacizumab could not be reached because of the 
short survival benefit provided by the drug.  If the drug were able to improve survival 
from 1.4 to 3 or 6 months, then the price per dose could be R400 and R1,780 and be 
considered cost effective in South Africa according to the WHO criteria. 
Conclusions:  A value based pricing approach using PE modelling and the WHO 
criteria for economic value is feasible for South Africa. 
 
 
Key Words:  drug pricing, South Africa, cost analysis, chemotherapy, value 
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INTRODUCTION 
 Cancer is a global problem with 7.4 million deaths per year, which is approximately 
13% of all cause mortality.1  The populations of many countries around the world are 
ageing and cancer is more prevalent in older people.  Therefore, cancer clinics can also 
expect an increase in the number of patients seeking treatment.  In one study, Wilking 
and Jonsson estimated a 10% increase in the number of new diagnoses in 25 European 
countries from 2002 to 2006.2,3  Encouragingly, these same investigators also reported 
stability in the number of deaths over the same time period.2,4  Similar findings have 
also been reported by the Surveillance Epidemiology and End Results (SEER) of the 
United States.
 For many years, the backbone of cancer treatment has been the use of cytotoxic 
agents such as anthracyclines, alkylating agents, taxanes and platinum analogues.
5 
6  
One characteristic of traditional chemotherapy is its non-specificity to the target.  As a 
result, side effects such as neutropenia, anemia, thrombocytopenia, alopecia and 
decreased renal function are common.6  Over the past decade, there has been an 
emergence of new anticancer agents that are more specific to the target.  These new 
compounds which include agents such as imatinib, rituximab, cetuximab and 
trastuzumab are collectively known as “targeted therapies”.7-10 In contrast to traditional 
chemotherapy which affects both healthy and malignant cells, targeted agents are 
specific to the latter.  Therefore, they tend to be better tolerated than chemotherapy and 
the side effects described above are less common.  In addition, at least part of the 
stabilization in overall cancer mortality has been attributed to the availability of these 
newer targeted drugs.
 
2,4 
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 The new targeted drugs have taken patient care forward towards more personalized 
care.  However, despite their effectiveness and improved safety profile, not all cancer 
patients in South Africa have access to them.  One of the single biggest barriers to drug 
access is the high cost of these new agents.  In one editorial published in the Journal of 
the National Cancer Institute of the United States, the annual cost for an average 60 kg 
patient for the targeted therapies erlotinib, sorafenib, bevacizumab and cetuximab was 
estimated to be $U.S.15,752 (R109,400), $U.S.34,373 (R238,700), $U.S.80,352 
(R558,000) and $U.S.90,816 (R630,600) respectively.10  These costs would be 
prohibitively high for most non-insured patients in South Africa.  Even in wealthier 
countries with socialized health care systems, such drugs have either been rejected for 
reimbursement by national health care agencies or patient access has been delayed or 
limited following initial regulatory approval.11,12
 Pharmacoeconomics (PE) is an analytical technique that compares the costs and 
benefits of alternative pharmaceutical interventions to determine which treatment offers 
the best value for limited resources.
  Therefore, both public and private 
payers need to make decisions about which drugs provide the greatest economic value. 
  There are several methods available to evaluate 
economic efficiency and these include cost minimization, cost benefit and cost 
effectiveness analysis.13   With respect to oncology drugs, cost utility analysis is the 
preferred method because it considers cost, overall survival and quality of life 
differences between two competing therapies.13  Quality adjusted life years or QALYs 
are a way of measuring the impact of new treatments for cancer.  They include both the 
quantity and quality of life experienced by patients during treatment with alternative 
 126 
options.  Therefore, the outcomes of cost utility studies are reported as an incremental 
cost per QALY gained when a new drug is used over a lower cost alternative.   
 PE evaluations of new drugs provide an important component to the overall process 
of formulary decision making.  However, they may have an additional and perhaps more 
valuable role in estimating or negotiating a drug price based on societal value 
thresholds.  PE has been used in this role for a few cancer drugs assessed by the 
National Institute of Clinical Excellence (NICE) of the United Kingdom, which is a 
national body that assesses the cost effectiveness of new drugs.  NICE was able to 
secure price reductions from manufacturers for erlotinib, lenalidomide and sunitinib 
based on cost effectiveness.14
 One of the outstanding issues in estimating a value based price for new cancer 
drugs is in establishing the value cut off.  The World Health Organization (WHO) has 
proposed to use multiples of a country’s per capita gross domestic product (GDP) to 
establish thresholds for economic value.
  However, what has not been extensively examined was 
the estimation of drug price before a drug receives regulatory approval. 
12,15,16  Products less than or equal to the per 
capita GDP would be considered very cost effective, one to three times would be cost 
effective and more than three times would be cost ineffective.12  Using South Africa as 
an illustration  (i.e. per capita GDP = $US 10,000 or R73,000) the three time threshold 
for cost effectiveness of new anticancer drugs would be approximately $U.S.30,000 
(R210,000) per QALY gained.
 The use of thresholds based on per capita GDP in combination with PE modeling to 
establish a value-based price for cancer drugs is novel because it incorporates product 
attributes such as disease response, survival, quality of life improvements and impact 
17 
 127 
on health care resource use. To illustrate its application, PE modelling was used to 
estimate a value-based price for bevacizumab, a commercially available drug that 
provides a survival benefit to patients with metastatic colorectal cancer (mCRC) when 
added to first line chemotherapy.18 Bevacizumab was chosen because its economic 
value questioned in recent PE studies.19,20
 
  The analysis was conducted from a South 
African public health care scheme perspective because our objective was to identify a 
pricing strategy for the country that would potentially improve drug access by making 
them more affordable to patients and government payers. 
METHODS 
Modeling the Pharmacoeconomic Outcomes of mCRC 
 
 A decision model for the management of mCRC was developed with the DATA 
software (Treeage Software Inc., Williamstown, MA, USA).  The timeframe was from the 
first cycle of first line chemotherapy until death.  In many countries including South 
Africa, the addition of oxaliplatin to infusional 5-fluorouracil (FOLFOX) is considered a 
standard of care for the first line treatment of mCRC.21  If disease progression or 
treatment related toxicity develops, then irinotecan with infusional 5-fluorouracil 
(FOLFIRI) is a recommended second line treatment.21,22  There is also data from a large 
randomized trial to suggest that safety and efficacy with sequential schedules of 
FOLFOX and FOLFIRI (or the reverse order) are equally effective for the first and 
second line treatment of mCRC.23  Lastly, clinical practice guidelines recommend the 
addition of bevacizumab at some point during chemotherapy for mCRC.24 
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 Using these recommended standards of care, a PE model was developed to 
simulate the management of mCRC with FOLFOX (± bevacizumab) followed by 
FOLFIRI upon disease progression or the discontinuation of first line therapy because of 
intolerable toxicity (Figure 1). The primary endpoint of the model was the achievement 
of successful therapy defined as complete tumour response (CR), partial response (PR) 
or stable disease (SD).  However, all outcomes of the PE model resulted in eventual 
death, which is the unfortunate reality for patients with mCRC.  The face and content 
validity of the model was verified by three clinical oncologists who had experience in the 
treatment of mCRC.   
 The PE model began at the choice node where a first line therapeutic decision 
between FOLFOX + “the new drug (bevacizumab)” or FOLFOX alone would have to be 
made (Figure 1).  At the completion of the first two cycles of chemotherapy, patients 
would be evaluated for intolerable toxicity.  In situations of severe toxicity, the initial first 
line regimen would be permanently stopped and second line FOLFIRI would be offered 
until disease progression or treatment related death.  Upon disease progression, best 
supportive care would be offered to all patients until eventual death.  In patients who 
tolerate first line FOLFOX (± “the new drug”), treatment would be continued until 
disease progression.  Second line FOLFIRI would then be offered but the new drug 
would be discontinued.  Upon progression following second line FOLFIRI, best 
supportive care would be available to all patients until death (Figure 1).  Epidermal 
growth factor receptor (EGFR) inhibitors such as cetuximab in mCRC patients with 
KRAS wild type tumours were not considered in the model because we did not want to 
unnecessarily complicate the analysis.  Notwithstanding, such agents would be available 
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to both treatment options following a first line progression, so their inclusion would not 
affect the final results. 
 
Clinical Data 
The clinical data to populate the economic model were obtained from a literature 
search.  A search of Medline, Embase and the Cochrane databases was performed 
from 2000 through 2010 for human clinical studies involving FOLFOX, FOLFIRI and 
bevacizumab as first and second line therapy in mCRC.  The objective of the review was 
to identify the most up-to-date clinical data which included tumour response, treatment 
discontinuations because of severe side effects, progression free and overall survival. 
 
Estimation of Treatment Costs 
 The economic model began from the first cycle of FOLFOX chemotherapy (± the 
“new drug (bevacizumab)”, followed by second line sequential chemotherapy until 
disease progression and eventual death.  Costs for anticancer drugs, materials for drug 
delivery, patient monitoring and other related hospital resources (e.g. laboratory and 
diagnostic tests) were obtained from Wilgers Oncology Center in Pretoria.  Palliative 
care costs for terminally ill cancer patients were obtained from the South African 
palliative care literature.25  All costs in the current study were reported in 2010 South 
African Rand.  Costs from previous years were converted into 2010 estimates using the 
South African consumer price index. 
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Health State Utilities 
 Health state utilities are scores between 0 and 1, where 0 represents death and 1 is 
a state of perfect health or optimal quality of life.  In economic evaluations, they are 
used to adjust the survival benefit of a new drug by the quality of life experienced by a 
patient during that time period.  So a cancer drug that improves survival but is 
associated with severe toxicity would have a reduced quality adjusted survival period.  
In the current study, the Time Trade-off technique was used to measure the utility for 
each of the health states described in the PE model (Figure 1).26  The  quality adjusted 
life periods were measured as "healthy months equivalent" for the time spent in each 
outcome of the decision model (Figure 1).27  The scores in months were then converted 
to utility measures and applied to each of the respective branches of the economic 
model. 
 There is currently some debate in the health economic literature as to which 
population should provide health state utility estimates.  The Canadian Guidelines for 
Economic Evaluations and the Panel on Cost-Effectiveness in Health and Medicine of 
the United States recommend that treatment preferences be measured from members 
of the general public who are potential candidates of the new medical intervention.13,28  
However it has been our experience that members of the general public have difficulty 
understanding cancer related utility questionnaires.  As an alternative, we used 
oncology nurses as a patient surrogate sample to provide estimates for the health state 
utilities required by the model.  Such a sample is reasonable because they are 
members of the general public and have a good understanding of the treatments and 
their side effects that are under investigation.  There is also evidence in the oncology 
 131 
literature to suggest that nurses are suitable patient surrogates for objective outcomes, 
and that utility estimates derived from such a sample do not substantially alter the 
findings of cost utility studies.29,30  Therefore, a patient surrogate sample consisting of 
16 oncology nurses provided utility values for the model.  With a sample of 16 
respondents, healthy month equivalence was measured with a precision of ± 1.5 month, 
with a 95% probability. 
 After informed consent was obtained, a local investigator interviewed each 
participant.  The interviewer presented each respondent with information on FOLFOX, 
bevacizumab and FOLFIRI.  This included method of administration, treatment efficacy 
in terms of tumour response, progression free and overall survival as well as the major 
toxicities reported in the literature.  The interviewer then presented a detailed 
description of the 16 health state as depicted in the model and the length of time a 
patient would live in each of the health states (Figure 1).  To apply the Time Trade-off 
technique, respondents were then asked how many lesser months of "optimal health" 
they considered being equivalent to the time spent in each of the less than optimal 
health states described in the model.  Hence, they are trading length of life in a poorer 
health state for a lesser period of time in a state of optimal quality of life.  This is the 
“trade off” component of the health state utility assessment.  The final health state 
utilities were then used to weigh each branch of the model by the quality of life 
experienced by a patient living through that time period.  An identical process was used 
for each of the 16 outcomes (Figure 1).  A standardized questionnaire supported by 
printed interview tools with graphical displays was used to facilitate the participant’s 
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understanding of the Time Trade-off technique. To minimize the framing effect, all 
pathways were presented in a consistent manner pictorially. 
 
 
Estimating a Value Based Price for new Cancer Drugs in South Africa 
A cost utility analysis was undertaken to estimate a value based price for the “new 
drug” in the first line treatment of mCRC in South Africa.  The base case analysis 
assumed that the addition of the “new drug (bevacizumab)” to first line oxaliplatin-based 
chemotherapy would provide a survival benefit of 1.4 months as reported in the 
literature.31  The main outcome of the analysis was to estimate a price per dose for the 
“new drug” using an incremental cost of R219,000 per QALY gained, which is three 
times the South Africa per capita GDP.17  Secondary to the short time periods involved, 
future costs and benefits were not discounted.  However, the base case results were 
evaluated for uncertainty by a series of one-way sensitivity analyses.  This consisted of 
applying variations in the survival benefit, costs of care and substituting the 95% 
confidence intervals (CIs) for the health-state utilities.  Specifically, the survival gain was 
increased to 3 and 6 months from the base case of 1.4 months.  Costs were changed 
by ±15% to account for possible variations across South Africa for both private and 
public health care schemes. 
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RESULTS 
 Upon review of the oncology trial literature, two key studies were identified and 
provided the clinical data to populate the model.23,31  Data on the sequential use of first 
line FOLFOX followed by second line FOLFIRI were provided in a randomized trial 
reported by Tournigand et al.23  In that study, patients were randomized to receive 
sequential FOLFOX followed by FOLFIRI upon progression or the reverse sequence.  
There was no significant difference in progression free and overall survival (FOLFOX – 
FOLFIRI = 21.5 vs. FOLFIRI – FOLFOX = 20.6 months; p=0.99) between the two 
sequences.28  With second line FOLFIRI, 51% of patients experienced disease 
progression for an overall progression free survival of 2.5 months respectively.28  
Approximately 3% of patients died within the first 60 days of second line FOLFIRI. 
 The clinical data for the addition of bevacizumab to first line FOLFOX were provided 
from a randomized trial reported by Saltz et al.31  In that study, patients were 
randomized to receive FOLFOX or a clinically similar regimen XELOX (capecitabine 
plus oxaliplatin) ± bevacizumab (every two weeks with FOLFOX and every 3 weeks with 
XELOX) in the first line treatment of mCRC.31  A total of 1,401 patients were 
randomized to receive FOLFOX/XELOX + bevacizumab (n=699) or FOLFOX/XELOX + 
placebo (n=701).  A 9.4 month median progression free survival was reported in the 
bevacizumab group compared to 8.0 months with placebo (HR=0.83; p=0.023).  
Patients in the bevacizumab group also experienced a 1.4 month improvement in 
survival (HR = 0.89, p = 0.077).  Overall, 30% of patients in the bevacizumab group 
required a permanent treatment discontinuation because of adverse events compared 
to 20% in the control. 
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Estimation of Treatment Costs 
 Using unit cost estimates obtained from the Wilgers Oncology Center in Pretoria, 
 
the 
cost per cycle of FOLFOX was estimated to be R12,040.  However before the first cycle 
of FOLFOX, the protocol start up costs were estimated to be approximately R1,227 
(Table 1).  The costs per cycle for FOLFIRI were slightly less at R9,985 with the 
associated start up costs being R1,398.  Additional costs required to populate the model 
which included costs for the management of severe toxicity, administration of the “new 
drug” and best supportive care are presented in Table 2.  These estimates were then 
incorporated into the PE model for the subsequent pricing analysis. 
Health State Utility Assessments 
 To fully populate the model, health state utilities for the time period spent in each of 
the 16 health outcomes were required for the analysis (Figure 1).  The utility estimates 
were measured in a sample of 16 oncology nurses.  The sample had a mean age of 
47.3 years, an average of 14.8 years of direct oncology experience (range 2.5 – 27 
years) and all had experience in the treatment of colorectal cancer patients.  In addition, 
all respondents had direct clinical experience in the preparation/administration and 
follow up care associated with FOLFOX (mean = 6.6 years), FOLFIRI (mean = 6.5 
years) chemotherapy and the newer targeted therapies bevacizumab (mean = 5.5 
years) and cetuximab (mean = 4.2 years) which are used in mCRC.  In addition, 13 of 
16 (81.2%) respondents had been involved in the development of systemic treatment 
guidelines for mCRC within the last two years.  Respondents were then asked to state 
their knowledge of costs for modern oncology drugs because this could affect their 
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health state utilities.  The findings revealed that 100% were “very familiar” with the high 
cost of the newer drugs used to treat cancer.  Therefore, the oncology nurses who 
provided information for the assessment of health state utilities associated with mCRC 
were a well informed sample. 
 The health state utilities from the respondents are presented in Table 3.  
Considering that utilities are anchored between 0 and 1, where 0 represents death and 
1 is a state of perfect health or optimal quality of life, all of the health states depicted in 
the model had estimates below 0.5 suggesting that patients with mCRC who are 
receiving chemotherapy have a poor quality of life during treatment.  The branches with 
the highest utilities (i.e. branches 8 and 16) were those where the patient initially 
tolerated the treatment, but had a rapid cancer death with 2 months of starting therapy.  
The interpretation of this finding is that in cases of terminal disease, respondents may 
not be averse to a rapid death that would avoid prolonged pain and suffering.   
 
Value Based Pricing Analysis 
The clinical, health state utility and cost data were then applied to the model to 
derive a value based price for South Africa using R219,000 per QALY gained as the 
threshold for cost effectiveness.  For a 1.4 month survival benefit when added to 
FOLFOX chemotherapy, a final price for bevacizumab that would be considered cost 
effective in South Africa could not be identified.  The major factor behind this finding 
was that the 1.4 month survival gain was too small to overcome the value threshold. 
The investigation was continued with a one way sensitivity evaluation on the key 
value drivers.  These consisted of using the upper 95% CI of the health state utilities, 
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variations (± 15%) in the cost of chemotherapy, best supportive care and the 
management of side effects from anticancer therapy.  The results indicated that despite 
reasonable variations in the above parameters, a final price that would be considered 
cost effective could not be identified.  The sensitivity analysis was continued with 
variations in the overall survival gain offered by the “new drug”.  When the overall 
survival gain was changed to 3 and 6 months respectively, a price per dose considered 
to be cost effective by the WHO criteria was identified.  If the “new drug” were able to 
provide a 3 or 6 month benefit in survival, it could be priced at R400 and R1,780 and be 
considered cost effective in South Africa.  The current price per dose of bevacizumab in 
South Africa is approximately R10,216 (5 mg/mg for a 60 kg patient).  At this price, our 
analysis indicated that bevacizumab is not cost effective using the WHO value criteria  
and is well beyond the R219,000 value threshold (Table 4).  To summarize, the only 
major factor that would affect the economic value of a “new drug” for mCRC would be 
its ability to improve overall survival by at least 3 months. 
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DISCUSSION 
 With a per capita GDP of only R73,000, the South African government faces the 
challenge of making modern cancer drugs available to its citizens.  To address this 
important issue, strategies need to be identified that will increase patient access, but at 
the same time, ensure a reasonable return on research and development cost to the 
innovating company.  Without such a return, new drug discovery may be compromised 
or the pharmaceutical industry will simply not launch new products in South Africa.  To 
reduce drug costs, several European governments such as Greece, Spain and France 
have recently mandated price cuts of up to 23% for branded products.32,33,34  We 
believe that this is not a correct policy because it is not based on cost effectiveness 
analysis nor does it consider the value that a new drug brings to society.  There are 
many examples in the medical literature where new drugs have saved lives and 
reduced overall health care costs.35  Therefore, a scientifically sound and systematic 
process for estimating a value based drug price is recommended over draconian 
measures such as government mandated price cuts. 
 In the current study, we provide such an approach. Using principles of 
pharmacoeconomic analysis and value thresholds recommended by the WHO that 
consider the wealth of a nation, we were able to demonstrate its application in 
estimating a value based price for bevacizumab in mCRC.  The findings suggested that 
any new drug in mCRC would need to provide at least a 3 month survival benefit for a 
value based price to be derived.  Taking bevacizumab, which provides only a 1.4 month 
survival gain as an example, a value based price could not be identified.  This finding 
suggests that at its current price and with the modest 1.4 month survival benefit, 
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bevacizumab is not cost effective in South Africa and is in fact excessively priced.  
Therefore our approach is sound and can be applied to all future cancer drugs to 
estimate a value based price prior to launch in South Africa.  Even though the estimated 
price should not be seen as final, it can be the starting point for committed negotiations 
between the manufacturer and public/private payers. 
 Value-based drug pricing will likely have a major role to play in Europe over the next 
few years.  The new government of the UK recently announced its intent to revise the 
current drug pricing scheme and move towards a value based approach that will be 
delivered by NICE on behalf of the National Health Service.36  Specifics of this new 
system have yet to be announced, however previous initiatives by NICE would suggest 
that value estimations involving cost per QALY gained coupled with comprehensive PE 
models would drive new product pricing.  The UK has established a threshold for drug 
coverage at £30,000 per QALY gained (equivalence to approximately $U.S.50,000).37 In 
many other jurisdictions, a $U.S.50,000 cost per QALY threshold has been used; which 
was based on a 1982 valuation and is now equivalent to approximately $U.S.197,000 
per QALY in 2007 U.S. dollars (after a 5.5% annual adjustment in health care 
inflation).12  However, the $U.S.50,000 threshold continues to be used and quoted in the 
pharmacoeconomic literature.  Therefore, it is possible that the new value based pricing 
scheme proposed by the UK government will revolve around the use of PE modeling 
and current value thresholds even though they are outdated. 
 There are several limitations in our study and in our proposed approach that need to 
be addressed.  For the proposed methodology to be viable, complete data from 
randomized trials on a drug by drug basis is required.  One of the limitations of using the 
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per capita GDP for value based pricing is that it represents a national average and does 
not consider income dispersion.  Moving forward, it would be relevant to identify a 
threshold for value based pricing that incorporates both income dispersion and the per 
capita GDP.  Many of the newer cancer drugs have not demonstrated a significant 
improvement in patient quality of life (QOL) and their survival benefit has been less than 
3 months.31,38,39  For our modeling strategy to be applied, a new drug must demonstrate 
either an improvement in QOL over the standard of care or a survival of sufficient 
magnitude to identify a final price point for cost effectiveness.  Oncology nurses and 
pharmacists were used as patient surrogates in the utility assessments.  Even though 
respondents had an average of 14.8 years cancer experience and 100% also had 
experience with FOLFOX and FOLFIRI chemotherapy as well as the the newer targeted 
therapies, patients would have been preferable to surrogates.  Lastly, indirect costs 
such as time off work secondary may be relevant in this setting, but were not 
considered in this analysis.  Future modeling should consider their inclusion. 
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CONCLUSIONS 
Improving patient access to new cancer drugs is an important objective of the South 
African government.  In this study, we present a novel approach to estimating a value 
based drug price that can be the starting point for negotiations.  The ultimate outcome 
of these discussions between the key stakeholders is to identify a final drug price that 
would simultaneously reflect what the South African government can pay and provide a 
reasonable return on investment by the innovating company. 
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Table 1.  Mean cost per cycle of FOLFOX and FOLFIRI. 
Resource Itema FOLFOX FOLFIRI 
Drug acquisitiona 
 
Ancillary drugsb 
 
Preparation and 
administrationc 
 
Patient monitoringd 
 
Protocol start up 
costse 
 
Total cost per cycle 
R9,129 
 
R961 
 
R1,572 
 
 
R378 
 
R1,227 
 
 
R12,040 
R7,572 
 
R483 
 
R859 
 
 
R771 
 
R1,398 
 
 
R9,685 
 
aAssuming a 60 kg patient with a body surface area of 1.6 m2. 
bIncludes standard premedication such as loperamide and antiemetics such as ondansetron 
and dexamethasone. 
cIncludes materials, supplies, personnel, chemotherapy unit stays and physician visits. 
dStandard laboratory and diagnostic tests. 
eThese costs are a one-time cost in order to prepare the patient for the associated 
chemotherapy protocol.  In the case of FOLFOX and FOLFIRI, preparations and materials for 
infusional 5-fluorouracil made up the bulk of the costs.  For the economic analysis, the start up 
costs were only applied once over the estimated median number of cycles delivered.  Thus 
avoiding double counting.  
 148 
Table 2.  Hospital costs for the treatment of metastatic colorectal cancer in South Africa.  
Recourse Item Hospital Cost 
FOLFOX chemotherapya 
 
R12,040 / cycle 
 
FOLFIRI chemotherapyb 
 
R9,685 / cycle 
 
Cost for a permanent chemotherapy 
discontinuation because of toxicityc 
 
R19,800 
 
 
Cost to administer the “new drug” after 
FOLFOX chemotherapy 
 
R440 
 
 
Cost of best supportive cared R869 / month 
 
aOxaliplatin in combination with infusional 5-fluorouracul.  Cost per cycle includes resources for 
drug administration and routine patient monitoring. 
bIrinotecan in combination with infusional 5-fluorouracil. 
cPatients would be admitted for 3 days for the management of side effects and for 
reassessment.  The principle side effects that would lead to the discontinuation of therapy would 
be febrile neutropenia and grade III/IV diarrhea. 
dFrom Uys and Hensher (2002)25.  The 2002 estimate was converted in 2010 South Africa Rand 
using the consumer price index. 
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Table 3.  Health state utilities derived using the Time Trade-Off technique. 
Sixteen Health Outcomes Evaluated 
in the Decision Model 
Time in 
Health Statea 
Utility Estimateb 
[mean (SD)] 
FOLFOX + “new drug” → Folfiri → BSC until death 
Branch #1:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI for 4 cycles.  There was disease progression.  
The patient received BSC and died 6 months later. 
 
Branch #2:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI.  There was a response to FOLFIRI and the 
patient went on to receive 8 cycles.  Upon progression, 
the patient received BSC and died 22 months later. 
 
Branch #3:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI.  There was a response to FOLFIRI and the 
patient went on to receive 8 cycles.  Upon progression, 
the patient received BSC and died 2 months later. 
 
Branch #4:  Stopped FOLFOX + the “new drug” after 2 
cycles due to side effects and was then treated with 
FOLFIRI for 2 cycles.  However, the patient died due to 
cancer progression within the first 2 months. 
 
Branch #5:  Tolerated side effects but had disease 
progression after 4 cycles of FOLFOX + the “new drug”.  
The patient was then treated with FOLFIRI for 4 cycles 
but the disease did not respond.  The patient received 
BSC and died 2 months later. 
 
Branch #6:  Tolerated side effects and responded 
FOLFOX + the “new drug”.  The patient went on to 
receive a total of 17 cycles of first line therapy.  Upon 
progression, the patient went on to receive 6 cycles of 
FOLFIRI.  Upon progression, the patient received BSC 
and died 21 months later. 
 
Branch #7:  Tolerated side effects and responded 
FOLFOX + the “new drug”.  The patient went on to 
receive a total of 17 cycles of first line therapy.  Upon 
progression, the patient went on to receive 2 cycles of 
FOLFIRI but died 2 months later. 
 
Branch #8:  Tolerated side effects and but had disease 
progression after 2 cycles of FOLFOX + the “new drug”.  
The patient died due to the cancer one month later. 
 
10 months 
 
 
 
 
28 months 
 
 
 
 
 
8 months 
 
 
 
 
 
4 months 
 
 
 
 
6 months 
 
 
 
 
 
29 months 
 
 
 
 
 
 
11 months 
 
 
 
 
 
2 months 
 
0.29 (0.14) 
 
 
 
 
0.21 (0.16) 
 
 
 
 
 
0.28 (0.11) 
 
 
 
 
 
0.34 (0.21) 
 
 
 
 
0.26 (0.13) 
 
 
 
 
 
0.19 (0.21) 
 
 
 
 
 
 
0.28 (0.17) 
 
 
 
 
 
0.39 (0.20) 
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Table 3.  Continued… 
FOLFOX → FOLFIRI → BSC until death 
Branch #9:  Stopped FOLFOX after 2 cycles due to side 
effects and was then treated with FOLFIRI for 4 cycles.  
There was disease progression.  The patient received 
BSC and died 6 months later. 
 
Branch #10:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI.  There 
was a response to FOLFIRI and the patient went on to 
receive 8 cycles.  Upon progression, the patient 
received BSC and died 22 months later. 
 
Branch #11:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI.  There 
was a response to FOLFIRI and the patient went on to 
receive 8 cycles.  Upon progression, the patient 
received BSC and died 2 months later. 
 
Branch #12:  Stopped FOLFOX after 2 cycles due to 
side effects and was then treated with FOLFIRI for 2 
cycles.  However, the patient died due to cancer 
progression within the first 2 months. 
 
Branch #13:  Tolerated side effects but had disease 
progression after 4 cycles of FOLFOX.  The patient was 
then treated with FOLFIRI for 4 cycles but the disease 
did not respond.  The patient received BSC and died 2 
months later. 
 
Branch #14:  Tolerated side effects and responded 
FOLFOX.  The patient went on to receive a total of 15 
cycles of first line therapy.  Upon progression, the 
patient went on to receive 6 cycles of FOLFIRI.  Upon 
progression, the patient was offered BSC and died 21 
months later. 
 
Branch #15:  Tolerated side effects and responded 
FOLFOX.  The patient went on to receive a total of 15 
cycles of first line therapy.  Upon progression, the 
patient went on to receive 2 cycles of FOLFIRI but died 
2 months later. 
 
Branch #16:  Tolerated side effects and but had disease 
progression after 2 cycles of FOLFOX.  The patient died 
due to cancer progression one month later. 
 
10 months 
 
 
 
 
28 months 
 
 
 
 
 
8 months 
 
 
 
 
 
4 months 
 
 
 
 
6 months 
 
 
 
 
 
32 months 
 
 
 
 
 
 
11 months 
 
 
 
 
 
2 months 
 
 
0.26 (0.11) 
 
 
 
 
0.20 (0.16) 
 
 
 
 
 
0.24 (0.06) 
 
 
 
 
 
0.34 (0.22) 
 
 
 
 
0.20 (0.09) 
 
 
 
 
 
0.19 (0.19) 
 
 
 
 
 
 
0.21 (0.11) 
 
 
 
 
 
0.38 (0.20) 
aAs presented in each branch of the decision analysis model. bA quality of life score for a health 
state between 0 and 1, with 0 = death and 1 = optimal health. Abbreviations: FOLFOX = 
oxaliplatin+ infusional 5-FU. FOLFIRI = irinotecan + infusional 5-FU, BSC = best supportive care 
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Table 4.  Sensitivity analysis on the unit price for the “new drug” 
Sensitivity Manoeuvre1 Price per Dose 
Base case 
 
Upper 95% CI of health state utilities for 
chemotherapy + the “new drug” 
 
Changing cost of FOLFOX chemotherapy 
by ± 15% 
 
Changing cost of FOLFIRI chemotherapy 
by ± 15% 
 
Changing cost of BSC cost by ± 15% 
 
Changing cost of ADR cost by ± 15% 
 
Changing survival benefit of the “new drug” 
from 1.4 to 3 months 
 
Changing survival benefit of the “new drug” 
from 1.4 to 6 months 
 
Using the current price of bevacizumab 
(R10,216) in South Africa 
Not reached 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
 
Not reached 
 
Not reached 
 
R400 
 
 
R1,780 
 
 
Not cost effective 
 
 
Abbreviations:   FOLFOX = Oxaliplatin in combination with infusional 5-fluorouracul.  FOLFIRI = 
Irinotecan in combination with infusional 5-fluorouracul.  BSC = best supportive care, ADR = 
adverse drug reaction. 
1For a target threshold of R219,000 per QALY when the new drug is added to FOLFOX 
chemotherapy. 
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Figure 1.  Decision analysis model for the treatment of metastatic colorectal cancer. 
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6.10   Chapter Summary 
 
 The intent of this study was to develop a pricing index that could be used across many 
countries to estimate a value based price for new drugs in patients with mCRC.  The PE 
model had to be populated with cost and utility data in order to generate the cost 
effectiveness pricing outputs required to develop the pricing index.  The required data 
were collected in cancer centers from Canada, Spain, South Africa, Malaysia and India.  
The selection of these countries provided a per capita GDP ranging from $3,100 to 
$39,000 (Table 5.1).  Notwithstanding, the inclusion of more countries in the model 
development phase would have added precision to the final predictive index. 
 Using the country specific cost and utility data, a cost utility analysis was performed 
to estimate a value based price for the “new drug” in the first line treatment of mCRC.  
The base case analysis assumed that the addition of the “new drug” to first line 
oxaliplatin-based chemotherapy would provide a survival benefit of 1.4 months as 
reported in the literature for bevacizumab (Saltz et al., 2008).  The main outcome of the 
analysis was to estimate a price per dose for the “new drug” using an incremental cost 
per QALY gained threshold, which was three times the respective countries’ per capita 
GDP (Table 5.1).  The survival gain was then increased to approximately 3 and 6 
months from the base case of 1.4 months to determine how the price points would 
change for each country.  Such a procedure provided 15 data points for the subsequent 
multivariable analysis. 
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Table 6.1.  Value based price points for absolute survival benefits in the five countries. 
 
Country 1.4 mon survival1 3 mon survival 3 6 mon survival 
Canada 
Spain 
Malaysia
South Africa
2 
India
2 
$830 
2 
$465 
0.0 
0.0 
0.0 
$2,180 
$1,145 
$567 
$57.00 
$98.00 
$3,430 
$2,905 
$1,258 
$254 
$253 
 
1All currencies are in 2010 U.S. dollars. 2In these countries, a cost effective price could 
not be found because a 1.4 month survival was simply too short. 3The survival benefit 
reported for bevacizumab from the Saltz et al. trial (2008).
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 After application of the PE model towards a cost utility analysis, the evaluation in 
each country provided three price points for the “new drug” that were linked to the 
associated gains in survival.  A multivariable regression analysis, which was adjusted 
for clustering on the variable “country”, was then conducted with “drug price” as the 
dependent variable and survival gain, per capita GDP and the Gini coefficient, which is 
a measure of income dispersion (a value of 0 represents absolute equality, and 100 is 
absolute inequality) as independent variables (De Maio, 2007).  The unit of analysis was 
“country”.  Therefore, country level variables that are associated with a country’s ability 
to pay for high cost cancer drugs were evaluated in the model.  Since the level of 
income dispersion is a relevant factor, it was considered in the model.  The Gini 
coefficient was used for several reasons.  It is presented on a standardized linear scale 
from 0 to 100, there is the availability of data for most countries around the world and 
lastly, it has been accepted by the WHO as a measure of income dispersion globally 
(The World Fact Book, 2010). 
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6.11 Statistical Issues 
 Given the small sample size consisting of only 15 price points in total from the five 
countries, nonparametric bootstrapping was applied. Resampled data (1000 iterations) 
were used to generate bootstrap estimates of the regression coefficients within the 
multivariable model.  The final regression coefficients were of primary importance 
because their relative magnitude was used to estimate the weighting for each predictor 
variable in the final pricing algorithm.  Standard errors and confidence intervals were of 
secondary importance because the intent was not to measure the statistical significance 
between the dependent variable, drug price and the three predictor variables (i.e. 
survival gain, per capita GDP and the Gini coefficient).  To simplify calculations with the 
pricing algorithm, the regression coefficients were transformed by multiplying each by a 
constant (in this case -5%, derived by trial and error) and then rounding to the nearest 
unit value. This would allow the estimation of a drug pricing estimate as guided by a 
country’s per capita GDP, Gini coefficient and survival benefit offered by the new drug. 
 A simple main effects multivariable linear regression was used to determine the 
relative magnitude of the final regression coefficients.  Interaction effects were not 
evaluated in the model because the objective was not to perform a subgroup analysis 
between countries.  The linearity assumption was also evaluated in the model through 
the application of polynomials.  The findings suggested that the associations between 
the dependent variable (i.e. drug price) and the predictor variables (i.e. survival gain, 
per capita GDP and the Gini coefficient) were indeed linear. 
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6.12   Conclusions 
 This chapter described the seven scientific papers that were generated from this 
research.  There is a section on introduction, methods, results and discussion within 
each paper.  Therefore, the intent of this thesis was to conduct high quality research 
that can be published in peer reviewed journals.  This objective has been met. 
 
167 
 
CHAPTER 7 
CONCLUSIONS 
7.1 Introduction 
 Chapter seven summarizes the major findings from the five countries in terms of 
price points for different gains in overall survival.  The chapter describes a multivariate 
regression model that was built around these price points.  The chapter also illustrates 
how relative weight of the multivariate coefficients were used to develop the final value 
based pricing index.  Lastly, the chapter demonstrates how the index can be applied to 
estimate a value based price for any new drug in mCRC.  The chapter closes by 
providing recommendations on how the pricing index can be used by formulary 
committees and the pharmaceutical industry in estimate a launch price for a new drug in 
a given country. 
 
7.2 The value based pricing index for new drugs in metastatic colorectal cancer 
Government mandated cuts of branded drugs do not serve patients in the long term 
because such actions will only serve as a disincentive for pharmaceutical companies to 
invest in new drug discovery.  A better alternative to such actions would be to set 
product price based on several factors such as performance under a controlled clinical 
trial setting, a nation’s ability to pay a price premium for exceptional products, how 
uniformly income is distributed within a given country, and the overall cost effectiveness 
of the product measured against some reasonable societal value threshold.  In the 
oncology setting, drug performance is best measured by the incremental survival benefit 
that is offered over the standard of care.  Estimating an overall product value threshold 
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is more challenging, but a reasonable starting point is three times the per capita GDP as 
recommended by the WHO (Murray et al., 2000; Hillner and Smith, 2009). 
In this study, a PE model for a hypothetical “new drug” in mCRC that was populated 
with cost and utility data from five different countries was used to develop an index to 
estimate a value based price.   From the PE model, price points were estimated for 
survival increments of 1.4, 3 and 6 months using three times the per capita GDP as the 
target value threshold from each country.  Multivariable analysis was then applied to the 
price points to measure the contribution of survival benefit, per capita GDP and income 
dispersion on the final price estimate.  The coefficients from the multivariable model 
were then used to develop the final pricing index, which can be used to estimate a value 
based price for a new drug in mCRC.   The final product was a pricing algorithm where 
higher survival benefits are associated with a price premium.  The starting point and 
score assigned to each of the pricing factors is as follows: 
• Start at base score of $11,000 
• Multiply the Gini coefficient for that country by $300 and add to base score 
• Subtract the country specific per capita GDP 
• Multiply the drug’s survival benefit in months by $6,000 and subtract 
• Add the above scores and then multiply by - 5% 
 
The above pricing index is easy to apply and best illustrated with an example.  
Suppose there is a new drug for mCRC that has demonstrated a four month survival 
benefit in a recent randomized trial.  What would be a value based price for the drug in 
a country like Argentina, with a per capita GDP of $15,000 and a Gini coefficient of 
51.3?  Going through the pricing index, a value based launch price in Argentina for a 
drug that provides a 4 month survival benefit would be $630 per dose.  If the same drug 
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were to be launched in Norway, whose per capita GDP and Gini coefficient is $50,000 
and 25 respectively, the price per dose for the same drug would be $2,775 per dose.  
Through the application of our price index, it is ensured that the final launch price of a 
new drug is linked to a country’s ability to pay as well as income dispersion.  Therefore, 
government payers in countries like Argentina and Norway would then have a better 
indication of what a cost effective price should be relative to the survival benefit offered 
by the drug. 
 
7.3  Limitations 
 There are a number of limitations in pricing index that need to be acknowledged.  
The intent of our initiative was to develop a tool that can be applied to mCRC drugs for 
estimating a value based price that would potentially increase patient access.  For the 
proposed methodology to be applied to other disease sites, complete data from 
randomized trials on a drug by drug basis will be required to develop disease specific 
pricing indexes.  Our index can only be applied towards new drugs in mCRC and for 
countries that fall within our range of per capita GDP.  Our sample size was small (only 
five countries) and this may limit the generalizability of our index.  In addition, external 
validation in other countries outside of our GDP range is warranted.  The original WHO 
threshold for cost effectiveness (i.e. < 3 times the per capita GDP) was initially 
developed for global health care programmes (e.g. the use of malaria nets) as opposed 
to specific treatment interventions.  As a result, it has not been fully validated for 
application to pharmaceuticals.  Therefore, additional empirical work is needed to 
evaluate its appropriateness for evaluating individual treatments.  The equal application 
of a per capita GDP threshold may not be applicable to both rich and poor countries. It 
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may have been more appropriate to use threshold beyond three times the per capita 
GDP for less resource rich countries.  Future work is needed to test various thresholds 
based on a countries wealth. 
 
7.4   Summary of major findings 
 The first key finding in this study was that the WHO criteria for estimating a value 
based price is feasible and can be applied to a wide variety to countries with unique 
health care systems.  This was demonstrated through the successful PE modeling 
analyses conducted in the five reference countries.  With the pricing information 
generated from each country specific analysis, an index to estimate a value based price 
for new drugs in mCRC was developed.  The index is easy to apply using data that is 
readily available to drug formulary committees.  With a scientifically based estimate on 
what a cost effective price for a new drug should be for their country, public payers 
would be in a more informed position as they enter price negotiations with the 
manufacturer.  Therefore, the second key finding in this study is that the methodological 
approach used in this thesis can be applied to other cancer sites such as breast and 
lung cancer in order to develop similar value based pricing indexes.  The development 
of pricing indexes across the major tumour types can empower public payers with better 
information which could lead to reduced prices for new cancer drugs.  Reduced costs 
for new drugs would mean better patient access, particularly in lower income countries. 
A major advantage of the pricing index is its transparency and the ability to apply it 
to approximately 140 countries whose per capita GDP falls within the range evaluated in 
this study.  In addition, the index is able to rapidly estimate a value based price using 
international recommendations for economic value (Hillner and Smith, 2009).  Such an 
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index would also be important to manufacturers who are considering launching their 
products in lower income countries.  If they were to launch a critically important product 
at a high price that is simply out of reach for that country’s health care budget, the 
national government may issue a compulsory license, which would enable local 
production of the patented drug. This is possible under the Trade Related Intellectual 
Property Rights agreement of the World Trade Organisation and has already occurred 
with some HIV drugs (Shashikant, 2005). Alternatively, a value based price estimated 
with this index could be the starting point for negotiations between government payers 
and the manufacturer, which could lead to a more affordable launch price for that 
country. 
 
7.5  Implementation of the Pricing: Practical Considerations 
A pricing index has been developed to allow the estimation of drug price based on what 
a country can afford to pay, national income dispersion and the survival benefit offered 
by the new treatment over the standard of care.  The strength of this index is its 
transparency and ease of administration.  However, there are some practical challenges 
that would need to be overcome before widespread implementation.  As a first step, a 
partnership between the drug manufacturer and the respective national government 
would need to be established.  The primary objective of the partnership should be to 
ensure patient access to effective cancer therapies.  This partnership should be initiated 
with a binding agreement where both parties would accept the initial price point 
estimated by the pricing index.  This estimate would then be the starting point for 
negotiations.  If the manufacturer would like to launch the drug at a price beyond the 
estimated price point, they would need to provide evidence to government negotiators 
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that a higher price is warranted.  Alternatively, the manufacturer may offer a risk sharing 
program where the higher price would be reimbursed by the government only in cases 
where the drug meets its primary clinical endpoint.  For patients who do not derive 
clinical benefit from the drug, the manufacturer would reimburse the health care system 
for the cost of the drug.  These are but a few practical suggestions on how the pricing 
index can be used to initiate a discussion between the manufacturer and all of the key 
stakeholders.  A key factor for making a drug affordable in a given county would be 
transparency, good will and the willingness for both parties to make price concessions 
in sufficient supporting evidence is available. 
 
7.6 Conclusions 
 The present study describes the development of a global pricing index that can be 
used to estimate a value based price in different countries for new drugs in mCRC.  The 
application of this index to estimate a cost effective drug price would be a good starting 
point for opening dialogue between the key stakeholders and a better alternative to 
government mandated price cuts.  However, this does not necessarily mean that annual 
drug expenditures will be contained.  True therapeutic innovation requires an 
investment by society.  Ultimately, the final price that is negotiated must create a 
balance that will reward innovation and maximize patient access to new drugs. 
 
7.7 Recommendations 
PE analyses are typically undertaken once a new product receives regulatory approval 
and the price has been set by the manufacturer.  This may not be the optimal use of PE 
evaluations. 
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Recommendation # 1 
• A potentially more powerful use of PE analysis would be in estimating a drug price 
using predetermined thresholds of economic value.  This would allow a more 
transparent drug price to be determined. 
 
Before initiating pricing negotiations, drug formulary committees typically do not 
undertake their own PE studies to determine a final price that would make a new 
product cost effective for their patient populations. 
 
Recommendation # 2 
• In preparation for their pricing negotiations with manufacturers, drug formulary 
committees should undertake PE modeling analyses using the WHO criteria for 
economic value to estimate value based prices for all new cancer drugs, particularly 
the ones where the manufacture will likely request a premium price.  With such 
information, public payers will be in a stronger position to negotiate a better price for 
their health care system. 
 
There are multiple factors such as overall survival, the cost per QALY gained over the 
standard of care, income dispersion and a country’s ability to pay that can influence the 
final drug price. 
 
Recommendation # 3 
• The pricing index that was developed in the current study can be used to estimate a 
price for new drugs in mCRC.  Formulary committees can use this index to 
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determine a value based price for new products in mCRC, which will be critical in 
their price negotiations with manufacturers. 
 
It has been demonstrated in this study that a value based pricing index for new drugs in 
mCRC can be developed using standard cost utility methodology and internationally 
recommended thresholds for economic value.  However, the index should not be 
applied to other disease sites. 
 
Recommendation # 4 
The methodology used in this study should be applied to develop pricing indexes for 
new drugs in other important disease sites such as breast, lung and prostate cancer. 
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Appendix 1. Survey instrument used for the utility assessment. 
 
Utility Measurement for Targeted 
Treatments of Metastatic 
Colorectal 
 
 
202 
 
Introduction 
Thank respondent for agreeing to participate in the interview.  Review the material describing the two 
treatment options for metastatic colorectal cancer. 
 
 
Purpose and confidentiality 
Explain that: 
 The purpose of this is to explore the trade off between length of life versus quality 
of life whilst being on a new “hypothetical” targeted drug (when combined with the 
standard of care chemotherapy), taking into account the efficacy and side effect 
profile of the treatment. 
 We are totally independent in this research and would like everybody to be 
completely honest with their views. 
 Anything said will be treated as confidential unless you have given your consent to 
the contrary. 
 
 
NOTE TO INTERVIEWER:  
 
Throughout this interview the respondent will be required to imagine that they are a colorectal cancer 
patient with metastatic disease, about to undergo treatment with chemotherapy, without or without a 
new “targeted” drug.  The purpose of this is to explore the trade off between length of life versus quality 
of life whilst being on chemotherapy ± a new “targeted” drug, taking into account the efficacy and side 
effect profile of each treatment (see additional supportive material).  There are 16 questions, for each of 
the various health outcomes. 
 
If the respondent appears to have difficulty understanding what they are being asked then you could use 
the following example to help explain it to them. 
 
Ask the respondent to imagine themselves being in a wheelchair for 12 months. Then tell them that they 
have an option of being completely healthy but for a less amount of time. So the question is, how many 
of these 12 months of being in a wheelchair would they give up in order to be completely healthy? Eg. If 
9 months being completely healthy is equivalent to 12 months in a wheelchair, then they should answer 
that they are willing to give up 3 months of their time.  
 
NOTE TO INTERVIEWER: 
Check that the respondent has understood the information regarding the cancer treatments before 
proceeding. If not, take some time to review the information again. Before to review how the 
chemotherapy is delivered and what the common grade III/IV side effects are. 
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1.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks of intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #9 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 10 months where you received 2 cycles of FOLFOX + the New Drug, and then 4 
cycles of FOLFIRI chemotherapy.  Note the side effect rates associated with FOLFOX + the New Drug and FOLFIRI (refer to 
the Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  For a 
10 month survival, only show the scale up to 10 months). 
 
Outcome # 1 where survival = 10 months:  Lesser Months in optimal health: ________ 
2.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #9 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 10 months where you received 2 cycles of FOLFOX alone, and then 4 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX alone and FOLFIRI (refer to the Tables 1 and 2 for the 
clinical and side effect information).  Also, use the linear time scale to help their response.  For a 10 month survival, only 
show the scale up to 10 months). 
 
Outcome # 2 where survival = 10 months:  Lesser Months in optimal health: ________ 
3.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #10 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 28 months where you received 2 cycles of FOLFOX + the New Drug, and then 
the 8 cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug and with FOLFIRI 
(refer to the Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  
For a 28 month survival, only show the scale up to 28 months). 
 
Outcome # 3 where survival = 28 months:  Lesser Months in optimal health: ________ 
4.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #10 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 28 months where you received 2 cycles of FOLFOX alone, then the 8 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX and with FOLFIRI (refer to the Tables 1 and 2 for the 
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clinical and side effect information).  Also, use the linear time scale to help their response.  For a 28 month survival, only 
show the scale up to 28 months). 
 
Outcome # 4 where survival = 28 months:  Lesser Months in optimal health: ________ 
5.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #12 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 8 months where you received 2 cycles of FOLFOX + the New Drug, and then the 
8 cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug and with FOLFIRI (refer to 
the Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  For an 
8 month survival, only show the scale up to 8 months). 
 
 
Outcome # 5 where survival = 8 months:  Lesser Months in optimal health: ________ 
6.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #12 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 8 months where you received 2 cycles of FOLFOX alone, and then the 8 cycles 
of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX and with FOLFIRI (refer to the Tables 1 and 2 for the 
clinical and side effect information).  Also, use the linear time scale to help their response.  For an 8 month survival, only 
show the scale up to 8 months). 
 
Outcome # 6 where survival = 8 months:  Lesser Months in optimal health: ________ 
7.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #12 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 4 months where you received 2 cycles of FOLFOX + the New Drug, and then 2 
cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug (refer to the Tables 1 and 2 
for the clinical and side effect information).  Also, use the linear time scale to help their response.  For a 4 month survival, 
only show the scale up to 4 months). 
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Outcome # 7 where survival = 4 months:  Lesser Months in optimal health: ________ 
8.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #12 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 4 months where you received 2 cycles of FOLFOX alone, and then 2 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX (refer to the Tables 1 and 2 for the clinical and side 
effect information).  Also, use the linear time scale to help their response.  For a 4 month survival, only show the scale up to 4 
months). 
Outcome # 8 where survival = 4 months:  Lesser Months in optimal health: ________ 
9.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #13 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 6 months where you received 4 cycles of FOLFOX + the New Drug, then 4 
cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug and FOLFIRI (refer to the 
Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  For a 6 
month survival, only show the scale up to 6 months). 
 
Outcome # 9 where survival = 6 months:  Lesser Months in optimal health: ________ 
10.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #13 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 6 months where you received 4 cycles of FOLFOX alone, then 4 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX and FOLFIRI (refer to the Tables 1 and 2 for the 
clinical and side effect information).  Also, use the linear time scale to help their response.  For a 6 month survival, only show 
the scale up to 6 months). 
 
Outcome # 10 where survival = 6 months:  Lesser Months in optimal health: ________ 
11.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #14 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 33 months where you received 17 cycles of FOLFOX + the New Drug, then the 6 
cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug and FOLFIRI (refer to the 
Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  For a 33 
month survival, only show the scale up to 33 months). 
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Outcome # 11 where survival = 33 months:  Lesser Months in optimal health: ________ 
 
What if Outcome # 11 survival = 39 months:  Lesser Months in optimal health: ________ 
 
What if Outcome # 11 survival = 28 months:  Lesser Months in optimal health: ________ 
12.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #14 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 8 months where you received 15 cycles of FOLFOX alone, then 6 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX and FOLFIRI (refer to the Tables 1 and 2 for the 
clinical and side effect information).  Also, use the linear time scale to help their response.  For a 32 month survival, only 
show the scale up to 32 months). 
 
Outcome # 12 where survival = 32 months:  Lesser Months in optimal health: ________ 
13.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #15 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 11 months where you received 17 cycles of FOLFOX + the New Drug, and then 
2 cycles of FOLFIRI?  Be aware of the side effect rates associated with FOLFOX + the New Drug and FOLFIRI (refer to the 
Tables 1 and 2 for the clinical and side effect information).  Also, use the linear time scale to help their response.  For an 11 
month survival, only show the scale up to 11 months). 
 
Outcome # 13 where survival = 11 months:  Lesser Months in optimal health: ________ 
14.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #15 for pathway). 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 10 months where you received 15 cycles of FOLFOX alone, and then 2 cycles of 
FOLFIRI?  Be aware of the side effect rates associated with FOLFOX and FOLFIRI (refer to the Tables 1 and 2 for the 
clinical and side effect information).  Also, use the linear time scale to help their response.  For a 10 month survival, only 
show the scale up to 10 months). 
 
 
207 
 
Outcome # 12 where survival = 10 months:  Lesser Months in optimal health: ________ 
15.  Treatment with FOLFOX chemotherapy + the New Drug 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy.  
After the FOLFOX chemotherapy, you are also given the New Drug through a one hour infusion (see slide #16 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 2 months where you received 2 cycles of FOLFOX + the New Drug?  Be aware 
of the side effect rates associated with FOLFOX + the New Drug (refer to the Tables 1 and 2 for the clinical and side effect 
information).  Also, use the linear time scale to help their response.  For a 2 month survival, only show the scale up to 2 
months). 
 
Outcome # 15 where survival = 2 months:  Lesser Months in optimal health: ________ 
16.  Treatment with FOLFOX chemotherapy alone 
Imagine you are a colorectal cancer patient with metastatic disease and are about to undergo treatment with FOLFOX 
chemotherapy (see slide #2).  This would require coming to the chemotherapy suite every 2 weeks for intravenous therapy 
(see slide #15 for pathway). 
 
If you could trade length of life for a shorter time with much better quality of life, what lesser number of months in optimal 
health would you consider equivalent to the 2 months where you received 2 cycles of FOLFOX alone?  Be aware of the side 
effect rates associated with FOLFOX (refer to the Tables 1 and 2 for the clinical and side effect information).  Also, use the 
linear time scale to help their response.  For a 2 month survival, only show the scale up to 2 months). 
 
Outcome # 16 where survival = 2 months:  Lesser Months in optimal health: ________ 
DEMOGRAPHIC DATA 
A. Specify health profession:  Nurse    Pharmacist    
B. How many years of oncology experience do you have?:  ______ 
C. Do you have experience in treating colorectal cancer patients?: YES     NO    
D. Do you have experience in giving FOLFOX to patients? YES    NO    
E. If yes, how many years of experience do you have?: _________ 
F. Do you have experience in giving bevacizumab (Avastin) to patients? YES    NO    
G. If yes, how many years of experience do you have?: _________ 
H. Do you have experience in giving cetuximab (Erbitux) to patients? YES    NO    
I. If yes, how many years of experience do you have?: _________ 
J. Do you have experience in giving FOLFIRI to patients? YES    NO    
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K. If yes, how many years of experience do you have?: _________ 
L. In the past 2 years, have you been directly involved in the development of systemic treatment 
guidelines/criteria for the treatment of colorectal cancer patients? YES     NO    
M. How familiar would you consider yourself to be with the cost of new cancer drugs? 
 Very familiar   Somewhat familiar     Not familiar   
N. Has anybody in your family ever developed a colorectal cancer? YES     NO    
O. Respondent year of birth: _________ 
 
 
 
 
Decision Model for the Treatment of Colorectal Cancer 
Appendix 2.  Graphical displays was used to facilitate participant’s understanding of the Time 
Trade-off technique. 
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Treatment of Metastatic Colorectal Cancer 
Background Information 
 
• Colorectal cancer is the fourth most common type of cancer world wide. 
 
• The World Health Organization estimated that in 2008, there were 639,000 deaths from 
colorectal cancer. 
 
• When the cancer spreads to distant sites, chemotherapy is given but the cancer remains 
incurable. 
 
• The intent of chemotherapy is to prolong life and to enhance patient quality of life. 
 
• The chemotherapy drugs are referred to as a “regimen”.  The first regimen given is called 
“first line”. 
 
• For the regimen to be administered, patients need to visit the cancer clinic every 2 to 3 
weeks. 
 
• If patients progresses after the initial chemotherapy, then a second regimen is give (called 
second line chemotherapy). 
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First Line Chemotherapy for Advanced Colorectal 
Cancer 
 
 
FOLFOX- 4 
 
Oxaliplatin 85 mg/m^2 on day 1 
Leucovorin 200 mg/m^2, then 5-fluorouracil 4-00 mg/m^2 bolus and 
then 600/m^2 of 5- 5-fluorouracil by continuous infusion over 22 
hours. 
 
Cycle gets repeated every 2 weeks 
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Second Line Chemotherapy for Advanced 
Colorectal Cancer 
 
 
FOLFIRI 
 
Irinotecan 180 mg/m^2 on day 1 
Leucovorin 200 mg/m^2, then 5FU 400 mg/m^2 bolus and then 2.4 
g/m^2 of 5FU by continuous infusion over 46 hours. 
 
Cycle gets repeated every 2 weeks 
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CHEMOTHERAPY BEING GIVEN  
213
A new drug to treat colorectal and other tumours such as lung 
and breast cancer 
 
• With the use of FOLFOX chemotherapy, which is then followed by FOLFIRI, 
patients live for an average of 20 months. 
 
• Suppose there is a “hypothetical” new drug that is now available. 
 
• The new drug is not chemotherapy, but a “targeted” therapy that is more specific 
to the cancer. 
 
• The new drug is given with first line FOLFOX, on the same day of 
chemotherapy. 
 
• The new drug is administered as a one hour infusion after the chemotherapy is 
completed.  Before the new drug is given, patients receive a 10 mg injection of 
dexamethasone to prevent infusion reactions. 
 
• Studies have shown that the new drug improves response rates, progression 
free survival and overall survival when added to chemotherapy.  
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Table 1.  Clinical outcomes when the new drug is added to first 
line FOLFOX 
Outcome FOLFOX FOLFOX + New Drug 
Cancer progression 
 
Average progression free 
survival 
 
Average overall survival 
47% 
 
8 months 
 
 
20 months 
29% 
 
10 months 
 
 
21 to 26 months 
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Toxicity FOLFOX FOLFOX 
+ New Drug 
Side effects leading to the 
permanent stoppage of treatment 
 
Serious side effects (grade III/IV) 
 
Key Grade III/IV Side Effects 
Deep vein thrombosis 
Diarrhea 
Bleeding 
Neutropenia 
20% 
 
 
8% 
 
 
5% 
11% 
1% 
44% 
30% 
 
 
16% 
 
 
8% 
18% 
2% 
50% 
Table 2.  Comparison of Side Effects 
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Toxicity FOLFIRI 
Diarrhea 
Nausea/vomiting 
Sensory neuropathy 
Neutropenia 
Febrile neutropenia 
Stomatitis 
Alopecia 
14% 
13% 
0% 
25% 
6% 
10% 
24% 
Grade III/IV Toxicity of FOLFIRI 
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Metastatic 
Colorectal cancer 
10 months of life 
Serious side effects: Stop 
regimen, offer FOLFIRI x 
4 cycles 
Outcome #1 
Outcome #2 
Serious side effects: Stop 
regimen, offer FOLFIRI x 
4 cycles 
Disease progression 
after 3 months 
Disease progression 
after 3 months 
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Metastatic 
Colorectal cancer 
28 months of life 
Serious side effects: Stop 
regimen, offer FOLFIRI x 8 
cycles 
Outcome #3 
Outcome #4 
Serious side effects: Stop 
regimen, offer FOLFIRI x 8 
cycles 
Clinical Benefit: 
Stable disease for     
4 months 
Offer palliative care until 
death – 22 months later 
Clinical Benefit: 
Stable disease for     
4 months 
Offer palliative care until 
death – 22 months later 
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Metastatic 
Colorectal cancer 
8 months of life 
Serious side effects: Stop 
regimen, offer FOLFIRI x 8 
cycles 
Outcome #5 
Outcome #6 
Serious side effects: Stop 
regimen, offer FOLFIRI x 8 
cycles 
Clinical Benefit: 
Stable disease for     
4 months 
Offer palliative care – died 
from cancer progression 
within 2 mon 
Clinical Benefit: 
Stable disease for     
4 months 
Offer palliative care – died 
from cancer progression 
within 2 mon 
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Metastatic 
Colorectal cancer 
4 months of life 
Serious side effects: Stop 
regimen, offer FOLFIRI x 2 
cycles 
Outcome #7 
Outcome #8 
Serious side effects: Stop 
regimen, offer FOLFIRI x 2 
cycles 
Died from cancer 
progression within 2 
months 
Died from cancer 
progression within 2 
months 
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Metastatic 
Colorectal cancer 
6 months of life 
Outcome #9 
Outcome #10 
No severe side effects, 
continue treatment for 2 mon 
No severe side effects, 
continue treatment for 2 mon 
At mon 2, disease 
progression, stop 
regimen and start 2nd 
line FOLFIRI (4 cycles). 
Treat for 2 months 
At mon 2, disease 
progression, stop 
regimen and start 2nd 
line FOLFIRI (4 cycles). 
Treat for 2 months 
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Metastatic 
Colorectal cancer 
32 months of life 
Outcome #11 
Outcome #12 
No severe side effects, 
continue treatment 
No severe side effects, 
continue treatment 
Response at mon 
2. Regimen given 
for a total of 9 
months until 
progression 
Offer 2nd line FOLFIRI x 6 
cycles until death – 24 
months later 
Response at mon 
2. Regimen given 
for a total of 8 
months until 
progression 
Offer 2nd line FOLFIRI x 6 
cycles until death – 24 
months later 
33 months of life 
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Metastatic 
Colorectal cancer 
10 months of life 
Outcome #13 
Outcome #14 
No severe side effects, 
continue treatment 
No severe side effects, 
continue treatment 
Response at mon 
2. Regimen given 
for a total of 9 
months until 
progression 
Offer 2nd line FOLFIRI x 2 
cycles until death – one 
months later 
Response at mon 
2. Regimen given 
for a total of 8 
months until 
progression 
Offer 2nd line FOLFIRI x 2 
cycles until death – one 
month later 
11 months of life 
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Metastatic 
Colorectal cancer 
2 months of life 
Outcome #15 
Outcome #16 
No severe side effects, 
continue treatment 
No severe side effects, 
continue treatment Died from cancer 
progression within 2 
months 
Died from cancer 
progression within 2 
months 
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Number of Health Months Equivalence 
0    2    4    6    8    10  12  14  16  18   20  22  24   26   28  30  32  34  36  
  
Months* 
*For each treatment regimen, only show the respective overall survival for that regimen. 
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Appendix 3.  Author guidelines for journals where the papers were accepted for publication. 
Appendix 3A:  PHARMACOECONOMICS 
 
Manuscript Format and Style  
 
PharmacoEconomics publishes several categories of review article, each with its own specific 
focus/format (see Appendix B for types of reviews and their scope) plus original research (see 
Appendix C for recommended guidelines) and letters to the editor. Authors should specify the article 
type of their submission.  
In general, manuscripts should be prepared and paginated in the following manner: 
  
• A. Title page: include title, authors (please also provide forename[s]) and institutions for each 
author where the work was done (indicating the city), and a condensed running title of not more 
than 50 characters including spaces.  
• B. Acknowledgments: See Appendix A, point 4.  
• C. Name and address for correspondence: Mailing address plus telephone and fax number. 
An e-mail address should also be supplied, but will not be published without your permission.  
• D. Table of contents  
• E. Figure captions  
• F. Abstract: The abstract should succinctly highlight, in an informative manner, the specific 
important points addressed in the main body of the text; it should not just describe the general 
areas covered in the manuscript. The aim is for the abstract to stand alone as a synopsis of the 
article to accommodate those readers who do not have access to the full article. The journal style 
is to not cite references in the abstract so as to provide a discrete synopsis of the article. The 
length can be up to 400-500 words. Authors of original research articles should submit a structured 
abstract as outlined in Appendix C.  
• G. Text pages: Text pages must have numbered pages. All review articles must include an 
introductory section that provides background on the topic and the aim should be clearly stated. If 
applicable, review articles should include details of the literature search parameters used to locate 
the material included in the review. The author should specify the databases searched, other 
sources of articles/data used, search terms and date limits, as well as inclusion/exclusion criteria if 
relevant. Review articles should finish with a conclusion section putting the area into perspective 
and pointing the way for future research. 
  
• H. Footnotes  
• I. Reference list (in Vancouver style)  
• J. Tables (begin each table on a new page)  
• K. Figures (place each figure in a separate file)  
• L. Supplementary digital content (place each item in a separate file)  
 
• Please put sections A-J into a single file.  
• 
 
Abbreviations and Symbols  
Use SI symbols and recognised abbreviations for units of measurement. The first time an abbreviation 
appears in the abstract and the text it should be preceded by the full name for which it stands, 
followed by the abbreviation in parentheses. Generally, abbreviations should be avoided as much as 
possible, and used only when the full term would make the text unduly cumbersome.  
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Tables and figures help to convey information to the reader. Please make every effort to include such 
items in your article. Tables can be used, for example, to summarise important points, to compare 
agents or treatment regimens, or to list information that would otherwise impede the flow of the text. 
Figures may be schematic diagrams, graphical representations of data, photographs or treatment 
algorithms. Large numbers of tables and figures and lengthy tables can be problematic in print – these 
can, however, be published online only as supplemental digital content.  
Tables and Figures  
 
Tables should be comprehensible without reference to the text, and data given in tables should in 
general not be duplicated in the text or figures. Any necessary descriptions should appear in the table 
heading, and abbreviations and footnotes should be placed immediately below the table. Each table 
should be cited in the text. Please prepare tables in ‘table format', rather than using ‘tab' or ‘indent' 
commands. Do not format tables using word spaces. Tables should be submit within the Microsoft 
Word manuscript file; do not submit Excel files for publication. 
Tables  
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Appendix 3B:  JOURNAL OF EVALUATION IN CLINICAL PRACTICE 
Articles are accepted for publication only at the discretion of the Editor and are subject to referee by 
two experts in the field. A manuscript may consist of a maximum of 5000 words. The first page 
Preparation of the Manuscript 
must
The text should be preceded by a short summary (approximately 250 words and structured, if 
applicable, according to (i) Rationale, aims and objectives; (ii) Method; (iii) Results; and (iv) 
Conclusion(s)) and followed by (1) Introduction, (2) Methods (and Materials where appropriate), (3) 
Results, (4) Discussion, (5) Acknowledgements, (6) References, (7) Figure legends, (8) Tables and (9) 
Figures. All pages must be numbered consecutively from the title page, and include the 
acknowledgements, references and figure legends, which should be submitted on separate sheets 
following the main text. The preferred position of tables and figures in the text should be indicated in 
the left-hand margin. It is essential that approval for the reproduction or modification of figures and 
tables published elsewhere is sought and obtained in writing from the authors and publishers prior to 
submission of papers. The original source must be quoted. 
 
display: article title; names of all authors, with job title / professional designation; professional and 
academic qualifications; the name(s) and address(es) of the institution(s) at which the work was 
carried out (the present addresses of the authors, if different from the above, should appear in a 
footnote); the name, address, telephone and fax numbers of the author to whom all correspondence 
and proofs should be sent; a suggested running title of not more than fifty characters, including 
spaces; and six keywords to aid indexing. 
Author material archive policy. Please note that unless specifically requested, Wiley-Blackwell will 
dispose of all hardcopy or electronic material submitted two months after publication. If you 
require the return of any material submitted, please inform the editorial office or Production Editor as 
soon as possible if you have not yet done so.  
These should be in the Vancouver style. References should be numbered sequentially as they occur 
in the text and identified in the main text by numbers in superscript after the punctuation. The 
reference list should be prepared on a separate sheet from the main text, and references should be 
listed numerically. The following are examples of the style. Where there more than ten authors, the 
first three should be listed followed by et al. If there are ten or fewer authors then all should be listed. 
Journal titles should not be abbreviated. Do not use opcit. etc. 
References 
1. Kassirer, J. P. (1994) Incorporating patients' preferences into medical decisions. New England 
Journal of Medicine,
2. Macklin, R. (1993) Enemies of Patients. How Doctors are Losing Their Power and Patients are 
Losing their Rights. New York: Oxford University Press. 
 330(26), 1895-1896. 
3. Coote, A. (1996) The democratic deficit. In Sense and Sensibility in Health Care (ed M. Marinker), 
pp. 173-197. London: BMJ Publishing. 
Work that has not been accepted for publication and personal communications should not appear in 
the reference list, but may be referred to in the text (e.g. A. Author, unpubl. observ.; A.N. Other, pers 
comm.). The editor and publisher recommend that citation of online published papers and other 
material should be done via a DOI (digital object identifier), which all repuatable online published 
material should have - see http://www.doi.org/ for more information. If an author cites anything which 
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Instructions for Contributors Instructions for Contributorsdoes not have a DOI they run the 
risk of the cited material not being traceable. It is the authors responsibility to obtain permission from 
colleagues to include their work as a personal communication. A letter of permission should 
accompany the manuscript. 
Tables should include only essential data. Each table must be typewritten on a separate sheet and 
should be numbered consecutively with Arabic numerals, e.g. Table 1, and given a short caption. No 
vertical rules should be used. Units should appear in parentheses in the column headings and not in 
the body of the table. All abbreviations should be defined in a footnote. 
Tables 
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Appendix 3C:  INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN 
HEALTH CARE 
 
Instructions for Contributors 
 
Preparation of Manuscript 
The entire manuscript (in MS Word format), including all notes and references, must be typed, double-
spaced on 8.5 × 11 inch or A4 page size document, with at least 1-inch (2.54 cm) margins. Manuscript 
pages should be numbered consecutively. Manuscripts should be arranged as follows: 1) cover sheet 
with title and short title; 2) abstract and key words; 3) acknowledgments, including source of funding; 
4) text; 5) references; 6) tables with titles; and 7) figures, with captions on a separate page. 
Manuscripts should typically have no more than 4,000 words— including the abstract, which should 
not exceed 250 words.  
 
 
Abstract ad Key Words 
 A 100-to 250-word abstract, submitted on a separate page, should summarize the objectives of the 
study or analysis, the article’s major arguments and/or results, and its conclusions/recommendations. 
Abstracts must be submitted in four sections: Objectives; Methods; Results; and Conclusions, except 
where the subject and/or format of the article do not permit. Three to five key words, using terms from 
the Medical Subject Headings from Index Medicus, should follow the abstract. 
 
References 
Bibliographic citations in the text should be indicated by numbers in parentheses usually at the end of 
the sentence after the period. When authors are mentioned in the text, the citation number should 
immediately follow the name(s) as follows: 
In-text citations 
 “Jones and Smith (7) maintained that. . . ” The reference list must be in alphabetical order if a work 
has more than five authors, the first three authors should be listed, followed by et al. Abbreviate 
journal titles according to the listing in the current Index Medicus. Book: 1. Jones AB, Smith JK. 
Computer diagnosis and results. New York: Penta Publishers; 1998. Journal: 1. Jones AB, Smith JK. 
The relationship between health needs, the hospital, and the patient. J Chron Dis. 1995;32:310-312. 
 
Cover Letter 
All authors, must attest that 1) each named author contributed to both the conception/design and/or 
analysis/interpretation of the project and the writing of the paper; 2) each has approved the version 
being submitted; and 3) the content has not been published nor is being considered for publication 
elsewhere. In the reference list, do not include material that has been submitted for publication but has 
not yet been accepted. This material, with its date, should be noted in the text as “unpublished data”. 
 
Tables and Figures 
Tables and figures should be numbered consecutively. All tables and figures must have a caption and 
must be cited in the text. Abbreviations in tables and figures should be avoided, except in the case of 
acronyms already used in the text. Table footnotes appear directly after the table; table references 
follow the footnotes. Figures must be submitted in Excel, PageMaker, or equivalent. 
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Appendix 3D:  JOURNAL OF ONCOLOGY PHARMACY PRACTICE 
 
Manuscript style 
File types 
Only electronic files conforming to the journal's guidelines will be accepted. Preferred formats 
for the text and tables of your manuscript are Word DOC, and tiff or jpeg for figures (ideally 
figures will use journal colours). Please also refer to additional guideline on submitting 
artwork [and supplemental files] below. 
 
Journal Style 
Journal of Oncology Pharmacy Practice conforms to the SAGE house style. Click here to 
review guidelines on SAGE UK House Style. 
 
Reference Style 
Journal of Oncology Pharmacy Practice adheres to the SAGE Vancouver reference style. 
Click here to review the guidelines on SAGE Vancouver to ensure your manuscript conforms 
to this reference style. Abbreviations for titles of periodicals should conform to those used in the latest 
edition of Index Medicus. References should include authors' last names and initials, article title, 
journal, volume, page range, and year. Include the city and publisher's name for books. For 
further information, consult the American Medical Association Manual of Style. 
 
Manuscript Preparation 
The text should be double-spaced throughout and with a minimum of 3cm for left and right 
hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. 
 
 Keywords and Abstracts 
The title, keywords and abstract are key to ensuring that readers find your article 
online through online search engines such as Google. Please refer to the information 
and guidance on how best to title your article, write your abstract and select your 
keywords by visiting SAGE’s Journal Author Gateway Guidelines on How to Help 
Readers Find Your Article Online. 
 
Corresponding Author Contact details 
Provide full contact details for the corresponding author including email, mailing 
address and telephone numbers. Academic affiliations are required for all co-authors. 
 
Guidelines for submitting artwork, figures and other graphics. For guidance on the preparation of 
illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission 
Guidelines. Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with 
a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vectorbased, separate 
.eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 600 dpi. 
Images should be clear, in focus, free of pixilation and not too light or dark. If, together with your 
accepted article, you submit usable colour figures, these figures will appear in colour online regardless 
of whether or not these illustrations are reproduced in colour in the printed version. For specifically 
requested colour reproduction in print, you will receive information regarding the possible costs from 
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Appendix 3E:  EUROPEAN J OURNAL OF HOSPITAL PHARMACY SCIENCE 
In March 2005 EAHP launched a strong platform – EJHP Science – for publication of scientific output 
from the hospital pharmacy profession and related disciplines. 
EJHP Science 
EJHP Science now makes pharmaceutical innovation and developments in pharmaceutical and 
biomedical sciences accessible to hospital pharmacists for use in all aspects of their clinical, scientific 
and professional work.  
To provide a strong platform that concentrates the scientific output of the pharmacy profession and 
related disciplines. This will make pharmaceutical innovation and developments in pharmaceutical and 
biomedical sciences accessible for hospital pharmacists to use in all aspects of their clinical, scientific 
and professional work.  
Mission statement 
The aim of EJHP Science is to publish high quality research papers, review articles and case studies 
which will be of interest and relevance to various disciplines within hospital and academic pharmacy. 
To meet these aims, the scope of the Journal is broad and of relevance to pharmacists working in all 
areas of hospital pharmacy and interested in research in clinical, technical and social pharmacy as 
well as pharmaco-epidemiology and pharmaco-economics.  
Scope and profile 
• Case studies 
Types of article published  
• Clinical pharmacy 
• Editorials 
• Letters to the Editor  
• Original research 
• Pharmaco-economics 
• Review articles 
• Scientific commentary / pharmacy 
• Social pharmacy 
• Technical pharmacy 
Governance
 
 
EJHP Science is fully compliant with ICMJE Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals. 
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Appendix 3F: MALAYSIAN J OURNAL OF MEDICAL SCIENCES  
Preparation of Manuscript 
General 
• Text: Use subheadings for long articles and double-space all portions of the manuscript. 
• Font: Times New Roman/Arial/Cambria, size 12pt, double-spaced, single column. 
• Authors should number all of the pages of the manuscript consecutively, beginning with the title 
page, to facilitate the editorial process. 
• Please note that, at the moment, we do not accept Microsoft Word 2007/2010 documents 
(*.docx). Please use Word’s “Save As” option to save your document as (.doc) file type. 
Each type of manuscript has its own formats; examples of published manuscript are available on our 
website. Authors may also consult the provided references—or other similar publications—for tips on 
preparing a scientific manuscript. 
Manuscripts should be organised in the following order: 
 
1. Title page 
The title page should be sent as a separate document from the main text in ScholarOne 
Manuscripts. This document will not be available for reviewers as we employ a double-blind review 
process. 
The title page should have the following information: 
a. Article title without abbreviations 
b. Running title/running head (a short title) of less than 50 characters 
c. Authors’ names and institutional affiliations: Full names are required; indicate last name with 
SMALL CAPS. For example, Mohammed Ali JAMALUDDIN. 
 
d. Contact information for correspondence. The name, academic qualification, address, 
telephone number, fax number, and email address of one of the authors who will be 
responsible for all communication concerning the manuscript are required. 
e. Acknowledgements. Because the title page will not be sent to the reviewers, we recommend 
this section to be included in the title page. 
 
2. Main document 
a. Title 
b. Abstract 
The length of abstract depends on the type of manuscript submitted. The abstract should 
state the purpose of the study, a brief description of the procedures employed, main findings 
and principal conclusions. Abbreviations, footnotes, references, and subheadings should be 
avoided. For original articles, the abstract format is structured as Background, Methods, 
Results, and Conclusion. For other articles, the abstract format is unstructured. 
 
c. Keywords 
Authors must provide between 4 and 6 keywords that characterise the main topics of the 
article. 
 
d. Text 
The text of observational and experimental articles is usually (but not necessarily) divided into 
Introduction, Materials (or Subjects) and Methods, Results, Discussion, and Conclusion. A 
case report is divided into Introduction, Case Report (or Series), and Discussion. Other types 
of manuscript may be divided into several sections, as seen necessary by the authors. 
Long articles may need subheadings within some sections (especially Results and 
Discussion) to clarify their content. Subheadings representing different hierarchical level must be 
readily distinguished by readers. 
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Appendix 3G: EUROPEAN JOURNAL OF CANCER 
The European Journal of Cancer (EJC) is an international comprehensive oncology journal that 
publishes original research, editorial comments, review articles and news on experimental oncology, 
translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer 
epidemiology and prevention. 
The EJC will consider manuscripts prepared according to the guidelines adopted by the International 
Committee of Medical Journal Editors ('Uniform requirements for manuscripts submitted to biomedical 
journals', available as a PDF from www.icmje.org). Authors are advised to read these guidelines. 
All original research manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some 
manuscripts may be rejected outright following this evaluation. Those manuscripts which are judged 
as being eligible for consideration by the Editors will be subject to peer-review. 
Submission of an article implies that the work described has not been published previously (except in 
the form of an abstract or as part of a published lecture or academic thesis), that it is not under 
consideration for publication elsewhere, that its publication is approved by all authors and tacitly or 
explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not 
be published elsewhere in the same form, in English or in any other language, without the written 
consent of the Publisher. 
 The EJC will consider the following types of manuscript for publication:  
Editorial comments: Editorial comments are generally invited by the EJC's Editorial Team. They are 
1,500 words in length with no abstract or keywords.  
Original research articles: Original research articles have a limit of 2,500 words and no more than 40 
references. Authors are asked to provide a structured abstract and a list of keywords. 
Review articles: Review articles have a limit of 3,000 words with an unlimited number of references. 
Authors are asked to provide an unstructured abstract and a list of keywords. 
Author Form: The corresponding author must submit a completed Author Form with their submission. 
The form must be signed by the corresponding author and uploaded to EES with the manuscript. 
 
Acknowledgements: All contributors who do not meet the criteria for authorship as defined above 
should be listed in an acknowledgements section. Examples of those who might be acknowledged 
include a person who provided purely technical help, writing assistance, or a department chair who 
provided only general support. Authors should disclose whether they had any writing assistance and 
identify the entity that paid for this assistance. 
Randomised Controlled Trials: All randomised controlled trials submitted for publication in the EJC 
should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. 
Please refer to the CONSORT statement website at http://www.consort-statement.org for more 
information. The EJC has adopted the proposal from the International Committee of Medical Journal 
Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, 
registration in a public trials registry. Trials must register at or before the onset of patient enrolment. 
The clinical trial registration number should be included at the end of the abstract of the article. For 
this purpose, a clinical trial is defined as any research project that prospectively assigns human 
subjects to intervention or comparison groups to study the cause-and-effect relationship between a 
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